The definitive BPC-157 reference: the angiogenesis+FAK mechanism, the full animal record, the three human studies, real dosing/routes/reconstitution, the 2026 FDA PCAC fight, the cancer question answered, grey-market sourcing reality, and where it fits for a spinal disc. 130 sources.
BPC-157 grows new blood vessels into damaged tissue, and that is the whole of what it does for a person: a torn tendon, a cut ligament or a crushed muscle rebuilds only as fast as blood reaches it, and no blood means no rebuilding. In rats, an Achilles tendon cut off the heel bone came back taking more load before it failed, stiffer and springier, with the collagen fibres running straight instead of scarred — at 10 µg/kg a day into the belly cavity, across roughly 150 animal papers pointing the same way. In rats it also undid the damage a corticosteroid injection does to healing tendon and muscle, at the same doses, in two separate studies. In people: five studies, about 130 people, none of which measured whether anything healed — and, at the exposure people actually run, a counted record of 37 first-person accounts, of which 18 said it worked, 5 partly, 10 said nothing happened and 4 got worse. No trial has ever studied that exposure, so those 37 are the only evidence there is about it. It is a short chain of 15 amino acids copied from a protein in human stomach juice, it has never been approved as a medicine anywhere, and it is banned in sport at all times.
What the evidence supports doing. Use it for a fresh injury to tendon, ligament, muscle, or the join between tendon and bone — and above all where a cortisone shot has already spoiled the healing, because that is the one place the animal record lines up exactly with a common human situation. Do not use it for long-standing overuse tendon pain, and do not use it for anything to do with a spinal disc. No animal model of either exists, and the disc has never been studied in any species. Those two are what it is most often bought for.
It is almost never taken alone, and the pairing is a mechanism argument with nothing measured behind it. BPC-157 grows the vessels. TB-500 is proposed to move the repair cells that travel down them. ARA-290 acts on nerve fibres, which neither of the other two touches. The three are proposed to compound because each is aimed at a different step of one repair job. No study in any species has given BPC-157 and TB-500 together, and none has given all three, so the number of animals or people who have taken either combination under measurement is nought.
Against what a doctor prescribes for the same problem. An anti-inflammatory reduces the pain by suppressing the process that repairs the tissue, and both halves of that are measured. The relief is real: ibuprofen 400 mg has a number-needed-to-treat of 2.5 for at least half the pain gone, across roughly 460 randomised trials and about 50,000 participants. The cost is not that healing is slower — it is that the healed thing comes back weaker. In rats, COX-2-selective and older anti-inflammatories significantly lowered the maximum pull-out strength and the stiffness of a repaired tendon at its bone anchor, and produced patchy, inconsistent regrowth of the fibrocartilage layer that anchors tendon to bone, where untreated animals rebuilt it by four weeks and had their collagen fibres in order by eight. There is no timing window that escapes this: impairment was measured giving the drug in the first five days, again at days 6 to 14, and again at days 11 to 20 after a rotator cuff repair. A herniated disc is an inflamed disc, and the inflammation is the resorption engine — corticosteroids inhibited resorption in preclinical work, and a clinical series that deliberately withheld anti-inflammatories reported resorption in every single patient. A steroid injection is the sharper case: it does not rebuild anything at all. It relieves for weeks to months, changes the long-term course not at all, and what it buys is deferral of a surgical decision. The systemic bill runs on top, by the year: upper gut complications 3.97× on ibuprofen and 4.22× on naproxen, heart failure risk roughly doubled across the class, three extra major vascular events per 1,000 people per year on a coxib or diclofenac with one of them fatal. In FDA's adverse event system the single most reported term for ibuprofen is not a harm at all but "drug ineffective", 27,383 times. In rats, three days of diclofenac produced severe stomach, gut and liver damage that went on to liver-driven brain failure with brain swelling, and BPC-157 blocked the entire cascade; a corticosteroid injection measurably impaired the tendon and muscle healing it was given for, and BPC-157 reversed that too. Held to one standard: no anti-inflammatory has ever been shown to rebuild a torn tissue in a person, and neither has BPC-157. The difference between the two is which direction each has been measured moving the repair. If the question is what will hurt less this afternoon, the answer is the drug, and a weaker repair is the price of it.
The operator of this site has a commercial interest in the compounds described here.
Made in the stomach, and it survives the stomach
The name is literal: Body Protection Compound. The 15-piece chain is a fragment of a larger protein that sits in human stomach juice, and its one genuinely odd physical property is that it does not fall apart in that juice for more than 24 hours. Almost no peptide survives a stomach. That single property is the only reason a swallowed form is discussed at all, and it points at the gut as the compound's home ground.
Nearly the whole research record traces to one group in Zagreb, Croatia, led by Predrag Sikirić, running since 1993 and now past 150 papers.
It is a coherent, decades-deep programme applying one consistent dosing scheme across dozens of tissues, and it is also most of the world's evidence coming from a single group with a stake in the answer. It is the reason independent trials in people matter more here than they would for a compound many labs had poked at.
What the different kinds of proof can and cannot tell you
Kind of study
What it can settle
What it cannot settle
Cells in a dish
That the compound touches a specific switch inside a cell
Anything about a whole animal, a dose, or a person
Rats and dogs
That it changes a real injury in a living body, and by how much
Whether the same thing happens in a human, at what dose, or with what harm
Small safety studies in people
That a given dose did not visibly hurt a few dozen people over days
Whether it works, for anything
Chart reviews and phone follow-ups
What people remembered when asked
Whether the compound or the passage of time caused it
Randomised placebo trials
Whether it works
Nothing else needed — this is the one that settles it, and for a torn tissue none has finished
Forum and social posts
What exposure people are actually running, and what harms turn up at that exposure
Whether it works. Not weakly — not at all
Five studies in people, and the biggest one about an injury was a round of phone calls
FDA compiled the total published human experience for its July 2026 review. It is short enough to print in full.
Study
How it was taken, and how much
People
Design
What happened
Healthy volunteers, rectal
up to 2 mg/kg daily × 8 days
24
Safety only
Nothing serious; headache and wind most common
Ulcerative colitis (Ruenzi 2005)
80 mg rectal daily × 2 weeks
~53 split into groups, ~26 treated
Randomised; published only as a conference abstract
Difference between groups 1.6 points, range −4.84 to 1.62 — the range crosses zero, so no effect was shown
Knee pain (Lee & Padgett 2021)
2–4 mg into the joint, 1–2 injections
17 found, 16 reached
Looked back at charts, then rang people up
14 of 16 (87.5%) said they felt better; no dummy injection, no pain score, no scan
The only randomised trial ever run on BPC-157 in a person was about an inflamed bowel, it exists only as a conference abstract, and the result range crosses zero — meaning the treated group and the untreated group cannot be told apart. And the only published report of BPC-157 doing anything for a musculoskeletal injury in a human is somebody reading old charts and then telephoning the people in them.
Eleven of twelve people who got BPC-157 alone in that knee series said they improved a lot. There was no dummy injection, no random assignment, no standard pain questionnaire and no imaging. That is exactly the design that cannot separate a real drug effect from the well-known fact that sticking a needle into a sore knee makes people feel better for a while.
Two registered trials matter. A 2015 safety and absorption study in 42 healthy volunteers in Mexico gave single swallowed doses of 1 mg, 3 mg or 6 mg, then 3 mg every eight hours for two weeks. It never posted results, and the results submission was formally cancelled in 2016. Nobody knows what it found.
The trial that could actually settle the tissue-repair question started recruiting in February 2026. It is randomised, double-blind, placebo-controlled, injected under the skin once a day for 14 days alongside a standard rehab programme, in 120 people aged 18–45 who have a grade II hamstring tear confirmed on a scan within 72 hours of doing it. The two things being measured are days until they can play sport again and the change in the size of the injury on the scan from day 0 to day 14. It is expected to finish in February 2027.
Until that reads out, there is nothing controlled in a human for any soft-tissue injury. Not weak data. None.
Rats: what happened, in which tissue, at what dose
The animals in every study below were young, healthy, and injured on purpose.
A rat Achilles torn off the bone came back mechanically stronger
The join between tendon and bone is the hardest soft-tissue repair in the body and the one that most often fails. In rats whose Achilles tendon was surgically cut off the heel bone, BPC-157 raised the load the repair could take before failing, its stiffness and its springiness, all significantly above untreated animals. Under the microscope the collagen fibres were better lined up, there was more type I collagen — the strong, rope-like kind — and more blood vessels had grown in. Dose was 10 µg/kg, 10 ng/kg or 10 pg/kg into the belly cavity once a day, starting 30 minutes after surgery.
The same paper carries the finding most relevant to anyone who has already had a cortisone shot: the steroid 6α-methylprednisolone consistently made the healing worse, and BPC-157 substantially undid that damage.
Cut a ligament, crush a muscle, or sever the join between them — all three healed faster
The ligament model cut through the medial collateral ligament in rats and followed them 90 days. Treated animals came out ahead on four separate measures at once: how the leg worked, how strong the ligament was, how it looked to the eye, and how it looked under the microscope. Three different ways of giving it each worked — injection into the belly cavity at 10 µg/kg or 10 ng/kg daily, a cream at 1.0 µg per gram rubbed on, and plain drinking water at 0.16 µg/mL.
The muscle model both cut through and crushed the rat calf muscle, and deliberately gave the animals a steroid to wreck the healing. The authors' finding is that BPC-157 completely reversed that steroid damage, given either by injection or as a cream, with the leg working normally again in treated animals.
The place where muscle turns into tendon — a classic site of grumbling strain that never settles — got its own study. In treated rats the injured leg's stiffening resolved completely, while untreated animals stayed disabled. The muscle wasting seen in untreated animals was prevented. By days 28 to 42 the new tissue ran in the right direction instead of being bridged by scar. Both the microgram and the nanogram doses worked.
The biggest recent study, from January 2025, pulled the quadriceps entirely off its bony anchors and then treated the rats only through their drinking water. The vastus muscles reattached as early as 21 days. Rectus femoris was back to normal anatomy at about 28 days. At three months the mature fibres ran parallel to the bone and sat right against it. Reattachment was tracked on ultrasound — the same imaging used on people.
The review that swept this whole literature screened 544 papers and kept 36. Thirty-five of the 36 were animal or lab work. Across muscle, tendon, ligament and bone the results point the same way: better function, better structure, better mechanical strength. The same authors put the counterweight in the same breath — harm is possible from unregulated manufacturing, contamination, and the fact that safety in people is unknown.
A cut sciatic nerve regrew faster, which is the nearest thing to a nerve finding
Rats with a completely severed sciatic nerve got 10 µg/kg or 10 ng/kg into the belly cavity, into the stomach, locally at the repair site, or loaded straight into the tube bridging a removed segment. Self-mutilation of the dead-feeling limb — the standard sign that a rat's nerve pain is bad — did not happen in treated animals. Electrical testing showed stronger muscle signals. Weekly walking tests improved. Counting fibres under the microscope found more of them, thicker, with better insulation around them, at one to two months.
It is a nerve cut clean through and sewn back together, not a nerve under slow mechanical compression. No study of BPC-157 in a compressed nerve has ever been published. The difference is not a technicality: a cut-and-repaired nerve regrows along a clear path, while a compressed nerve has to survive a mechanical problem that is still present. Different problems, different bottlenecks.
The two spinal studies squash the cord, and both used doses a hundred times higher
Two rat spinal-cord studies exist. Both compress the cord itself.
The 2019 study opened the spine at L2–L3 and compressed the tail end of the cord for 60 seconds, then gave a single injection into the belly cavity ten minutes later at 200 µg/kg or 2 µg/kg. Treated rats got progressively better tail movement, did not self-mutilate, and their spasticity had resolved by day 15, with less swelling and fewer dead motor nerve cells in the grey matter.
The 2022 follow-up is the more interesting one, because it waited before treating. After a one-minute squash by a 60–66 g weight that definitely paralysed the tail, one group got 2 µg/kg into the belly cavity at ten minutes. A second got a 10 ng/kg dose into the stomach on day 4. A third drank 10 µg/kg in water from day 4 to day 30. Recovery was described as fast and lasting out to a full year, with only patchy swelling, minimal bleeding and no loss of nerve insulation at day 30. Treatment started four days late still worked — which matters, because nobody turns up at a clinic ten minutes after their back goes.
The doses used in the spinal work run up to a hundred times the doses used in the tendon work, so no number carries across between them.
How the compound is supposed to build tissue back
BPC-157 raises the signals that grow new blood vessels at an injury. New vessels bring oxygen and repair cells to tissue that had neither. Alongside that, it pushes collagen production and gets tissue-building cells to crawl into the gap.
The receptor step has been worked out in detail. In the cells that line blood vessels, BPC-157 makes the cell pull VEGFR2 — the main docking point for the body's chief vessel-growing signal — inside itself, and then switches on the VEGFR2–Akt–eNOS chain over time. Block the pulling-inside step with a chemical called dynasore and the whole effect disappears, which means the pulling-inside is required, not incidental. Vessel density went up both in a dish and in living animals, and blood flow came back faster in muscle that had been starved of it.
The crawling step has its own named mechanism. In tissue-building cells taken from rat tendon, BPC-157 dose-dependently added phosphate groups to two proteins, FAK and paxillin, which are the machinery a cell uses to grip a surface and haul itself along. The total amount of those two proteins did not change; only the switched-on fraction rose. The same study found the cells were not making more of themselves, so the effect is cells moving and surviving, not cells multiplying in number.
A third mechanism sits underneath both. Tendon cells given BPC-157 at 0.5 µg/mL grew about seven times more growth hormone receptors by day three, measured both as the instruction and as the finished protein. The cell does not get more growth hormone. It gets better at hearing the growth hormone already going past.
Nitric oxide — the gas that makes vessels widen — is pushed up in some situations and down in others, always paired with mopping up damaging free radicals. The Zagreb group reads that two-way behaviour as the whole point of the molecule: it pushes tissue toward normal rather than in one fixed direction. FDA reads the same observation as the reason no dose-response curve has ever been drawn for it. Both readings fit the data.
Read the chain against the tissues it has been tested in. New vessels: shown in cells and in rats. Vessels feeding a starved tissue: shown in muscle. Cells restarting production of the molecules that hold water in a matrix: never studied for this compound, in any tissue.
The painkiller you are probably already taking runs the opposite way to expected
Most people who arrive with back pain are already on an anti-inflammatory, and most compounds interact badly with those. This one was studied as an antidote to them.
Diclofenac at 12.5 mg/kg into the belly cavity once daily for three days produced severe stomach, gut and liver damage in rats, raised bilirubin, AST and ALT, made the liver heavier, and caused prolonged drowsiness that progressed to liver-driven brain failure with brain swelling and damaged nerve cells. BPC-157 blocked that entire cascade at both the microgram and the nanogram dose, given either by injection or in drinking water.
Read carefully, that is a gut-and-liver protection finding, not proof that combining the two heals a tendon better. What it does mean is that the medicine most likely to already be in the room is not, in rats, a documented problem.
The steroid interaction is the more consequential one. Two separate studies show BPC-157 undoing the damage a corticosteroid does to healing tendon and muscle. In animals a steroid injection measurably impaired the repair it was given for, and this compound reversed that impairment.
It is gone from your blood in about fifteen minutes
The only published measurements of what the body does to this compound come from rats and beagles.
Average time to clear half of it: 15.2 minutes. In dogs given it into a vein, 5.27 minutes. Peak level in the blood arrived three minutes after an injection into muscle. How much reaches the blood after an injection into muscle (bioavailability) was 14–19% in rats and 45–51% in dogs — wildly different between two species, and far from all of it. It leaves in urine and bile. Levels in kidney, liver, stomach wall, thymus and spleen went well above the level in blood.
A compound cleared that fast cannot be working by keeping a steady level in your blood. Whatever it does, it does fast and locally, then sets off a slower tissue process that outlasts the exposure by weeks. Two practical things follow. First, that is the argument for splitting a daily dose rather than taking it all at once. Second, a once-a-week schedule has nothing behind it.
No measurement of any of this has ever been made in a person. Every number above comes from a rat or a dog and is carried across species by assumption.
Turning powder into a dose
BPC-157 arrives as a freeze-dried white powder in a sealed glass vial, usually 5 mg or 10 mg. You add liquid to it. The liquid is bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is the thing that lets you put a needle into the same vial repeatedly over weeks. Plain sterile water dissolves the powder fine but has no preservative, so that vial is a one-time proposition.
The measuring device is a U-100 insulin syringe. U-100 means 100 units in a millilitre, so one unit on the barrel is 0.01 mL. Every conversion you will ever need comes from two lines:
Micrograms per mL = total micrograms in the vial ÷ mL of water you added.
Micrograms per syringe unit = that number ÷ 100.
Worked through: a 10 mg vial holds 10,000 mcg. You add 2 mL of bacteriostatic water. 10,000 ÷ 2 = 5,000 mcg per mL. 5,000 ÷ 100 = 50 mcg in one unit. A 250 mcg dose is therefore 250 ÷ 50 = 5 units on the barrel.
Vial
Water added
Strength
Mcg per unit
Units for 250 mcg
Units for 500 mcg
Doses in the vial at 250 mcg
5 mg (5,000 mcg)
2.0 mL
2,500 mcg/mL
25
10
20
20
5 mg (5,000 mcg)
2.5 mL
2,000 mcg/mL
20
12.5
25
20
10 mg (10,000 mcg)
2.0 mL
5,000 mcg/mL
50
5
10
40
10 mg (10,000 mcg)
3.0 mL
3,333 mcg/mL
33.3
7.5
15
40
10 mg (10,000 mcg)
5.0 mL
2,000 mcg/mL
20
12.5
25
40
Adding more water does not add or remove peptide. The vial holds what it holds. More water only changes how many syringe units carry a given dose. More water gives you bigger, easier-to-read unit counts and a slightly bigger squirt going in. Less water gives you a smaller sting and finer lines to misread. Below about 5 units per dose, the error in reading a U-100 barrel starts to swamp the dose itself — which is the practical argument for putting 3 mL rather than 2 mL into a 10 mg vial.
Ruining the peptide by accident is easy. Let the vial come to room temperature first. Run the water slowly down the inside wall of the glass rather than blasting it onto the powder. Swirl until it dissolves. Never shake it — shaking tears at the surface where liquid meets air, which unfolds peptide chains and makes them clump together, and clumping is the exact thing FDA named as the trigger for the immune system reacting to it (immunogenicity).
A mixed vial lasts about four weeks
State
Temperature
How long it actually lasts
Sealed, still a powder
2–8 °C, out of the light
Months to years, to the maker's date; −20 °C for long holding
Mixed with bacteriostatic water
2–8 °C
About four weeks — that limit is set by the preservative, not the peptide
Mixed, left on the counter
20–25 °C
Hours to days; treat it as ruined
Mixed, then frozen
−20 °C
Do not. Freezing and thawing clumps the peptide
Do the arithmetic against your own plan before you buy. A 10 mg vial at 250 mcg a day is 40 doses. Four weeks is 28 doses. You will throw away roughly a third of the vial, or you must buy a smaller one, or take more per day. There is no fourth option — refreezing it is the one thing that definitely damages it.
No study compares injecting near the injury against injecting anywhere else
Two placements compete and the animal work cannot referee between them, because rats were dosed into the belly cavity, into the stomach or rubbed on the skin, almost never at a specific human-style injection site.
Under the skin, near the sore part. What most people do. The argument is a higher concentration where the repair is needed, which fits a 15-minute clearance and fits tissue levels running above blood levels.
Under the skin of the belly, anywhere. Standard for gut, nerve and organ targets, and easier to do to yourself. The argument is that a compound reaching kidney, liver and stomach wall above blood level obviously travels, so the entry point may not matter.
The evidence tilts slightly toward the entry point not mattering. Several of the strongest structural results in the entire literature — the cut ligament, the muscle-tendon junction, the quadriceps reattachment, the sciatic nerve, the spinal cord — were produced in rats that simply drank the compound and still repaired a specific injury a long way from their gut. Nothing anywhere in the record shows a local injection beating a systemic one head to head.
Here are the doses that exist, all of them either from rats or scaled up from rats:
Where the number comes from
The dose
How long
The standard rat tier
10 µg/kg, 10 ng/kg or 10 pg/kg once a day
For as long as the study ran
The rat drinking-water equivalent
0.16 µg/mL in water, about 12 mL per rat per day
For as long as the study ran
Scaling 10 µg/kg straight up to a 70 kg adult
about 0.7 mg per day
Not an established human dose. Just arithmetic
Given to humans into a joint, published
2–4 mg per injection, 1–2 injections
One course
Given to humans by mouth, published (2015 Phase 1)
1, 3 or 6 mg once; then 3 mg every 8 hours
Two weeks
There is no validated human dose, no validated cycle length, no taper and no ceiling. USADA states it without softening: nobody knows whether a safe dose exists, or whether there is any way to use this compound safely for a named condition.
Every dose ever given to a human in a published study is measured in milligrams. Scaling the standard rat dose up to an adult lands at roughly 0.7 mg. The regimens circulating on forums and printed on vendor sites are measured in micrograms — a thousandth of a milligram — and land around 250 to 500 mcg. That is roughly a hundredth of anything ever formally given to a person. Nothing in the literature supports the microgram regimens. Nothing in the literature refutes them either. The dose question is not contested; it is simply open, and everyone taking it is guessing.
The tablet and the vial are not the same product
Swallowed BPC-157 exists as capsules or tablets, commonly 500 mcg each, and the stomach-survival finding is what makes that format arguable at all. But surviving your stomach acid and getting into your bloodstream are two separate questions, and only the first has ever been shown in a person.
Tablet you swallow
Vial you mix and inject under the skin
What is actually proven about this route
Survives human stomach juice past 24 hours
In rats, 14–19% of an injection into muscle reaches the blood; in dogs, 45–51%
Animal evidence using this route
Substantial — the ligament, muscle-tendon junction, quadriceps reattachment, nerve and spinal cord studies all worked with the compound given by mouth or in water
Extensive, but nearly all of it into the belly cavity rather than under the skin
What has been given to humans this way
1–6 mg by mouth in the 2015 Phase 1; 80 mg per enema in the colitis trial
2–4 mg into a joint; 10–20 mg into a vein
Best-supported target
The gut, and any whole-body target where the rat drinking-water arm worked
Musculoskeletal — by convention, not by any head-to-head comparison
How much gets into a human's blood
Never measured
Never measured
What it costs you in practice
No needles, no mixing, no four-week clock
Needles, arithmetic, a fridge, and a four-week clock
The evidence is friendlier to the swallowed route than the injection convention implies. Several of the strongest structural repair results in the whole corpus — ligament, muscle-tendon junction, muscle reattached to bone, delayed spinal cord recovery — came from rats drinking it in water. What nobody has is a measurement of how much of a swallowed dose gets into a human's blood, so choosing between the two forms rests on rat route data and on convenience, not on anything measured in a person.
How long anything would take, if it worked
Timelines here are set by tissue biology, not by the compound. Collagen remodels at the speed collagen remodels. Nerves regrow at about a millimetre a day. Nothing changes that.
Model
Time to the reported result
Squashed spinal cord, spasticity gone
15 days
Quadriceps reattached to bone, vastus muscles
21 days
Quadriceps reattached to bone, rectus femoris
~28 days
Muscle-tendon junction, tissue running the right way
28–42 days
Cut sciatic nerve, function and microscope findings
1–2 months
Cut medial collateral ligament, full follow-up
90 days
Hamstring tear Phase 2, injury size on scan
14 days (the primary measure; reads out 2027)
No human timeline has been established, because no controlled human trial has finished.
The honest inference: these are collagen and nerve timescales, four to twelve weeks. A result reported inside a fortnight is pain relief, not repair. Pain relief arrives before tissue has been rebuilt, so a change in symptoms at day 10 says nothing about the structure.
FDA's own toxicology is more specific than the safety talk around it
The Zagreb group's stated position is that BPC-157 is very safe, with no side effects in trials and a lethal dose never reached in toxicology work. FDA read the same body of work and described it differently.
In 28-day repeat-dose studies injecting into muscle, rats showed shortened clotting time and dogs showed lengthened clotting time on the same test — an unexplained effect on clotting that runs in opposite directions in two species. Blood ALT, glucose and triglycerides went up. No cancer-causing study of BPC-157 in either of its two chemical forms has ever been done. It did not damage DNA, and no birth-defect signal appeared when it was injected through gestation days 6–15.
FDA raised four objections. They are independent of each other, which means answering one leaves the other three standing.
The objection
What it actually means
Not enough clinical safety information to describe the safety profile
The human safety file is too small to draw a picture from — not "reassuring so far", but too small to say anything
Real risk that the immune system reacts to it, made worse by clumping and by peptide impurities
Part of the risk comes from how it is made and handled, not from the molecule alone
No dose-response relationship established
The flat pattern where micrograms, nanograms and picograms all work reads to FDA as a weakness, not a feature
No molecular target identified
Despite the VEGFR2 and FAK work, no confirmed receptor has been pinned down
The cancer question has a real answer and a real hole in it
The worry is mechanically sensible. A tumour cannot grow past a millimetre or two without recruiting new blood vessels. A compound whose headline action is growing new blood vessels could, in principle, supply them. An independent 2025 review states the worry and lands on the practical version of it: a cancer nobody has found yet.
The Zagreb group published a formal rebuttal in the same journal. Their case is that BPC-157 strongly blocked vessel growth into the cornea, that it has shown anti-tumour activity both in living animals and in a dish, and that its nitric oxide effect is always paired with mopping up free radicals — that it pushes vessel growth toward the normal, self-limiting kind rather than driving it indiscriminately.
Where that leaves you: no published rodent study shows BPC-157 speeding up tumour growth. No cancer-causing study exists. There is zero human cancer safety data. An active or suspected cancer is the one situation the mechanism itself argues against, and the missing study means the argument cannot be closed either way. If you have had a cancer, this is the question to take to your oncologist rather than to a forum.
FDA said no, and its own advisory committee said yes by two votes
The regulatory position moved twice during 2026, and most summaries you will find online are stale.
Date
What happened
Sept 2023
FDA puts BPC-157 in Category 2 of the 503A bulk-substances list — significant safety risk, which bars compounding pharmacies from making it
14 May 2026
The revised interim list carries only six substances in Category 2. BPC-157 is in none of Categories 1, 2 or 3 — the nominations were withdrawn
July 2026
FDA's own briefing document recommends against adding BPC-157 to the 503A list
23 July 2026
The Pharmacy Compounding Advisory Committee votes 8–6, with one abstention, to recommend adding it — against FDA's own staff
If a page you are reading still says BPC-157 is FDA Category 2, it has not been updated since 14 May 2026.
One detail in the meeting agenda changes what that vote means. The only condition FDA evaluated was ulcerative colitis. Tendonitis was among the uses put forward, and FDA declined to evaluate it because there was not enough information. A favourable vote about a bowel condition is not a favourable vote about tendon or disc repair, and it is being quoted as though it were.
The committee itself was not persuaded of much. One panelist who voted yes described the thing being voted on as a black box. One who voted no pointed out that roughly 30% of people given a dummy treatment report improvement — sometimes even on objective measures — which is the entire difficulty with the uncontrolled reports the nomination rested on.
There are two legal ways to compound a peptide and BPC-157 is on neither list
503A covers traditional compounding pharmacies. 503B covers registered outsourcing facilities, and it is a separate list with a separate standard: an outsourcing facility may not compound with a bulk substance unless that substance is on the 503B list, or the finished medicine is on FDA's drug shortage list at the time. BPC-157 is not on the 503B list, and the July 2026 vote concerned 503A only.
That same page sets out what FDA expects of any lawfully compounded substance: a valid certificate of analysis, manufacture by an establishment registered under section 510 of the FD&C Act, and compliance with any applicable USP or National Formulary monograph. Grey-market BPC-157 meets none of the three.
If you compete in anything, this is a strict-liability problem
BPC-157 is named explicitly on the WADA 2026 Prohibited List under S0, Non-Approved Substances, banned at all times — not just on competition day. S0 covers any substance with no current approval by any government health authority for human use anywhere, which is exactly what BPC-157 is.
Strict liability means you are responsible for what is in your body regardless of intent and regardless of who recommended it. That applies at college, professional and masters level, in sports most people do not think of as drug-tested.
The Department of Defense goes further. Its Operation Supplement Safety programme lists BPC-157 on the Prohibited Dietary Supplement Ingredients List and states the position flatly: BPC-157 is not a dietary ingredient, it is an unapproved drug. That applies to service members however it is taken.
"Research use only" is a shipping label, not a legal category
Nearly all BPC-157 sold to the public is labelled a research chemical, not for human consumption. That phrase creates no lawful route to a person. It is a disclaimer attached to a product with no legal standing as a medicine, a food or a supplement in the United States. USADA names the tell directly: sites that print "research only" while also printing human dosing instructions are describing what they expect to happen.
The purity problem is the concrete risk, and it is bigger than the legal one. Independent testing of grey-market peptide samples finds mislabelling, wrong dosing or contamination in roughly 30%, and the contaminant classes are specific: bacterial toxins, incomplete chains that are missing pieces, leftover solvents, heavy metals, live microbes and breakdown products. Incomplete chains and clumping are the same two failure modes FDA named as the things that make an immune reaction more likely — which means the supply-chain risk and the drug risk are the same risk wearing two hats.
A certificate reading "99% by HPLC" does not clear a batch, and understanding why is worth two minutes. HPLC confirms the target peptide is there and measures how much of the total it is. It says nothing about what the other 1% consists of. An incomplete chain or a fever-causing bacterial toxin sits inside that remainder and never shows up. What you want is HPLC and mass spectrometry, done per batch, by a laboratory that is not the seller. A vendor's own certificate is not third-party testing, and a certificate photographed from a different batch is not a certificate at all.
Which problems the evidence actually reaches
Every positive animal model in this literature is an acute surgical injury — a tendon cut through, a ligament severed, a muscle crushed, a tendon torn off bone, a nerve cut. There is no rat model of a fifteen-year grumbling tendon, and no reason to assume a repair signal helps tissue whose problem is failed remodelling rather than an unfilled hole.
Your problem
What the animal data actually covers
How strong
Fresh tendon tear or rupture
Achilles cut through and torn off bone: strength to failure, stiffness, type I collagen all improved
Strongest animal case
Tendon pulling off bone
Achilles detachment and quadriceps reattachment, confirmed on ultrasound at 21–28 days
Strong in animals, nothing in humans
Ligament sprain
Medial collateral ligament cut through, 90-day follow-up, four measures
Strong in animals, nothing in humans
Fresh muscle strain
Calf muscle cut and crushed; the one Phase 2 trial targets a grade II hamstring
Animals plus one trial reading out 2027
Pain where muscle becomes tendon
Its own rat model; stiffening resolved, wasting prevented
Strong in animals, nothing in humans
Healing spoiled by a cortisone shot you already had
Two studies show the steroid damage to tendon and muscle healing reversed
Animals, directly relevant, nothing in humans
You are on daily anti-inflammatories
Diclofenac damage to gut, liver and brain fully blocked
Animals; a protection finding, not a repair finding
Nerve cut and surgically repaired
Sciatic nerve: electrical signals, walking, insulation all improved
Moderate in animals, nothing in humans
Long-standing overuse tendon pain
No model exists. Every positive study is a fresh injury
Weak — the mechanism does not obviously apply
Carpal tunnel or other trapped nerve
No compression model exists
Absent
Herniated lumbar disc, sciatica
No disc model exists. Nearest thing is a squashed rat spinal cord at a 100× dose
Absent
Degenerative disc disease itself
Nothing. Not one study, in any species
Absent
The cortisone-reversal row is the most useful finding in the entire animal literature, because a large share of people with a bad back arrive having already had a steroid injection that measurably worsened the healing they came in for. If any part of this compound's animal record applies to you, that is the part with the clearest logic behind it.
The long-standing-tendon-pain row is weak exactly where demand is highest.
Fifty people said what happened to them, and here is the count
This page holds 50 first-person accounts posted publicly between 2015 and 2026 — 40 on Reddit across r/Peptides, r/steroids, r/backpain, r/Sciatica, r/climbharder, r/PEDs, r/Biohackers, r/moreplatesmoredates, r/PeptideGuide, r/Peptidesource and r/Supplements, and 10 on X. Every one is self-reported by a person you cannot identify or question. Nobody assayed their vial, so the substance in the syringe is unknown in every single case. Nobody was randomly assigned. Almost nobody scanned the injury before and after. People who got better write posts more often than people who did not, so the set is filtered before you even read it.
It is here for one reason. No controlled trial in a human musculoskeletal injury has ever finished, so this is the entire record of people using it for the reasons you are considering it — and it is what you have already read by the time you got to this page.
The count, with the denominator
Of the 50 accounts, 13 report no personal result at all — they are protocols, questions, general threads about the science, or one person's dosing accident. That leaves 37 accounts that state what happened to the person writing. Here is the split:
What they reported
Count
Share of the 37
It helped — clear improvement they credit to it
18
49%
Partly, or it faded, or they could not separate it from other things
5
14%
Nothing happened
10
27%
It made something worse
4
11%
Half of the people who reported an outcome said it helped, and half did not. If you have seen this compound described online, you have almost certainly seen a version of that record where the 14 accounts reporting nothing or harm were left out. That version is a lie by selection, and it is the standard version.
Four more things the raw count hides.
The 10 "nothing happened" accounts are not shorter courses or smaller doses than the successes. Several ran six weeks or more at the same 500 mcg a day that the successes ran.
The 4 harm reports describe things the rat toxicology gives no reason to expect and the five human studies were far too small to catch: a joint that got worse and inflamed, vision going blurry over weeks, a finger swelling with fluid, and leg pain returning during treatment for a herniated disc.
One account reports a ten-fold dosing accident, which is a safety datapoint of its own and the reason the reconstitution arithmetic earlier on this page matters more than it looks.
And exactly one account in 50 reports an objective check by a clinician. One. Everybody else is reporting pain, movement and confidence — the three things most responsive to time, rest and expectation.
The account crediting a clinician with saying the tear was gone is the single best entry in the whole set, and even that was a re-examination, not a repeat scan. And the account that asks itself "is this placebo?" also added collagen and more protein in the same window, which the writer says outright — that honesty makes it more useful than the confident ones, not less.
The last one is a pattern with no counterpart anywhere in the published literature: the effect fading on a steady dose, then not returning when the dose was raised. Nothing in the rat work predicts that. Nothing in the pharmacology explains it.
The 10 who said nothing happened
These are the entries marketing copy leaves out. They are the same doses, the same durations, and several of them are longer courses than the successes.
The standard reply offered inside these threads to a negative report is that the person got a bad vial. That reply cannot be checked — nobody in this set tested their product — and it is the exact mechanism by which a grey-market compound builds a record that can never fail. Every success counts as evidence; every failure counts as a counterfeit.
That is ten times the intended dose, caused by misreading a syringe barrel. Nobody was hurt. It is on this page because the numbers everyone uses have nothing under them, and the people using them say so plainly:
Almost every account in the set describes 250 to 500 micrograms a day, under the skin, sometimes split into two or three shots, run for four to eight weeks. That band converged by copying, not by measurement. It is about a hundredth of the milligram doses used in every published human study.
The 13 that report no outcome at all — including the six loudest posts here
Thirteen of the 50 accounts state no personal result. Seven are the protocols and dosing arguments already shown above. The other six are X posts, and they are worth looking at separately, because they are almost certainly the format in which most people first meet this compound.
Four are summaries of the animal literature written in the voice of personal endorsement — "repaired 5 different tissues", "no compound heals as many tissue types" — with a dose attached at the end and no report of the writer's own outcome anywhere in them. One is a person asking for an alternative. One is a person saying they never took it but wish they had.
They are in this count because leaving them out would be dishonest, and they are separated out because counting them as successes would be worse. The most confident writing about this compound contains the least first-hand information in it, and that is the single most useful thing this section can tell you.
Where the accounts contradict the animal work
The animal record is strongest for fresh injuries and weakest for long-standing tendon pain.
The forum record inverts that. Long-standing elbow, wrist and shoulder tendon pain of one to five years' standing is the most common thing people treat, and spinal complaints — where no animal model exists — generate some of the most emphatic success reports.
The most emphatic of those accounts describes pain easing over six to seven weeks of injections after everything else had failed, and it is the one with the least behind it, because no animal study covers that tissue.
Two readings fit and the accounts cannot separate them. Either the compound reaches structures the animal work never tested, or long-standing pain that comes and goes was going to improve anyway and the compound arrived during a good month. Spontaneous improvement over roughly six to twelve weeks is well documented for several of these complaints, and that is exactly the window these protocols run.
The swallowed route contradicts the pharmacology the same way. Surviving stomach acid is proven; getting into a human's blood from the gut is not. People report the two forms doing different jobs, which is precisely what you would expect if the tablet works locally in the gut and never reaches a tendon at all.
The stacking problem, which is the biggest hole in the whole set
Almost nobody takes this alone. TB-500 is combined with it so routinely that a large share of these accounts cannot attribute any outcome to either compound. Others add growth hormone, testosterone, surgery, physiotherapy, diet changes and rest inside the same weeks.
The three most confident recovery stories on this page — the rotator cuff tear a clinician later called gone, the wrist rebuilt over seven vials, and the shoulder that felt 75% better in five days — were all run as BPC-157 plus TB-500, and two of them alongside structured rehab. Not one of them can tell you which part did the work.
It means a good share of the 18 positive accounts are reports about a combination, run alongside the two interventions with the best evidence in all of musculoskeletal medicine — load management and time.
What the counted record settles, and what it does not
It does not settle whether it works. Thirty-seven uncontrolled accounts filtered toward success are not weak evidence for a treatment effect; they are a different kind of object, and collecting three hundred more would change nothing about that. A 49% success rate in this set is not a 49% chance it works for you. It is a measurement of what people wrote down.
It does settle three things the published literature does not contain at all, and these are the reason it is worth counting rather than dismissing.
First, the real exposure. People are running 250–500 mcg a day under the skin for four to eight weeks, usually stacked with TB-500. No trial has ever studied that exposure. When somebody eventually does, this is the regimen they should test, and nobody would know it from the papers.
Second, harms at that exposure. Four of 37 accounts report getting worse — local swelling, a joint becoming more inflamed, blurred vision, and returning nerve pain. None of those appear in any published human safety dataset, because those datasets total about 130 people across five studies and would not detect a 1-in-10 problem if it existed.
Third, the mismatch. The two things people most often treat with it are long-standing tendon pain, which the animal literature supports least, and spinal complaints, which it does not cover at all.
The Phase 2 hamstring trial reading out in 2027 will answer the works-or-not question for one fresh injury in one muscle. Nothing currently running covers any spinal tissue.
What is settled about BPC-157, and what is not
Status
Statement
Settled
It survives human stomach juice for more than 24 hours
Settled
It switches on the VEGFR2–Akt–eNOS chain and increases blood vessel density in a dish and in rodents
Settled
It improves mechanical strength and microscope appearance across many fresh rat injuries
Settled
It reverses the damage a corticosteroid does to tendon and muscle healing in rats
Settled
It blocks diclofenac-caused gut, liver and brain damage in rats
Settled
Half of it clears a rat's blood in about 15 minutes; 14–19% of an intramuscular dose reaches the blood in rats
Settled
It is on the WADA 2026 Prohibited List under S0, banned at all times, in and out of competition
Not shown
That it does anything for a musculoskeletal injury in a person — no controlled soft-tissue trial has finished
Not shown
That a swallowed dose reaches the bloodstream of a human
Not shown
That it feeds tumours — and equally not shown that it is safe if you have a cancer
Unknown
The right human dose. Every published human study used milligrams; everyone taking it uses micrograms
Unknown
Long-term safety, interactions with your other medicines, and why clotting time moves in opposite directions in rats and dogs
Unknown
Whether any of this reaches a spinal disc. Nobody has looked, in any species
The verdict, stated so it decides something. For a fresh tear or detachment in tendon, ligament or muscle — and most of all for repair that a corticosteroid injection has already impaired — BPC-157 has the strongest animal case of any compound written up here: consistent across at least six injury models, mechanically explained down to the receptor step, and reproduced by three separate ways of giving it. Taking it for that, at 250–500 mcg a day under the skin for four to eight weeks, is a bet on rat evidence that is worth naming as a bet: no controlled human trial in any of those tissues has finished, and the first one reads out in February 2027. For long-standing overuse tendon pain, and for anything to do with a spinal disc, the answer is no — not "unproven", no. Every positive study in the whole literature is a fresh surgical injury, there is no animal model of a grumbling tendon, the two spinal studies squash a cord at up to a hundred times the tendon dose, and the disc has never been studied in any species. Those two are what it is most often bought for, and they are the two the evidence does not reach.
BPC-157 is not an approved medicine in any country. Everything sold to the public is grey-market and unverified. Nothing here is a dosing or treatment recommendation.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review“A total of 544 articles from 1993 to 2024 were identified. After duplicates were removed, 36 studies were included (35 preclinical studies, 1 clinical study). The studies suggest that BPC-157 enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis, while reducing inflammatory cytokines. In preclinical models, BPC-157 improved functional, structural”
SELFTEST graph fn ingest“mixed BPC gut results; stopped after nausea week 2”
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians“BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability.”
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing“Despite broad preclinical support, human data are extremely limited. Only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics. No adverse effects were reported, but rigorous, large-scale trials are lacking.”
What Science ACTUALLY Says About BPC 157 Benefits“However, its effectiveness and safety in humans remain unproven due to the lack of rigorous clinical trials. The only human study found was small and inconclusive, making it difficult to ascertain BPC 157's true benefits.”
BPC-157: Miracle Healing Peptide or Hidden Danger?“In summary, human evidence on BPC-157 is scant and of low quality . The few available human studies are small, unblinded, and often conducted by clinics with a stake in the outcome.”
How does the Peptide BPC-157 Work?“BPC‑157 is a synthetic peptide derived from a naturally occurring protein in the stomach and is being studied for potential roles in tissue repair and inflammation modulation.”
Stable Gastric Pentadecapeptide BPC 157 as a Therapy of ...“Stable Gastric Pentadecapeptide BPC 157 as a Therapy of ... BPC 157 controls angiogenesis and the NO-system's healing functions and ... Publication types. Review . Grants and funding. 10106-22-3071/University of Zagreb.”
Peptides and BPC-157 for Pain: What's the deal?“Peptides and BPC-157 for Pain: What's the deal? ... Key References Discussed • Józwiak et al. Multifunctionality and Possible Medical Application of BPC-157 — MDPI Pharmaceuticals (2025)”
Safety of Intravenous Infusion of BPC157 in Humans“For years, the peptide Body Protection Compound 157 (BPC-157) has been used to treat partial muscle or tendon tears. ... Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated.”
The Role of BPC-157 in Tissue Repair and Pain Management“Experimental evidence reveals that BPC - 157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways, contributing ...”
BPC-157 post“Short for Body Protection Compound, built off a protein found in your own gut. This was the backbone of the stack, calming the inflammation and helping my gut lining rebuild.”
PEPTIDE MASTERCLASS: BPC-157“No compound in preclinical research heals as many tissue types, as consistently, as BPC-157. Tendons. Ligaments. Muscle. Gut. Bone. Brain. ... Tendon and ligament healing. This is the most extensively studied application across animal models and the primary reason BPC-157 has become widely used in the peptide community.”
BPC-157 tendon healing details“Tendon and ligament healing. ... Studies across multiple animal models show BPC-157 dramatically accelerates tendon-to-bone healing, increases the tensile strength of healing tendons, and promotes the formation of organized collagen fibers rather than disorganized scar tissue.”
X post by @TakeThiamine“I’ve had gut issues for years and while I’m stable now (used to be really bad), I absolutely could’ve benefitted from BPC-157”
X post by @BasedBiohacker“bpc-157 is one of the FEW compounds that genuinely earns the word "healing" rather than just "performance" gut lining repair. tendon regeneration. neurotransmitter normalization. autonomic balance. ... → oral for gut and systemic effects. → subq near the injury site for targeted tissue repair. take it at night, 2-4 week cycle.”
X post by @HealthyAlfred“BPC-157 repaired 5 different tissues in published studies — without surgery ... Tendon — regrew after full transection Ligament — restored biomechanical strength Muscle — rebuilt after complete severance Bone — regenerated missing segments Nerve — regrew after transection ... 500mcg. Oral. Morning. Empty stomach.”
X post by @WovenDissent“Bro BPC-157 “research only” from a reputable lab changed my life From a year of constant pain to pain free in both elbows - totally healed my tendons in 6 weeks. Shit is a miracle”
BPC-157: experimental peptide creates risk for athletes — U.S. Anti-Doping Agency, Aug 4, 2026“no one knows if there is a safe dose, or if there is any way to use this compound safely to treat specific medical conditions”
What's changing with peptide regulation in 2026 — Banned Substances Control Group, May 3, 2026“mislabeling, improper dosing, or contamination in approximately 30% of peptide samples from grey-market sources”
Bulk drug substances used in compounding under section 503B of the FD&C Act — U.S. Food and Drug Administration, Aug 4, 2026“Outsourcing facilities... may not compound a drug product that includes a bulk drug substance unless: The bulk drug substance appears on a list identifying bulk drug substances for which there is a clinical need (the 503B bulks list), or The drug product compounded from such bulk drug substance appears on FDA's drug shortage list at the time of compounding, distribution and dispensing.”
Compound experience saturday bpc157“I did a total of 10mg at a dosage of 500 mcg each day, and noticed no difference. I am left to wonder if the source was just bunk because everybody else seems to love the stuff.”
Bpc 157 and tb 500 for herniated disc“I started taking bpc 157 and tb 500 and 500mcg a day to help with healing but I have started to feel worse and have pain going down my leg again.”
Bpc157 gone wrong“While the shoulder is seemingly better (just a bit sore the first day), my knees got way worse and got inflamed pretty bad. Going to stop to see it gets better”
1 month of bpc157 tb500 blend reviewblurry vision“After weeks of bpc tb blend. I noticed my vision was getting worse and worse.. blurry..some days worse than others. Even just trying to focus at distance.”
Bpc157 for shoulder injury“I’m taking about 500 MCG per day bpc157 and injecting it in my shoulder. I haven’t seen any results yet besides maybe better sleep. It’s day 5”
Bpc157 and tb4 has it not worked for you“I had high hopes for the peptide treatment but so far it hasn’t helped a lot. It has helped a bit but I expected more.”
Need guidance“I do see reduction in pain on my right arm but its not completely gone .. i do feel pressure on joint . There is no difference in condition of left arm .”
Compounds healing compounds bpc157 tb500 etc“Almost immediately the knee pain went away, although I have heard this is due to the anti-inflammatory effects rather than any actual healing. After three weeks when I stopped I noticed the knee pain came back almost immediately”
Compound experience saturday bpc157“Unfortunately it didn't seem to heal the actual tear quite as fast, but when coupled with isometric exercises prescribed by sports doctor, I gradually started to recover useab”
Compound experience saturday bpc157“I recommend if you're suffering an acute pain from ligament/muscle/soft tissue then use BPC-157 it's not a miracle by any means but I can improve mobility.”
And it begins bpc 157 and tb 500“Tbh, all dosages are completely unfounded on anything. Someone just made them up. There is literally no established clinical dosage.”
Experience with bpc157 and elbow tendinopathy“Things felt immediately better while I wasn't climbing. Though, to refer back to the variables, I felt better before the BPC as well.”
My experience case study recovering from an a2“My finger started to stay very swollen all day and felt like it was retaining fluid. It became somewhat difficult to do finger rolls because it felt like my digits were too swollen in the skin to close properly.”
Compounds healing compounds bpc157 tb500 etc“Weeks 1-2 I used 250 mcg BPC daily and 2 mg TB twice a week, weeks 3-8 I continued with the same BPC dose and dropped TB administration to once a week.”
Compounds healing compounds bpc157 tb500“I did 500mcg every 8 hours (3x a day) for 2 weeks. After the two weeks there was a substantial difference in pain levels.”
Bpc 157 tb500 side effect for 65 yrs old“Started BPC-157 three weeks after that injury, injecting 500mcg daily (left knee day 1, right knee day 2, etc). The chronic pain dissipated 3 weeks in and the injured knee felt stronger by week 4.”
Lifting 3 months after a broken wrist“7 bottles of bpc157 in the wrist later and im getting super close to being at my old ability. Max bench before was 315x1 and atm the highest I’ve gone is 275x1. It’s not 100% yet, still has minor pain or stiffness at times”
Accidentally took 30iu of bpc157 instead of 3iu“I did my first dose of bpc157 yesterday. And i made a mistake, i took 30IUs (3mg) instead of 3IUs (300mcg), because my f-ing syringe says 3 and not 30…”
Bpc157 and tb500 weekly update“500mcg of BCP EOD and 500mcg of TB EOD. This is day 5 not even a full week and I could fucking cry because my shoulder feels 75% better that fast.”
Is oral bpc157 less effective than injecting it“I partially tore my rotator cuff in early September. Injected 1500 mg BPC 157 for 3 weeks and I'm nearly fully recovered. I say this in terms of feel, not medical imaging.”
Pinched sciatic nerve“I tried ever and eventually decided to try injectable BPC 157 and within a few weeks pain started to ease, well this could be random so I continued use after about 6-7 weeks sciatic pain was almost all the way gone”
Bpc157 saved my foot“But now 3 months later it’s basically fully healed and feels great again. Could be coincidence, but the timeline felt way faster than any serious injury I’ve healed before.”
Bpc157peptides in general“started taking the bpc 157 and range of motion is 100%, random pain at certain angles is about home, still have a little pain if reach a certain area.”
the whole object this page is drawn from, as JSON
{
"schema":"https://miscsubjects.com/schemas/jarticle.json",
"status":"published",
"slug":"bpc-157",
"title":"BPC-157: Body Protection Compound",
"kind":"essay",
"summary":"The definitive BPC-157 reference: the angiogenesis+FAK mechanism, the full animal record, the three human studies, real dosing/routes/reconstitution, the 2026 FDA PCAC fight, the cancer question answered, grey-market sourcing reality, and where it fits for a spinal disc. 130 sources.",
"created":"2026-06-29 08:23:19",
"body": [
"BPC-157 grows new blood vessels into damaged tissue, and that is the whole of what it does for a person: a torn tendon, a cut ligament or a crushed muscle rebuilds only as fast as blood reaches it, and no blood means no rebuilding. In rats, an Achilles tendon cut off the heel bone came back taking more load before it failed, stiffer and springier, with the collagen fibres running straight instead of scarred — at 10 µg/kg a day into the belly cavity, across roughly 150 animal papers pointing the same way. In rats it also undid the damage a corticosteroid injection does to healing tendon and muscle, at the same doses, in two separate studies. In people: five studies, about 130 people, none of which measured whether anything healed — and, at the exposure people actually run, a counted record of 37 first-person accounts, of which 18 said it worked, 5 partly, 10 said nothing happened and 4 got worse. No trial has ever studied that exposure, so those 37 are the only evidence there is about it. It is a short chain of 15 amino acids copied from a protein in human stomach juice, it has never been approved as a medicine anywhere, and it is banned in sport at all times.\n\n**What the evidence supports doing.** Use it for a fresh injury to tendon, ligament, muscle, or the join between tendon and bone — and above all where a cortisone shot has already spoiled the healing, because that is the one place the animal record lines up exactly with a common human situation. Do not use it for long-standing overuse tendon pain, and do not use it for anything to do with a spinal disc. No animal model of either exists, and the disc has never been studied in any species. Those two are what it is most often bought for.\n\n**It is almost never taken alone, and the pairing is a mechanism argument with nothing measured behind it.** BPC-157 grows the vessels. TB-500 is proposed to move the repair cells that travel down them. ARA-290 acts on nerve fibres, which neither of the other two touches. The three are proposed to compound because each is aimed at a different step of one repair job. No study in any species has given BPC-157 and TB-500 together, and none has given all three, so the number of animals or people who have taken either combination under measurement is nought.\n\n**Against what a doctor prescribes for the same problem.** An anti-inflammatory reduces the pain by suppressing the process that repairs the tissue, and both halves of that are measured. The relief is real: ibuprofen 400 mg has a number-needed-to-treat of 2.5 for at least half the pain gone, across roughly 460 randomised trials and about 50,000 participants. The cost is not that healing is slower — it is that the healed thing comes back weaker. In rats, COX-2-selective and older anti-inflammatories significantly lowered the maximum pull-out strength and the stiffness of a repaired tendon at its bone anchor, and produced patchy, inconsistent regrowth of the fibrocartilage layer that anchors tendon to bone, where untreated animals rebuilt it by four weeks and had their collagen fibres in order by eight. There is no timing window that escapes this: impairment was measured giving the drug in the first five days, again at days 6 to 14, and again at days 11 to 20 after a rotator cuff repair. A herniated disc is an inflamed disc, and the inflammation is the resorption engine — corticosteroids inhibited resorption in preclinical work, and a clinical series that deliberately withheld anti-inflammatories reported resorption in every single patient. A steroid injection is the sharper case: it does not rebuild anything at all. It relieves for weeks to months, changes the long-term course not at all, and what it buys is deferral of a surgical decision. The systemic bill runs on top, by the year: upper gut complications 3.97× on ibuprofen and 4.22× on naproxen, heart failure risk roughly doubled across the class, three extra major vascular events per 1,000 people per year on a coxib or diclofenac with one of them fatal. In FDA's adverse event system the single most reported term for ibuprofen is not a harm at all but \"drug ineffective\", 27,383 times. In rats, three days of diclofenac produced severe stomach, gut and liver damage that went on to liver-driven brain failure with brain swelling, and BPC-157 blocked the entire cascade; a corticosteroid injection measurably impaired the tendon and muscle healing it was given for, and BPC-157 reversed that too. Held to one standard: no anti-inflammatory has ever been shown to rebuild a torn tissue in a person, and neither has BPC-157. The difference between the two is which direction each has been measured moving the repair. If the question is what will hurt less this afternoon, the answer is the drug, and a weaker repair is the price of it.\n\nThe operator of this site has a commercial interest in the compounds described here.\n## Made in the stomach, and it survives the stomach\n\nThe name is literal: Body Protection Compound. The 15-piece chain is a fragment of a larger protein that sits in human stomach juice, and its one genuinely odd physical property is that it does not fall apart in that juice for more than 24 hours. Almost no peptide survives a stomach. That single property is the only reason a swallowed form is discussed at all, and it points at the gut as the compound's home ground.\n\nNearly the whole research record traces to one group in Zagreb, Croatia, led by Predrag Sikirić, running since 1993 and now past 150 papers.\n\nIt is a coherent, decades-deep programme applying one consistent dosing scheme across dozens of tissues, and it is also most of the world's evidence coming from a single group with a stake in the answer. It is the reason independent trials in people matter more here than they would for a compound many labs had poked at.\n\n## What the different kinds of proof can and cannot tell you\n\n| Kind of study | What it can settle | What it cannot settle |\n|---|---|---|\n| Cells in a dish | That the compound touches a specific switch inside a cell | Anything about a whole animal, a dose, or a person |\n| Rats and dogs | That it changes a real injury in a living body, and by how much | Whether the same thing happens in a human, at what dose, or with what harm |\n| Small safety studies in people | That a given dose did not visibly hurt a few dozen people over days | Whether it works, for anything |\n| Chart reviews and phone follow-ups | What people remembered when asked | Whether the compound or the passage of time caused it |\n| Randomised placebo trials | Whether it works | Nothing else needed — this is the one that settles it, and for a torn tissue none has finished |\n| Forum and social posts | What exposure people are actually running, and what harms turn up at that exposure | Whether it works. Not weakly — not at all |\n\n## Five studies in people, and the biggest one about an injury was a round of phone calls\n\nFDA compiled the total published human experience for its July 2026 review. It is short enough to print in full.\n\n| Study | How it was taken, and how much | People | Design | What happened |\n|---|---|---|---|---|\n| Healthy volunteers, rectal | up to 2 mg/kg daily × 8 days | 24 | Safety only | Nothing serious; headache and wind most common |\n| Ulcerative colitis (Ruenzi 2005) | 80 mg rectal daily × 2 weeks | ~53 split into groups, ~26 treated | Randomised; published only as a conference abstract | Difference between groups 1.6 points, range −4.84 to 1.62 — the range crosses zero, so no effect was shown |\n| Knee pain (Lee & Padgett 2021) | 2–4 mg into the joint, 1–2 injections | 17 found, 16 reached | Looked back at charts, then rang people up | 14 of 16 (87.5%) said they felt better; no dummy injection, no pain score, no scan |\n| Interstitial cystitis | 10 mg into the bladder | 12 | No comparison group | Nothing serious reported |\n| Healthy volunteers, into a vein | 10 mg then 20 mg | 2 | Safety pilot | No harm seen |",
{
"type":"source",
"id":"w_9qu2rfyq"
},
"The only randomised trial ever run on BPC-157 in a person was about an inflamed bowel, it exists only as a conference abstract, and the result range crosses zero — meaning the treated group and the untreated group cannot be told apart. And the only published report of BPC-157 doing anything for a musculoskeletal injury in a human is somebody reading old charts and then telephoning the people in them.",
{
"type":"source",
"id":"w_nfh8rh08"
},
"Eleven of twelve people who got BPC-157 alone in that knee series said they improved a lot. There was no dummy injection, no random assignment, no standard pain questionnaire and no imaging. That is exactly the design that cannot separate a real drug effect from the well-known fact that sticking a needle into a sore knee makes people feel better for a while.",
{
"type":"source",
"id":"s3"
},
{
"type":"source",
"id":"s27"
},
"Two registered trials matter. A 2015 safety and absorption study in 42 healthy volunteers in Mexico gave single swallowed doses of 1 mg, 3 mg or 6 mg, then 3 mg every eight hours for two weeks. It never posted results, and the results submission was formally cancelled in 2016. Nobody knows what it found.",
{
"type":"source",
"id":"w_rwwqkuud"
},
"The trial that could actually settle the tissue-repair question started recruiting in February 2026. It is randomised, double-blind, placebo-controlled, injected under the skin once a day for 14 days alongside a standard rehab programme, in 120 people aged 18–45 who have a grade II hamstring tear confirmed on a scan within 72 hours of doing it. The two things being measured are days until they can play sport again and the change in the size of the injury on the scan from day 0 to day 14. It is expected to finish in February 2027.",
{
"type":"source",
"id":"s6"
},
"Until that reads out, there is nothing controlled in a human for any soft-tissue injury. Not weak data. None.\n\n## Rats: what happened, in which tissue, at what dose\n\nThe animals in every study below were young, healthy, and injured on purpose.\n\n### A rat Achilles torn off the bone came back mechanically stronger\n\nThe join between tendon and bone is the hardest soft-tissue repair in the body and the one that most often fails. In rats whose Achilles tendon was surgically cut off the heel bone, BPC-157 raised the load the repair could take before failing, its stiffness and its springiness, all significantly above untreated animals. Under the microscope the collagen fibres were better lined up, there was more type I collagen — the strong, rope-like kind — and more blood vessels had grown in. Dose was 10 µg/kg, 10 ng/kg or 10 pg/kg into the belly cavity once a day, starting 30 minutes after surgery.\n\nThe same paper carries the finding most relevant to anyone who has already had a cortisone shot: the steroid 6α-methylprednisolone consistently made the healing worse, and BPC-157 substantially undid that damage.",
{
"type":"source",
"id":"w_59xoi0m3"
},
"### Cut a ligament, crush a muscle, or sever the join between them — all three healed faster\n\nThe ligament model cut through the medial collateral ligament in rats and followed them 90 days. Treated animals came out ahead on four separate measures at once: how the leg worked, how strong the ligament was, how it looked to the eye, and how it looked under the microscope. Three different ways of giving it each worked — injection into the belly cavity at 10 µg/kg or 10 ng/kg daily, a cream at 1.0 µg per gram rubbed on, and plain drinking water at 0.16 µg/mL.",
{
"type":"source",
"id":"w_ccsq5zep"
},
"The muscle model both cut through and crushed the rat calf muscle, and deliberately gave the animals a steroid to wreck the healing. The authors' finding is that BPC-157 completely reversed that steroid damage, given either by injection or as a cream, with the leg working normally again in treated animals.",
{
"type":"source",
"id":"w_gttxaz57"
},
"The place where muscle turns into tendon — a classic site of grumbling strain that never settles — got its own study. In treated rats the injured leg's stiffening resolved completely, while untreated animals stayed disabled. The muscle wasting seen in untreated animals was prevented. By days 28 to 42 the new tissue ran in the right direction instead of being bridged by scar. Both the microgram and the nanogram doses worked.",
{
"type":"source",
"id":"w_urj74cu2"
},
"The biggest recent study, from January 2025, pulled the quadriceps entirely off its bony anchors and then treated the rats only through their drinking water. The vastus muscles reattached as early as 21 days. Rectus femoris was back to normal anatomy at about 28 days. At three months the mature fibres ran parallel to the bone and sat right against it. Reattachment was tracked on ultrasound — the same imaging used on people.",
{
"type":"source",
"id":"w_67ce14vu"
},
"The review that swept this whole literature screened 544 papers and kept 36. Thirty-five of the 36 were animal or lab work. Across muscle, tendon, ligament and bone the results point the same way: better function, better structure, better mechanical strength. The same authors put the counterweight in the same breath — harm is possible from unregulated manufacturing, contamination, and the fact that safety in people is unknown.",
{
"type":"source",
"id":"w_bburqn2u"
},
"### A cut sciatic nerve regrew faster, which is the nearest thing to a nerve finding\n\nRats with a completely severed sciatic nerve got 10 µg/kg or 10 ng/kg into the belly cavity, into the stomach, locally at the repair site, or loaded straight into the tube bridging a removed segment. Self-mutilation of the dead-feeling limb — the standard sign that a rat's nerve pain is bad — did not happen in treated animals. Electrical testing showed stronger muscle signals. Weekly walking tests improved. Counting fibres under the microscope found more of them, thicker, with better insulation around them, at one to two months.",
{
"type":"source",
"id":"w_032xvatb"
},
"It is a nerve cut clean through and sewn back together, not a nerve under slow mechanical compression. No study of BPC-157 in a compressed nerve has ever been published. The difference is not a technicality: a cut-and-repaired nerve regrows along a clear path, while a compressed nerve has to survive a mechanical problem that is still present. Different problems, different bottlenecks.\n\n### The two spinal studies squash the cord, and both used doses a hundred times higher\n\nTwo rat spinal-cord studies exist. Both compress the cord itself.\n\nThe 2019 study opened the spine at L2–L3 and compressed the tail end of the cord for 60 seconds, then gave a single injection into the belly cavity ten minutes later at 200 µg/kg or 2 µg/kg. Treated rats got progressively better tail movement, did not self-mutilate, and their spasticity had resolved by day 15, with less swelling and fewer dead motor nerve cells in the grey matter.",
{
"type":"source",
"id":"s127"
},
"The 2022 follow-up is the more interesting one, because it waited before treating. After a one-minute squash by a 60–66 g weight that definitely paralysed the tail, one group got 2 µg/kg into the belly cavity at ten minutes. A second got a 10 ng/kg dose into the stomach on day 4. A third drank 10 µg/kg in water from day 4 to day 30. Recovery was described as fast and lasting out to a full year, with only patchy swelling, minimal bleeding and no loss of nerve insulation at day 30. Treatment started four days late still worked — which matters, because nobody turns up at a clinic ten minutes after their back goes.",
{
"type":"source",
"id":"w_dmscp9sw"
},
"The doses used in the spinal work run up to a hundred times the doses used in the tendon work, so no number carries across between them.\n\n## How the compound is supposed to build tissue back\n\nBPC-157 raises the signals that grow new blood vessels at an injury. New vessels bring oxygen and repair cells to tissue that had neither. Alongside that, it pushes collagen production and gets tissue-building cells to crawl into the gap.\n\nThe receptor step has been worked out in detail. In the cells that line blood vessels, BPC-157 makes the cell pull VEGFR2 — the main docking point for the body's chief vessel-growing signal — inside itself, and then switches on the VEGFR2–Akt–eNOS chain over time. Block the pulling-inside step with a chemical called dynasore and the whole effect disappears, which means the pulling-inside is required, not incidental. Vessel density went up both in a dish and in living animals, and blood flow came back faster in muscle that had been starved of it.",
{
"type":"source",
"id":"w_fo79e9nk"
},
"The crawling step has its own named mechanism. In tissue-building cells taken from rat tendon, BPC-157 dose-dependently added phosphate groups to two proteins, FAK and paxillin, which are the machinery a cell uses to grip a surface and haul itself along. The total amount of those two proteins did not change; only the switched-on fraction rose. The same study found the cells were not making more of themselves, so the effect is cells moving and surviving, not cells multiplying in number.",
{
"type":"source",
"id":"w_ud0jx8hb"
},
"A third mechanism sits underneath both. Tendon cells given BPC-157 at 0.5 µg/mL grew about seven times more growth hormone receptors by day three, measured both as the instruction and as the finished protein. The cell does not get more growth hormone. It gets better at hearing the growth hormone already going past.",
{
"type":"source",
"id":"w_y4s15wvm"
},
"Nitric oxide — the gas that makes vessels widen — is pushed up in some situations and down in others, always paired with mopping up damaging free radicals. The Zagreb group reads that two-way behaviour as the whole point of the molecule: it pushes tissue toward normal rather than in one fixed direction. FDA reads the same observation as the reason no dose-response curve has ever been drawn for it. Both readings fit the data.",
{
"type":"source",
"id":"s38"
},
"Read the chain against the tissues it has been tested in. New vessels: shown in cells and in rats. Vessels feeding a starved tissue: shown in muscle. Cells restarting production of the molecules that hold water in a matrix: never studied for this compound, in any tissue.\n\n## The painkiller you are probably already taking runs the opposite way to expected\n\nMost people who arrive with back pain are already on an anti-inflammatory, and most compounds interact badly with those. This one was studied as an antidote to them.\n\nDiclofenac at 12.5 mg/kg into the belly cavity once daily for three days produced severe stomach, gut and liver damage in rats, raised bilirubin, AST and ALT, made the liver heavier, and caused prolonged drowsiness that progressed to liver-driven brain failure with brain swelling and damaged nerve cells. BPC-157 blocked that entire cascade at both the microgram and the nanogram dose, given either by injection or in drinking water.",
{
"type":"source",
"id":"w_odtbasyy"
},
"Read carefully, that is a gut-and-liver protection finding, not proof that combining the two heals a tendon better. What it does mean is that the medicine most likely to already be in the room is not, in rats, a documented problem.\n\nThe steroid interaction is the more consequential one. Two separate studies show BPC-157 undoing the damage a corticosteroid does to healing tendon and muscle. In animals a steroid injection measurably impaired the repair it was given for, and this compound reversed that impairment.\n\n## It is gone from your blood in about fifteen minutes\n\nThe only published measurements of what the body does to this compound come from rats and beagles.\n\nAverage time to clear half of it: 15.2 minutes. In dogs given it into a vein, 5.27 minutes. Peak level in the blood arrived three minutes after an injection into muscle. How much reaches the blood after an injection into muscle (bioavailability) was 14–19% in rats and 45–51% in dogs — wildly different between two species, and far from all of it. It leaves in urine and bile. Levels in kidney, liver, stomach wall, thymus and spleen went well above the level in blood.",
{
"type":"source",
"id":"w_n7ahbrni"
},
"A compound cleared that fast cannot be working by keeping a steady level in your blood. Whatever it does, it does fast and locally, then sets off a slower tissue process that outlasts the exposure by weeks. Two practical things follow. First, that is the argument for splitting a daily dose rather than taking it all at once. Second, a once-a-week schedule has nothing behind it.\n\nNo measurement of any of this has ever been made in a person. Every number above comes from a rat or a dog and is carried across species by assumption.\n\n## Turning powder into a dose\n\nBPC-157 arrives as a freeze-dried white powder in a sealed glass vial, usually 5 mg or 10 mg. You add liquid to it. The liquid is bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is the thing that lets you put a needle into the same vial repeatedly over weeks. Plain sterile water dissolves the powder fine but has no preservative, so that vial is a one-time proposition.\n\nThe measuring device is a U-100 insulin syringe. U-100 means 100 units in a millilitre, so one unit on the barrel is 0.01 mL. Every conversion you will ever need comes from two lines:\n\n- Micrograms per mL = total micrograms in the vial ÷ mL of water you added.\n- Micrograms per syringe unit = that number ÷ 100.\n\nWorked through: a 10 mg vial holds 10,000 mcg. You add 2 mL of bacteriostatic water. 10,000 ÷ 2 = 5,000 mcg per mL. 5,000 ÷ 100 = 50 mcg in one unit. A 250 mcg dose is therefore 250 ÷ 50 = 5 units on the barrel.\n\n| Vial | Water added | Strength | Mcg per unit | Units for 250 mcg | Units for 500 mcg | Doses in the vial at 250 mcg |\n|---|---|---|---|---|---|---|\n| 5 mg (5,000 mcg) | 2.0 mL | 2,500 mcg/mL | 25 | 10 | 20 | 20 |\n| 5 mg (5,000 mcg) | 2.5 mL | 2,000 mcg/mL | 20 | 12.5 | 25 | 20 |\n| 10 mg (10,000 mcg) | 2.0 mL | 5,000 mcg/mL | 50 | 5 | 10 | 40 |\n| 10 mg (10,000 mcg) | 3.0 mL | 3,333 mcg/mL | 33.3 | 7.5 | 15 | 40 |\n| 10 mg (10,000 mcg) | 5.0 mL | 2,000 mcg/mL | 20 | 12.5 | 25 | 40 |\n\nAdding more water does not add or remove peptide. The vial holds what it holds. More water only changes how many syringe units carry a given dose. More water gives you bigger, easier-to-read unit counts and a slightly bigger squirt going in. Less water gives you a smaller sting and finer lines to misread. Below about 5 units per dose, the error in reading a U-100 barrel starts to swamp the dose itself — which is the practical argument for putting 3 mL rather than 2 mL into a 10 mg vial.\n\nRuining the peptide by accident is easy. Let the vial come to room temperature first. Run the water slowly down the inside wall of the glass rather than blasting it onto the powder. Swirl until it dissolves. Never shake it — shaking tears at the surface where liquid meets air, which unfolds peptide chains and makes them clump together, and clumping is the exact thing FDA named as the trigger for the immune system reacting to it (immunogenicity).\n\n## A mixed vial lasts about four weeks\n\n| State | Temperature | How long it actually lasts |\n|---|---|---|\n| Sealed, still a powder | 2–8 °C, out of the light | Months to years, to the maker's date; −20 °C for long holding |\n| Mixed with bacteriostatic water | 2–8 °C | About four weeks — that limit is set by the preservative, not the peptide |\n| Mixed, left on the counter | 20–25 °C | Hours to days; treat it as ruined |\n| Mixed, then frozen | −20 °C | Do not. Freezing and thawing clumps the peptide |\n\nDo the arithmetic against your own plan before you buy. A 10 mg vial at 250 mcg a day is 40 doses. Four weeks is 28 doses. You will throw away roughly a third of the vial, or you must buy a smaller one, or take more per day. There is no fourth option — refreezing it is the one thing that definitely damages it.\n\n## No study compares injecting near the injury against injecting anywhere else\n\nTwo placements compete and the animal work cannot referee between them, because rats were dosed into the belly cavity, into the stomach or rubbed on the skin, almost never at a specific human-style injection site.\n\n- **Under the skin, near the sore part.** What most people do. The argument is a higher concentration where the repair is needed, which fits a 15-minute clearance and fits tissue levels running above blood levels.\n- **Under the skin of the belly, anywhere.** Standard for gut, nerve and organ targets, and easier to do to yourself. The argument is that a compound reaching kidney, liver and stomach wall above blood level obviously travels, so the entry point may not matter.\n\nThe evidence tilts slightly toward the entry point not mattering. Several of the strongest structural results in the entire literature — the cut ligament, the muscle-tendon junction, the quadriceps reattachment, the sciatic nerve, the spinal cord — were produced in rats that simply drank the compound and still repaired a specific injury a long way from their gut. Nothing anywhere in the record shows a local injection beating a systemic one head to head.\n\nHere are the doses that exist, all of them either from rats or scaled up from rats:\n\n| Where the number comes from | The dose | How long |\n|---|---|---|\n| The standard rat tier | 10 µg/kg, 10 ng/kg or 10 pg/kg once a day | For as long as the study ran |\n| The rat drinking-water equivalent | 0.16 µg/mL in water, about 12 mL per rat per day | For as long as the study ran |\n| Scaling 10 µg/kg straight up to a 70 kg adult | about 0.7 mg per day | Not an established human dose. Just arithmetic |\n| Given to humans into a joint, published | 2–4 mg per injection, 1–2 injections | One course |\n| Given to humans by mouth, published (2015 Phase 1) | 1, 3 or 6 mg once; then 3 mg every 8 hours | Two weeks |\n\nThere is no validated human dose, no validated cycle length, no taper and no ceiling. USADA states it without softening: nobody knows whether a safe dose exists, or whether there is any way to use this compound safely for a named condition.",
{
"type":"source",
"id":"w_af5ht9pr"
},
"Every dose ever given to a human in a published study is measured in **milligrams**. Scaling the standard rat dose up to an adult lands at roughly 0.7 mg. The regimens circulating on forums and printed on vendor sites are measured in **micrograms** — a thousandth of a milligram — and land around 250 to 500 mcg. That is roughly a hundredth of anything ever formally given to a person. Nothing in the literature supports the microgram regimens. Nothing in the literature refutes them either. The dose question is not contested; it is simply open, and everyone taking it is guessing.\n\n## The tablet and the vial are not the same product\n\nSwallowed BPC-157 exists as capsules or tablets, commonly 500 mcg each, and the stomach-survival finding is what makes that format arguable at all. But surviving your stomach acid and getting into your bloodstream are two separate questions, and only the first has ever been shown in a person.\n\n| | Tablet you swallow | Vial you mix and inject under the skin |\n|---|---|---|\n| What is actually proven about this route | Survives human stomach juice past 24 hours | In rats, 14–19% of an injection into muscle reaches the blood; in dogs, 45–51% |\n| Animal evidence using this route | Substantial — the ligament, muscle-tendon junction, quadriceps reattachment, nerve and spinal cord studies all worked with the compound given by mouth or in water | Extensive, but nearly all of it into the belly cavity rather than under the skin |\n| What has been given to humans this way | 1–6 mg by mouth in the 2015 Phase 1; 80 mg per enema in the colitis trial | 2–4 mg into a joint; 10–20 mg into a vein |\n| Best-supported target | The gut, and any whole-body target where the rat drinking-water arm worked | Musculoskeletal — by convention, not by any head-to-head comparison |\n| How much gets into a human's blood | Never measured | Never measured |\n| What it costs you in practice | No needles, no mixing, no four-week clock | Needles, arithmetic, a fridge, and a four-week clock |\n\nThe evidence is friendlier to the swallowed route than the injection convention implies. Several of the strongest structural repair results in the whole corpus — ligament, muscle-tendon junction, muscle reattached to bone, delayed spinal cord recovery — came from rats drinking it in water. What nobody has is a measurement of how much of a swallowed dose gets into a human's blood, so choosing between the two forms rests on rat route data and on convenience, not on anything measured in a person.\n\n## How long anything would take, if it worked\n\nTimelines here are set by tissue biology, not by the compound. Collagen remodels at the speed collagen remodels. Nerves regrow at about a millimetre a day. Nothing changes that.\n\n| Model | Time to the reported result |\n|---|---|\n| Squashed spinal cord, spasticity gone | 15 days |\n| Quadriceps reattached to bone, vastus muscles | 21 days |\n| Quadriceps reattached to bone, rectus femoris | ~28 days |\n| Muscle-tendon junction, tissue running the right way | 28–42 days |\n| Cut sciatic nerve, function and microscope findings | 1–2 months |\n| Cut medial collateral ligament, full follow-up | 90 days |\n| Hamstring tear Phase 2, injury size on scan | 14 days (the primary measure; reads out 2027) |\n\nNo human timeline has been established, because no controlled human trial has finished.\n\nThe honest inference: these are collagen and nerve timescales, four to twelve weeks. A result reported inside a fortnight is pain relief, not repair. Pain relief arrives before tissue has been rebuilt, so a change in symptoms at day 10 says nothing about the structure.\n\n## FDA's own toxicology is more specific than the safety talk around it\n\nThe Zagreb group's stated position is that BPC-157 is very safe, with no side effects in trials and a lethal dose never reached in toxicology work. FDA read the same body of work and described it differently.\n\nIn 28-day repeat-dose studies injecting into muscle, rats showed shortened clotting time and dogs showed lengthened clotting time on the same test — an unexplained effect on clotting that runs in opposite directions in two species. Blood ALT, glucose and triglycerides went up. No cancer-causing study of BPC-157 in either of its two chemical forms has ever been done. It did not damage DNA, and no birth-defect signal appeared when it was injected through gestation days 6–15.\n\nFDA raised four objections. They are independent of each other, which means answering one leaves the other three standing.\n\n| The objection | What it actually means |\n|---|---|\n| Not enough clinical safety information to describe the safety profile | The human safety file is too small to draw a picture from — not \"reassuring so far\", but too small to say anything |\n| Real risk that the immune system reacts to it, made worse by clumping and by peptide impurities | Part of the risk comes from how it is made and handled, not from the molecule alone |\n| No dose-response relationship established | The flat pattern where micrograms, nanograms and picograms all work reads to FDA as a weakness, not a feature |\n| No molecular target identified | Despite the VEGFR2 and FAK work, no confirmed receptor has been pinned down |",
{
"type":"source",
"id":"w_9qu2rfyq"
},
"## The cancer question has a real answer and a real hole in it\n\nThe worry is mechanically sensible. A tumour cannot grow past a millimetre or two without recruiting new blood vessels. A compound whose headline action is growing new blood vessels could, in principle, supply them. An independent 2025 review states the worry and lands on the practical version of it: a cancer nobody has found yet.",
{
"type":"source",
"id":"w_uhm2s5ar"
},
"The Zagreb group published a formal rebuttal in the same journal. Their case is that BPC-157 strongly *blocked* vessel growth into the cornea, that it has shown anti-tumour activity both in living animals and in a dish, and that its nitric oxide effect is always paired with mopping up free radicals — that it pushes vessel growth toward the normal, self-limiting kind rather than driving it indiscriminately.",
{
"type":"source",
"id":"s131"
},
"Where that leaves you: no published rodent study shows BPC-157 speeding up tumour growth. No cancer-causing study exists. There is zero human cancer safety data. An active or suspected cancer is the one situation the mechanism itself argues against, and the missing study means the argument cannot be closed either way. If you have had a cancer, this is the question to take to your oncologist rather than to a forum.\n\n## FDA said no, and its own advisory committee said yes by two votes\n\nThe regulatory position moved twice during 2026, and most summaries you will find online are stale.\n\n| Date | What happened |\n|---|---|\n| Sept 2023 | FDA puts BPC-157 in Category 2 of the 503A bulk-substances list — significant safety risk, which bars compounding pharmacies from making it |\n| 14 May 2026 | The revised interim list carries only six substances in Category 2. BPC-157 is in none of Categories 1, 2 or 3 — the nominations were withdrawn |\n| July 2026 | FDA's own briefing document recommends against adding BPC-157 to the 503A list |\n| 23 July 2026 | The Pharmacy Compounding Advisory Committee votes 8–6, with one abstention, to recommend adding it — against FDA's own staff |\n\nIf a page you are reading still says BPC-157 is FDA Category 2, it has not been updated since 14 May 2026.",
{
"type":"source",
"id":"w_ghpbaz64"
},
"One detail in the meeting agenda changes what that vote means. The only condition FDA evaluated was ulcerative colitis. Tendonitis was among the uses put forward, and FDA declined to evaluate it because there was not enough information. A favourable vote about a bowel condition is not a favourable vote about tendon or disc repair, and it is being quoted as though it were.",
{
"type":"source",
"id":"w_38qd7eam"
},
"The committee itself was not persuaded of much. One panelist who voted yes described the thing being voted on as a black box. One who voted no pointed out that roughly 30% of people given a dummy treatment report improvement — sometimes even on objective measures — which is the entire difficulty with the uncontrolled reports the nomination rested on.",
{
"type":"source",
"id":"w_oje4lc91"
},
"Reporting on the meeting noted that a majority of the panelists voting yes had ties to the peptide industry.",
{
"type":"source",
"id":"w_lkfuwkh8"
},
"The vote creates no authority. It is advisory, FDA is not bound by it, and a formal rulemaking cycle realistically runs eight to twelve months.",
{
"type":"source",
"id":"s129"
},
"## There are two legal ways to compound a peptide and BPC-157 is on neither list\n\n503A covers traditional compounding pharmacies. 503B covers registered outsourcing facilities, and it is a separate list with a separate standard: an outsourcing facility may not compound with a bulk substance unless that substance is on the 503B list, or the finished medicine is on FDA's drug shortage list at the time. BPC-157 is not on the 503B list, and the July 2026 vote concerned 503A only.",
{
"type":"source",
"id":"w_iff2eacs"
},
"That same page sets out what FDA expects of any lawfully compounded substance: a valid certificate of analysis, manufacture by an establishment registered under section 510 of the FD&C Act, and compliance with any applicable USP or National Formulary monograph. Grey-market BPC-157 meets none of the three.\n\n## If you compete in anything, this is a strict-liability problem\n\nBPC-157 is named explicitly on the WADA 2026 Prohibited List under S0, Non-Approved Substances, banned at all times — not just on competition day. S0 covers any substance with no current approval by any government health authority for human use anywhere, which is exactly what BPC-157 is.",
{
"type":"source",
"id":"w_u19qrezt"
},
"Strict liability means you are responsible for what is in your body regardless of intent and regardless of who recommended it. That applies at college, professional and masters level, in sports most people do not think of as drug-tested.\n\nThe Department of Defense goes further. Its Operation Supplement Safety programme lists BPC-157 on the Prohibited Dietary Supplement Ingredients List and states the position flatly: BPC-157 is not a dietary ingredient, it is an unapproved drug. That applies to service members however it is taken.",
{
"type":"source",
"id":"w_h2eu8h3c"
},
"## \"Research use only\" is a shipping label, not a legal category\n\nNearly all BPC-157 sold to the public is labelled a research chemical, not for human consumption. That phrase creates no lawful route to a person. It is a disclaimer attached to a product with no legal standing as a medicine, a food or a supplement in the United States. USADA names the tell directly: sites that print \"research only\" while also printing human dosing instructions are describing what they expect to happen.\n\nThe purity problem is the concrete risk, and it is bigger than the legal one. Independent testing of grey-market peptide samples finds mislabelling, wrong dosing or contamination in roughly 30%, and the contaminant classes are specific: bacterial toxins, incomplete chains that are missing pieces, leftover solvents, heavy metals, live microbes and breakdown products. Incomplete chains and clumping are the same two failure modes FDA named as the things that make an immune reaction more likely — which means the supply-chain risk and the drug risk are the same risk wearing two hats.",
{
"type":"source",
"id":"w_macsi7l3"
},
"> 30% contained incorrect amino acid sequences and two-thirds of samples fell below the 95% purity threshold.",
{
"type":"source",
"id":"s130"
},
"A certificate reading \"99% by HPLC\" does not clear a batch, and understanding why is worth two minutes. HPLC confirms the target peptide is there and measures how much of the total it is. It says nothing about what the other 1% consists of. An incomplete chain or a fever-causing bacterial toxin sits inside that remainder and never shows up. What you want is HPLC *and* mass spectrometry, done per batch, by a laboratory that is not the seller. A vendor's own certificate is not third-party testing, and a certificate photographed from a different batch is not a certificate at all.\n\n## Which problems the evidence actually reaches\n\nEvery positive animal model in this literature is an acute surgical injury — a tendon cut through, a ligament severed, a muscle crushed, a tendon torn off bone, a nerve cut. There is no rat model of a fifteen-year grumbling tendon, and no reason to assume a repair signal helps tissue whose problem is failed remodelling rather than an unfilled hole.\n\n| Your problem | What the animal data actually covers | How strong |\n|---|---|---|\n| Fresh tendon tear or rupture | Achilles cut through and torn off bone: strength to failure, stiffness, type I collagen all improved | Strongest animal case |\n| Tendon pulling off bone | Achilles detachment and quadriceps reattachment, confirmed on ultrasound at 21–28 days | Strong in animals, nothing in humans |\n| Ligament sprain | Medial collateral ligament cut through, 90-day follow-up, four measures | Strong in animals, nothing in humans |\n| Fresh muscle strain | Calf muscle cut and crushed; the one Phase 2 trial targets a grade II hamstring | Animals plus one trial reading out 2027 |\n| Pain where muscle becomes tendon | Its own rat model; stiffening resolved, wasting prevented | Strong in animals, nothing in humans |\n| Healing spoiled by a cortisone shot you already had | Two studies show the steroid damage to tendon and muscle healing reversed | Animals, directly relevant, nothing in humans |\n| You are on daily anti-inflammatories | Diclofenac damage to gut, liver and brain fully blocked | Animals; a protection finding, not a repair finding |\n| Nerve cut and surgically repaired | Sciatic nerve: electrical signals, walking, insulation all improved | Moderate in animals, nothing in humans |\n| Long-standing overuse tendon pain | No model exists. Every positive study is a fresh injury | Weak — the mechanism does not obviously apply |\n| Carpal tunnel or other trapped nerve | No compression model exists | Absent |\n| Herniated lumbar disc, sciatica | No disc model exists. Nearest thing is a squashed rat spinal cord at a 100× dose | Absent |\n| Degenerative disc disease itself | Nothing. Not one study, in any species | Absent |\n\nThe cortisone-reversal row is the most useful finding in the entire animal literature, because a large share of people with a bad back arrive having already had a steroid injection that measurably worsened the healing they came in for. If any part of this compound's animal record applies to you, that is the part with the clearest logic behind it.\n\nThe long-standing-tendon-pain row is weak exactly where demand is highest.\n\n## Fifty people said what happened to them, and here is the count\n\nThis page holds 50 first-person accounts posted publicly between 2015 and 2026 — 40 on Reddit across r/Peptides, r/steroids, r/backpain, r/Sciatica, r/climbharder, r/PEDs, r/Biohackers, r/moreplatesmoredates, r/PeptideGuide, r/Peptidesource and r/Supplements, and 10 on X. Every one is self-reported by a person you cannot identify or question. Nobody assayed their vial, so the substance in the syringe is unknown in every single case. Nobody was randomly assigned. Almost nobody scanned the injury before and after. People who got better write posts more often than people who did not, so the set is filtered before you even read it.\n\nIt is here for one reason. No controlled trial in a human musculoskeletal injury has ever finished, so this is the entire record of people using it for the reasons you are considering it — and it is what you have already read by the time you got to this page.\n\n### The count, with the denominator\n\nOf the 50 accounts, 13 report no personal result at all — they are protocols, questions, general threads about the science, or one person's dosing accident. That leaves **37 accounts that state what happened to the person writing**. Here is the split:\n\n| What they reported | Count | Share of the 37 |\n|---|---|---|\n| It helped — clear improvement they credit to it | 18 | 49% |\n| Partly, or it faded, or they could not separate it from other things | 5 | 14% |\n| Nothing happened | 10 | 27% |\n| It made something worse | 4 | 11% |\n\nHalf of the people who reported an outcome said it helped, and half did not. If you have seen this compound described online, you have almost certainly seen a version of that record where the 14 accounts reporting nothing or harm were left out. That version is a lie by selection, and it is the standard version.\n\nFour more things the raw count hides.\n\nThe 10 \"nothing happened\" accounts are not shorter courses or smaller doses than the successes. Several ran six weeks or more at the same 500 mcg a day that the successes ran.\n\nThe 4 harm reports describe things the rat toxicology gives no reason to expect and the five human studies were far too small to catch: a joint that got worse and inflamed, vision going blurry over weeks, a finger swelling with fluid, and leg pain returning during treatment for a herniated disc.\n\nOne account reports a ten-fold dosing accident, which is a safety datapoint of its own and the reason the reconstitution arithmetic earlier on this page matters more than it looks.\n\nAnd exactly one account in 50 reports an objective check by a clinician. One. Everybody else is reporting pain, movement and confidence — the three things most responsive to time, rest and expectation.\n\n### The 18 who said it helped",
{
"type":"source",
"id":"w_xmo3vo5n"
},
{
"type":"source",
"id":"w_xypc4fgc"
},
{
"type":"source",
"id":"w_ihoinuk1"
},
{
"type":"source",
"id":"w_iquapnzf"
},
{
"type":"source",
"id":"w_vhlzhg4n"
},
{
"type":"source",
"id":"w_mez2amn7"
},
{
"type":"source",
"id":"w_z8sd87d2"
},
{
"type":"source",
"id":"w_5icolfqk"
},
{
"type":"source",
"id":"w_8uy508st"
},
{
"type":"source",
"id":"w_e1ub04di"
},
{
"type":"source",
"id":"w_as6ue9dv"
},
{
"type":"source",
"id":"w_e8sw6xul"
},
{
"type":"source",
"id":"w_qqu8pdaq"
},
{
"type":"source",
"id":"w_q512lyfs"
},
{
"type":"source",
"id":"s82"
},
{
"type":"source",
"id":"s83"
},
{
"type":"source",
"id":"s93"
},
{
"type":"source",
"id":"s101"
},
"The account crediting a clinician with saying the tear was gone is the single best entry in the whole set, and even that was a re-examination, not a repeat scan. And the account that asks itself \"is this placebo?\" also added collagen and more protein in the same window, which the writer says outright — that honesty makes it more useful than the confident ones, not less.\n\n### The 5 who got part of a result, or lost it",
{
"type":"source",
"id":"w_sg898nqt"
},
{
"type":"source",
"id":"w_vljlka3r"
},
{
"type":"source",
"id":"w_q3b1i12c"
},
{
"type":"source",
"id":"w_iqb7rlvn"
},
{
"type":"source",
"id":"w_brwijbo1"
},
"The last one is a pattern with no counterpart anywhere in the published literature: the effect fading on a steady dose, then not returning when the dose was raised. Nothing in the rat work predicts that. Nothing in the pharmacology explains it.\n\n### The 10 who said nothing happened\n\nThese are the entries marketing copy leaves out. They are the same doses, the same durations, and several of them are longer courses than the successes.",
{
"type":"source",
"id":"w_jdqqio36"
},
{
"type":"source",
"id":"w_fhil2can"
},
{
"type":"source",
"id":"w_8dxl599w"
},
{
"type":"source",
"id":"w_0t8zcb1s"
},
{
"type":"source",
"id":"w_txuoas2j"
},
{
"type":"source",
"id":"w_9l5g0ldo"
},
{
"type":"source",
"id":"w_8kdirxz8"
},
{
"type":"source",
"id":"w_18w5khoc"
},
{
"type":"source",
"id":"w_hf6dcwyh"
},
{
"type":"source",
"id":"w_mjx06qhj"
},
"The standard reply offered inside these threads to a negative report is that the person got a bad vial. That reply cannot be checked — nobody in this set tested their product — and it is the exact mechanism by which a grey-market compound builds a record that can never fail. Every success counts as evidence; every failure counts as a counterfeit.\n\n### The 4 who got worse",
{
"type":"source",
"id":"w_epyzmnva"
},
{
"type":"source",
"id":"w_ucf38h39"
},
{
"type":"source",
"id":"w_usaqx7am"
},
{
"type":"source",
"id":"w_0d8jnd1s"
},
"The first is a harm report during a course taken for a herniated disc: leg pain returning and worsening on treatment.\n\nThe second describes one joint improving while another got inflamed and worse in the same person, on the same dose, in the same course.\n\n### The dosing accident, and where the numbers came from",
{
"type":"source",
"id":"w_wnund5ki"
},
"That is ten times the intended dose, caused by misreading a syringe barrel. Nobody was hurt. It is on this page because the numbers everyone uses have nothing under them, and the people using them say so plainly:",
{
"type":"source",
"id":"w_o9okgjxa"
},
{
"type":"source",
"id":"w_mzg8md2j"
},
{
"type":"source",
"id":"w_xk3kn65m"
},
{
"type":"source",
"id":"w_1t3oc07y"
},
"Almost every account in the set describes 250 to 500 micrograms a day, under the skin, sometimes split into two or three shots, run for four to eight weeks. That band converged by copying, not by measurement. It is about a hundredth of the milligram doses used in every published human study.\n\n### The 13 that report no outcome at all — including the six loudest posts here\n\nThirteen of the 50 accounts state no personal result. Seven are the protocols and dosing arguments already shown above. The other six are X posts, and they are worth looking at separately, because they are almost certainly the format in which most people first meet this compound.",
{
"type":"source",
"id":"s88"
},
{
"type":"source",
"id":"s89"
},
{
"type":"source",
"id":"s99"
},
{
"type":"source",
"id":"s100"
},
{
"type":"source",
"id":"s95"
},
{
"type":"source",
"id":"s96"
},
"Four are summaries of the animal literature written in the voice of personal endorsement — \"repaired 5 different tissues\", \"no compound heals as many tissue types\" — with a dose attached at the end and no report of the writer's own outcome anywhere in them. One is a person asking for an alternative. One is a person saying they never took it but wish they had.\n\nThey are in this count because leaving them out would be dishonest, and they are separated out because counting them as successes would be worse. The most confident writing about this compound contains the least first-hand information in it, and that is the single most useful thing this section can tell you.\n\n### Where the accounts contradict the animal work\n\nThe animal record is strongest for fresh injuries and weakest for long-standing tendon pain.\n\nThe forum record inverts that. Long-standing elbow, wrist and shoulder tendon pain of one to five years' standing is the most common thing people treat, and spinal complaints — where no animal model exists — generate some of the most emphatic success reports.\n\nThe most emphatic of those accounts describes pain easing over six to seven weeks of injections after everything else had failed, and it is the one with the least behind it, because no animal study covers that tissue.\n\nTwo readings fit and the accounts cannot separate them. Either the compound reaches structures the animal work never tested, or long-standing pain that comes and goes was going to improve anyway and the compound arrived during a good month. Spontaneous improvement over roughly six to twelve weeks is well documented for several of these complaints, and that is exactly the window these protocols run.\n\nThe swallowed route contradicts the pharmacology the same way. Surviving stomach acid is proven; getting into a human's blood from the gut is not. People report the two forms doing different jobs, which is precisely what you would expect if the tablet works locally in the gut and never reaches a tendon at all.",
{
"type":"source",
"id":"w_1bbc6bfn"
},
"### The stacking problem, which is the biggest hole in the whole set\n\nAlmost nobody takes this alone. TB-500 is combined with it so routinely that a large share of these accounts cannot attribute any outcome to either compound. Others add growth hormone, testosterone, surgery, physiotherapy, diet changes and rest inside the same weeks.",
{
"type":"source",
"id":"w_ahk1cevh"
},
"The three most confident recovery stories on this page — the rotator cuff tear a clinician later called gone, the wrist rebuilt over seven vials, and the shoulder that felt 75% better in five days — were all run as BPC-157 plus TB-500, and two of them alongside structured rehab. Not one of them can tell you which part did the work.\n\nIt means a good share of the 18 positive accounts are reports about a combination, run alongside the two interventions with the best evidence in all of musculoskeletal medicine — load management and time.\n\n### What the counted record settles, and what it does not\n\nIt does not settle whether it works. Thirty-seven uncontrolled accounts filtered toward success are not weak evidence for a treatment effect; they are a different kind of object, and collecting three hundred more would change nothing about that. A 49% success rate in this set is not a 49% chance it works for you. It is a measurement of what people wrote down.\n\nIt does settle three things the published literature does not contain at all, and these are the reason it is worth counting rather than dismissing.\n\nFirst, the real exposure. People are running 250–500 mcg a day under the skin for four to eight weeks, usually stacked with TB-500. No trial has ever studied that exposure. When somebody eventually does, this is the regimen they should test, and nobody would know it from the papers.\n\nSecond, harms at that exposure. Four of 37 accounts report getting worse — local swelling, a joint becoming more inflamed, blurred vision, and returning nerve pain. None of those appear in any published human safety dataset, because those datasets total about 130 people across five studies and would not detect a 1-in-10 problem if it existed.\n\nThird, the mismatch. The two things people most often treat with it are long-standing tendon pain, which the animal literature supports least, and spinal complaints, which it does not cover at all.\n\nThe Phase 2 hamstring trial reading out in 2027 will answer the works-or-not question for one fresh injury in one muscle. Nothing currently running covers any spinal tissue.\n\n## What is settled about BPC-157, and what is not\n\n| Status | Statement |\n|---|---|\n| Settled | It survives human stomach juice for more than 24 hours |\n| Settled | It switches on the VEGFR2–Akt–eNOS chain and increases blood vessel density in a dish and in rodents |\n| Settled | It improves mechanical strength and microscope appearance across many fresh rat injuries |\n| Settled | It reverses the damage a corticosteroid does to tendon and muscle healing in rats |\n| Settled | It blocks diclofenac-caused gut, liver and brain damage in rats |\n| Settled | Half of it clears a rat's blood in about 15 minutes; 14–19% of an intramuscular dose reaches the blood in rats |\n| Settled | It is on the WADA 2026 Prohibited List under S0, banned at all times, in and out of competition |\n| Not shown | That it does anything for a musculoskeletal injury in a person — no controlled soft-tissue trial has finished |\n| Not shown | That a swallowed dose reaches the bloodstream of a human |\n| Not shown | That it feeds tumours — and equally not shown that it is safe if you have a cancer |\n| Unknown | The right human dose. Every published human study used milligrams; everyone taking it uses micrograms |\n| Unknown | Long-term safety, interactions with your other medicines, and why clotting time moves in opposite directions in rats and dogs |\n| Unknown | Whether any of this reaches a spinal disc. Nobody has looked, in any species |\n\n**The verdict, stated so it decides something.** For a fresh tear or detachment in tendon, ligament or muscle — and most of all for repair that a corticosteroid injection has already impaired — BPC-157 has the strongest animal case of any compound written up here: consistent across at least six injury models, mechanically explained down to the receptor step, and reproduced by three separate ways of giving it. Taking it for that, at 250–500 mcg a day under the skin for four to eight weeks, is a bet on rat evidence that is worth naming as a bet: no controlled human trial in any of those tissues has finished, and the first one reads out in February 2027. For long-standing overuse tendon pain, and for anything to do with a spinal disc, the answer is no — not \"unproven\", no. Every positive study in the whole literature is a fresh surgical injury, there is no animal model of a grumbling tendon, the two spinal studies squash a cord at up to a hundred times the tendon dose, and the disc has never been studied in any species. Those two are what it is most often bought for, and they are the two the evidence does not reach.\n\n*BPC-157 is not an approved medicine in any country. Everything sold to the public is grey-market and unverified. Nothing here is a dosing or treatment recommendation.*\n\n![[tb-500]]\n\n![[ara-290]]\n\n![[kpv]]\n\n![[wolverine-stack]]\n\n![[bpc-157-vs-nsaids]]\n\n![[what-are-peptides-herniated-disc]]\n\n![[herniated-disc]]"
],
"facts": {
"converted_from":"markdown",
"original_updated":"2026-09-06T15:27:35.043Z",
"register":"essay",
"category":null
},
"hero":"https://miscsubjects.com/img/gen/arcads-gpt-image-d93cb8ef-592b-4b12-9ea1-447135df3f93.png",
"model":"Fable 5 (Claude Code)",
"tags": [
"peptide",
"bpc-157",
"disc",
"tendon",
"gut"
],
"sources": [
{
"id":"s1",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/30915550/",
"title":"Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing",
"quote":"Currently, all studies investigating BPC 157 have demonstrated consistently positive and prompt healing effects for various injury types",
"summary":"Review summarizing consistent preclinical healing observations across injury models.",
"claim_ids": [
"c1",
"c67",
"c308",
"c310",
"c313",
"c317"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:26:03.386Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"mechanism_support",
"prev":"genesis",
"hash":"f624ee00ce42ab3fac3cd9496f3f03c440d3aaaa629543bead7f1b1e0ac0fd4b",
"quote_sha256":"07d500b5e56d03c34e9b61acc3be25c8d350c0e9726a45ce49c1c5440bbb616a"
},
{
"id":"s3",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40131143/",
"title":"Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study",
"quote":"Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated.",
"summary":"Pilot safety data in two participants; no measurable biomarker changes or side effects reported.",
"claim_ids": [
"c3",
"c11"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:26:03.386Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"adjacent_context",
"prev":"f624ee00ce42ab3fac3cd9496f3f03c440d3aaaa629543bead7f1b1e0ac0fd4b",
"hash":"e9ad77a3ef6f0a4e03befa49cb70a86806df8db50e9a96051ddf1688a6e64b6c",
"quote_sha256":"62a9cb8a150b38f765e384ba6ceeda39c832783caa2cfdde8f3f4f1bedb2bde3"
},
{
"id":"s4",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40789979/",
"title":"Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing",
"quote":"BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, positioning it as a potentially valuable tool in ...",
"summary":"Narrative review on BPC-157 for musculoskeletal healing, highlighting preclinical regenerative effects.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c11",
"c308",
"c309",
"c314",
"c317",
"c318"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:34:55.266Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"e9ad77a3ef6f0a4e03befa49cb70a86806df8db50e9a96051ddf1688a6e64b6c",
"hash":"3ce360d0e98db92d8beb66b0eb9271342c3f3f5138ff8dd9680014754f328e32",
"quote_sha256":"00abebfd026f76106cc9867349bbbde4b6c87604ae5517a5ead74095dabe2366"
},
{
"id":"s5",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40005999/",
"title":"Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review",
"quote":"BPC 157 , known as the \"Body Protection Compound\", is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects.",
"summary":"2025 literature and patent review on multifunctionality and medical applications of BPC-157.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c12",
"c308",
"c313",
"c317"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:34:55.266Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"3ce360d0e98db92d8beb66b0eb9271342c3f3f5138ff8dd9680014754f328e32",
"hash":"927dfcc38868fbcc13647944972af4cfe111c3bb753848505e5735891809bbb7",
"quote_sha256":"fbcdd08193add994239d212cf3f512bb486d4ca5c7bb370eb69ff254d2f2ae33"
},
{
"id":"s6",
"type":"pubmed",
"url":"https://clinicaltrials.gov/study/NCT07437547",
"title":"BPC 157 for Acute Hamstring Muscle Strain Repair",
"quote":"This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 ( BPC-157 ), an investigational peptide ...",
"summary":"Ongoing Phase 2 RCT for BPC-157 in acute grade II hamstring strain repair (published 2026).",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c13"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:34:55.266Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"adjacent_context",
"prev":"927dfcc38868fbcc13647944972af4cfe111c3bb753848505e5735891809bbb7",
"hash":"71ebec839015316135250415a048ef191c06863ccc5cb5295431ef1bb6341e46",
"quote_sha256":"5fc2d6977291461f58b07d05b83c73ca9bd84403c7c0b582f762edca3c6dbb1f"
},
{
"id":"s7",
"type":"pubmed",
"url":"https://journals.sagepub.com/doi/abs/10.1177/15563316251355551",
"title":"Emerging Use of BPC-157 in Orthopaedic Sports Medicine",
"quote":"The review looked at 36 studies published from 1993 to 2024. The findings showed that BPC-157 helps promote healing by boosting growth factors ...",
"summary":"2025 systematic review of 36 studies (mostly preclinical) on BPC-157 for musculoskeletal injuries.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c11",
"c308",
"c309",
"c314",
"c317",
"c318"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:34:55.266Z",
"link_status":"http_403",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"71ebec839015316135250415a048ef191c06863ccc5cb5295431ef1bb6341e46",
"hash":"9d192da31d82204fcf040771911071e1f18effe50e6bdd9823f28989c0007dfe",
"quote_sha256":"2b6794553356e9706d9554ac14e975df106812bcb47281f00e1b482a83978308"
},
{
"id":"s8",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11053547/",
"title":"The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity",
"quote":"This review highlights the particular aspects of the stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity",
"summary":"2024 PMC review on pleiotropic beneficial activity of BPC-157.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c15",
"c317"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:34:55.266Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"mechanism_support",
"prev":"9d192da31d82204fcf040771911071e1f18effe50e6bdd9823f28989c0007dfe",
"hash":"51ea06cef70f63e3a7dedb7fed55ac778d58c5fecfbbf02f94ba0435995774f5",
"quote_sha256":"91f6f0216117a042c6faadb69a2beb076eb718ce38714e155e2faba60f67235c"
},
{
"id":"s10",
"type":"youtube",
"url":"https://www.youtube.com/watch?v=HIrI8STJPJo",
"title":"Peptide BPC-157 - Does It Work? Breaking Down ...",
"quote":"I started taking BPC 157 and TB500 , my elbow tendinitis is almost gone. I really can't believe it.",
"summary":"YouTube video discussing BPC-157 efficacy with user anecdotes on tendon healing.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c17",
"c71",
"c309",
"c312",
"c316"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:34:55.266Z",
"link_status":"http_429",
"quote_status":"unverified",
"source_role":"anecdotal_report",
"prev":"51ea06cef70f63e3a7dedb7fed55ac778d58c5fecfbbf02f94ba0435995774f5",
"hash":"7718eaf22000d2353f049b7412f84bf30e62fc2a54918e24555dbb50c5380406",
"quote_sha256":"6f6389d9486bd07c569eefc178e8ea56555fb32bc4b84a2ef98e415508526ce8"
},
{
"id":"s11",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40756949/",
"title":"Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review",
"quote":"A total of 544 articles from 1993 to 2024 were identified. After duplicates were removed, 36 studies were included (35 preclinical studies, 1 clinical study). The studies suggest that BPC-157 enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis, while reducing inflammatory cytokines. In preclinical models, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries.",
"summary":"Systematic review of BPC-157 literature focusing on orthopaedic sports medicine; synthesizes preclinical benefits for musculoskeletal healing and limited human data.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c11",
"c308",
"c309",
"c314",
"c317",
"c318"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:35:14.329Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"mechanism_support",
"prev":"7718eaf22000d2353f049b7412f84bf30e62fc2a54918e24555dbb50c5380406",
"hash":"dce12504934e5e9b212084055d5259f3dfbec74618c2ee27345a30ffde88ca62",
"quote_sha256":"e9d909b5724d58f193edaaa857d87faf92d61e0fe98b2ad83c04c86cdd8d12b6"
},
{
"id":"s12",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40759852/",
"title":"Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT)",
"quote":"This article discusses the lengthy review by Pedrag Sikiric and twenty one (21) co-authors in Inflammopharmacology (2024) 32:3119-3161.",
"summary":"Commentary on a major 2024 review of BPC-157's cytoprotective and organoprotective effects, particularly in GIT and multiorgan failure models.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c19",
"c310",
"c317"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:35:14.329Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"mechanism_support",
"prev":"dce12504934e5e9b212084055d5259f3dfbec74618c2ee27345a30ffde88ca62",
"hash":"0920e75acdf2255a252f16f434f3b734ca126c5c6d8ae849324fa36c054980fd",
"quote_sha256":"288a7c0601fc6708c021df6069ee5e28ae30e7f7645d45e48e467968ffaf28f6"
},
{
"id":"s16",
"type":"x",
"url":"",
"title":"SELFTEST graph fn ingest",
"quote":"mixed BPC gut results; stopped after nausea week 2",
"summary":"Negative anecdote — selftest graph populate",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c23"
],
"found_by":"system/selftest",
"extra": {
"question_node_id":"qn_tb_500_selftest_graph_what_is_documented_about_t_2c5076f0",
"ingest_channel":"selftest"
},
"accessed_at":"2026-06-29T09:23:53.759Z",
"link_status":"invalid",
"quote_status":"unverified",
"source_role":"anecdotal_report",
"prev":"0920e75acdf2255a252f16f434f3b734ca126c5c6d8ae849324fa36c054980fd",
"hash":"784c6ba86e09638996094217764668841c58900a39c403e5991c099e07fd75b7",
"quote_sha256":"f3eb1839ccf5041cd2450a1d7eab10120602934a16c9ca993f55c9dab11ccccb"
},
{
"id":"s19",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41476424/",
"title":"Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians",
"quote":"BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability.",
"summary":"2026 narrative review in Am J Sports Med on various peptides including BPC-157, noting limited human evidence and methodological issues in existing case series.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c24"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:35:08.979Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"mechanism_support",
"prev":"784c6ba86e09638996094217764668841c58900a39c403e5991c099e07fd75b7",
"hash":"a4f27086caabf33f5394b26975d797e63b204efe72d7b73ef53a0fb84b65d60d",
"quote_sha256":"2fb25517fd0254ad55a5d608ac692b0b798ccea6e3b1c425b5a5e9b596cafb28"
},
{
"id":"s20",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/",
"title":"Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing",
"quote":"Despite broad preclinical support, human data are extremely limited. Only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics. No adverse effects were reported, but rigorous, large-scale trials are lacking.",
"summary":"2025 narrative review summarizing preclinical mechanisms and noting minimal human data; calls for well-designed trials.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c11"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:35:08.979Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"mechanism_support",
"prev":"a4f27086caabf33f5394b26975d797e63b204efe72d7b73ef53a0fb84b65d60d",
"hash":"64af56a446f234a55fd39544a2cb0f7828d1f96d7656f07ecf5343e68d9197fc",
"quote_sha256":"d2df6bab94c6950192cbd0970144ecf22f2bc5fe917f3052b1014e63a566876c"
},
{
"id":"s21",
"type":"pubmed",
"url":"https://www.mdpi.com/1424-8247/18/2/185",
"title":"Multifunctionality and Possible Medical Application of the Stable Gastric Pentadecapeptide BPC 157",
"quote":"BPC 157 , known as the “Body Protection Compound”, is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects.",
"summary":"2025 review on pleiotropic effects of BPC-157 from MDPI Pharmaceuticals journal.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c26"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:35:08.979Z",
"link_status":"http_403",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"64af56a446f234a55fd39544a2cb0f7828d1f96d7656f07ecf5343e68d9197fc",
"hash":"30c0b52275eab08a553cf3a432fed5e1eac5eb8aef9306dbf0929894fe7beaa8",
"quote_sha256":"23b5a8b55e296157f08cf3c6927eb7baadbf8d7e08b17a5cc09bf90585529c52"
},
{
"id":"s23",
"type":"youtube",
"url":"https://www.youtube.com/watch?v=gaQwrB8HW4o",
"title":"What Science ACTUALLY Says About BPC 157 Benefits",
"quote":"However, its effectiveness and safety in humans remain unproven due to the lack of rigorous clinical trials. The only human study found was small and inconclusive, making it difficult to ascertain BPC 157's true benefits.",
"summary":"YouTube video reviewing scientific evidence on BPC-157, emphasizing lack of robust human RCTs.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c28"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:35:08.979Z",
"link_status":"http_429",
"quote_status":"unverified",
"source_role":"anecdotal_report",
"prev":"30c0b52275eab08a553cf3a432fed5e1eac5eb8aef9306dbf0929894fe7beaa8",
"hash":"236a4b525a0f984d2268780bdef34639f3bab7b96fe6ae0d03df67a5799fd70e",
"quote_sha256":"9a9916377fe71b0b280865be914238ed26d96a188eab5244681f5d262ea6ac30"
},
{
"id":"s24",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41898733/",
"title":"The Role of BPC-157 in Tissue Repair and Pain Management",
"quote":"BPC-157 remains a promising candidate for regenerative medicine, yet comprehensive evaluation is required before clinical translation can be recommended.",
"summary":"2026 review on BPC-157's reparative and anti-inflammatory properties in preclinical models, noting need for more human data.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c11"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:35:30.556Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"mechanism_support",
"prev":"236a4b525a0f984d2268780bdef34639f3bab7b96fe6ae0d03df67a5799fd70e",
"hash":"25e94cc34851f375ae6cfb114a68efe191652ee3ea792f57afa3e4cc661982f4",
"quote_sha256":"2099861f0d6d49f4ce25c77a054ed1e711871f191c03daffacc2eb94d9d0a0b5"
},
{
"id":"s25",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41754849/",
"title":"Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review",
"quote":"Contrarily, proposed as a cytoprotection mediator, BPC 157 acts alone with a full cytoprotection range, given systemically or locally.",
"summary":"2026 systematic review comparing BPC-157 to growth factors for musculoskeletal injuries, highlighting its consistent efficacy in rat studies across administration routes.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c30"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:35:30.556Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"mechanism_support",
"prev":"25e94cc34851f375ae6cfb114a68efe191652ee3ea792f57afa3e4cc661982f4",
"hash":"b90df66c8aa76272338e8543fea13142ef59bf4ee8d187672ad9f8d658934bde",
"quote_sha256":"492c3e7969c10e1e3b795140316ce80371efe789050c3984f1b4ef2a00f2a65a"
},
{
"id":"s26",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/",
"title":"Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review",
"quote":"BPC 157, known as the “Body Protection Compound”, is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects",
"summary":"2025 review on BPC-157's pleiotropic effects and potential medical applications from literature and patents.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c31"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:35:30.556Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"b90df66c8aa76272338e8543fea13142ef59bf4ee8d187672ad9f8d658934bde",
"hash":"6e7c32c3bb1c32b94917c0d476fe6e177e222496522c0e7ce5fefea1f9622d36",
"quote_sha256":"b06fb72e18bf6c50b1652d4b5dc316d51b77a989b3c6b718168d77537268f4e5"
},
{
"id":"s27",
"type":"news",
"url":"https://www.mcgill.ca/oss/article/medical-critical-thinking-health-and-nutrition-contributors/body-protection-compound-no-proof-required",
"title":"BPC-157 – No Proof Required!",
"quote":"To date, only 3 publications have reported on the administration of BPC 157 to humans.",
"summary":"2026 McGill OSS article critically examining limited human evidence for BPC-157 and ongoing clinical trial.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c11"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:35:30.556Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"adjacent_context",
"prev":"6e7c32c3bb1c32b94917c0d476fe6e177e222496522c0e7ce5fefea1f9622d36",
"hash":"b5d2253200ed80e1227b9a8917389eff03514117452f7cb2c35e0e432521b40b",
"quote_sha256":"6f0c0534cdd5306165ce320c61fcb90abb0a0965ac7f672613459ba4f1d7c88a"
},
{
"id":"s28",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13026520/",
"title":"From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management",
"quote":"Experimental evidence reveals that BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways",
"summary":"2026 review detailing BPC-157 mechanisms in tissue repair and pain management from preclinical studies.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c11"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:35:30.556Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"b5d2253200ed80e1227b9a8917389eff03514117452f7cb2c35e0e432521b40b",
"hash":"f513fa7700b16d6047485589c673ccdf8f6d4c3e5a4199bfa0f6d3a3a9fae46f",
"quote_sha256":"d96d99d8ac5c12199a8092b6af28059531934a7038471aa1057dff11cca0514d"
},
{
"id":"s32",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/34380875/",
"title":"Pentadecapeptide BPC 157 and the central nervous system",
"quote":"We reviewed the pleiotropic beneficial effects of the stable gastric pentadecapeptide BPC 157 , BPC 157 counteracted bilateral clamping of the common carotid ...",
"summary":"2022 review on BPC-157 effects on CNS, gut-brain axis, and potential in neurological disorders from animal studies.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c37"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:36:13.134Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"f513fa7700b16d6047485589c673ccdf8f6d4c3e5a4199bfa0f6d3a3a9fae46f",
"hash":"f52dc08b1da2fb7dffba35d078d7d351f184229db2f579b863d95d710f676f55",
"quote_sha256":"1b8c175e8cb3ae9a708adc51e13822dad71b92ab25f1bca1a163e89aa53ce7f5"
},
{
"id":"s33",
"type":"news",
"url":"https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger",
"title":"BPC-157: Miracle Healing Peptide or Hidden Danger?",
"quote":"In summary, human evidence on BPC-157 is scant and of low quality . The few available human studies are small, unblinded, and often conducted by clinics with a stake in the outcome.",
"summary":"2025 article reviewing limited human data, safety concerns, and lack of rigorous trials for BPC-157.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c38"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:36:13.134Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"adjacent_context",
"prev":"f52dc08b1da2fb7dffba35d078d7d351f184229db2f579b863d95d710f676f55",
"hash":"732b69180db5f00474df9d51af143426b9c09647ca5240543b01ca773eed1eec",
"quote_sha256":"7feb62ad57a6e014fb628c9232defc0955307c7813380051e72ec2045aea5d25"
},
{
"id":"s36",
"type":"news",
"url":"https://wellfounded.health/insights/bpc-157-and-the-difference-between-an-evidence-gap-and-a-cover-up",
"title":"BPC-157 and the Difference Between an Evidence Gap and a Cover-Up",
"quote":"In rodent models, BPC-157 accelerates tendon healing, gastric ulcer closure, skin and muscle wound repair , and recovery from several forms of ...",
"summary":"2026 analysis of BPC-157 evidence base, human data limitations, and regulatory investigations.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c41"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:36:13.134Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"adjacent_context",
"prev":"732b69180db5f00474df9d51af143426b9c09647ca5240543b01ca773eed1eec",
"hash":"f9fbae3b603cc1516e7d29fbe40ecba9797a638e1a5d1e173d89a59d79438270",
"quote_sha256":"820086fcba8469030c8b699e89216e5f1d3591ffe0fd2a54e50ee089e4cba3fd"
},
{
"id":"s37",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/36551977/",
"title":"Stable Gastric Pentadecapeptide BPC 157 and Striated, ...",
"quote":"We review the definitively severed myotendinous junction and recovery by the cytoprotective stable gastric pentadecapeptide BPC 157 therapy.",
"summary":"2022 review on BPC-157 for muscle-tendon junction healing in animal models.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c42"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:36:13.134Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"f9fbae3b603cc1516e7d29fbe40ecba9797a638e1a5d1e173d89a59d79438270",
"hash":"b7b90b4e3048c45da546fe30bbeab77c6fb2c621eaeaf42c24d98ae0330d8497",
"quote_sha256":"a6c06c27502f53c87ea5021904a4a73c26e30e7ab9e9d7a9f8f9dbf39bb64ebc"
},
{
"id":"s38",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41155565/",
"title":"BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide",
"quote":"BPC 157 exhibits a distinctive effect on NO-level (increase vs. decrease), always combined with counteraction of free radicals formation, and in ...",
"summary":"2025 review on BPC-157's effects on angiogenesis, NO system, and potential medical applications.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c43"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:37:05.720Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"b7b90b4e3048c45da546fe30bbeab77c6fb2c621eaeaf42c24d98ae0330d8497",
"hash":"a33dd0d464711f2291a07a3650cd4264b6527fc24b520ef0ce1a3222355c6290",
"quote_sha256":"42af4f706f33299242070741a6874e10bee503ea0122bde337167af99147b08d"
},
{
"id":"s39",
"type":"pubmed",
"url":"https://journals.lww.com/ajg/fulltext/2025/10002/s808_oral_peptide_bpc_157_an_emerging_adjunct_to.809.aspx",
"title":"S808 Oral Peptide BPC-157—An Emerging Adjunct to Gastrointestinal Therapies?",
"quote":"BPC-157 shows promise from pre- clinical studies for a range of GI pathologies—particularly in mucosal protection, wound healing, inflammatory bowel disease, and ...",
"summary":"2025 systematic review on oral BPC-157 for GI therapies.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c44"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:37:05.720Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"adjacent_context",
"prev":"a33dd0d464711f2291a07a3650cd4264b6527fc24b520ef0ce1a3222355c6290",
"hash":"2998e5c342d13f4b5f2eacbc8c0e44673a841d143b2899d8e469a48544d13321",
"quote_sha256":"87524546df528bfb78875806e61d623b089ae5444232cbd16726a44f7fc862f8"
},
{
"id":"s40",
"type":"news",
"url":"https://www.mdorthospecialists.com/2026/04/28/peptides-in-orthopedics-bpc-157-what-patients-should-know-about-safety-efficacy-and-sourcing/",
"title":"Peptides in Orthopedics: BPC-157 — What Patients Should Know About Safety, Efficacy, and Sourcing",
"quote":"virtually all of the robust evidence for BPC-157 comes from animal studies, not human clinical trials.",
"summary":"2026 orthopedic clinic article discussing preclinical evidence and limited human data for BPC-157.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c11"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:37:05.720Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"adjacent_context",
"prev":"2998e5c342d13f4b5f2eacbc8c0e44673a841d143b2899d8e469a48544d13321",
"hash":"2d45948b727962523f8bb55a7f17fb14baa673e0d6519be1c00ed1fcc73194cd",
"quote_sha256":"2ac62eb23929c521edf33e7accf4c1b0e9c7e275c5da5ccb3a58361b2742bf15"
},
{
"id":"s43",
"type":"youtube",
"url":"https://www.youtube.com/watch?v=WjCtQM_rfBE",
"title":"How does the Peptide BPC-157 Work?",
"quote":"BPC‑157 is a synthetic peptide derived from a naturally occurring protein in the stomach and is being studied for potential roles in tissue repair and inflammation modulation.",
"summary":"2026 video explaining BPC-157 mechanisms for tissue repair.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c48"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:37:05.720Z",
"link_status":"http_429",
"quote_status":"unverified",
"source_role":"anecdotal_report",
"prev":"2d45948b727962523f8bb55a7f17fb14baa673e0d6519be1c00ed1fcc73194cd",
"hash":"adffa5cec283245c74b5ab8e692192cafb7c056998ee372bf5dada5d0085b2dd",
"quote_sha256":"25ddd3374f5c9a1120fb7ce6ae55aef6782bf10a6a1dc464c755981175e104d5"
},
{
"id":"s44",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40573323/",
"title":"Stable Gastric Pentadecapeptide BPC 157 as a Therapy of ...",
"quote":"Stable Gastric Pentadecapeptide BPC 157 as a Therapy of ... BPC 157 controls angiogenesis and the NO-system's healing functions and ... Publication types. Review . Grants and funding. 10106-22-3071/University of Zagreb.",
"summary":"2025 review on BPC 157's therapeutic potential in various conditions, focusing on angiogenesis and healing.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c49"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:37:28.449Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"adffa5cec283245c74b5ab8e692192cafb7c056998ee372bf5dada5d0085b2dd",
"hash":"57628eb8792c7e1ff52405c7400e1df4ce924872e10731ec9ba12a70ffed8feb",
"quote_sha256":"72a281b0eea6830339fa4716d847ee1949107ccc70a6828969a9e60a4f573ac2"
},
{
"id":"s45",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41832718/",
"title":"Stable Gastric Pentadecapeptide BPC 157 as a Therapy of ...",
"quote":"This review explores the therapeutic potential of the stable gastric pentadecapeptide BPC 157 in addressing electrolyte imbalances, specifically ...",
"summary":"Review on BPC 157 for electrolyte imbalances.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c50"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:37:28.449Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"57628eb8792c7e1ff52405c7400e1df4ce924872e10731ec9ba12a70ffed8feb",
"hash":"73b324e3810e2c2e44f42ec14b2f7cb6c588793a17f34c2f9c0ae8661edda381",
"quote_sha256":"904ed1e72981363793639fbef3cdb22d053c9dfe22f617fe1b741e29a0e67ab2"
},
{
"id":"s46",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/39861766/",
"title":"Stable Gastric Pentadecapeptide BPC 157 as Therapy ...",
"quote":"This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric ...",
"summary":"Rat study on BPC 157 for muscle-bone reattachment.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c51"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:37:28.449Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"73b324e3810e2c2e44f42ec14b2f7cb6c588793a17f34c2f9c0ae8661edda381",
"hash":"773c74e99d2e2478d4282604d1ca821ed5411d063c66e4c87ea2f9a7d8324409",
"quote_sha256":"5a05a2b277f3b9c6a30ef0ae47bad5252ea7eb785b7fbf48a36072c75bbc3513"
},
{
"id":"s47",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11857380/",
"title":"Protective Effects of BPC 157 on Liver, Kidney, and Lung ...",
"quote":"A total of 24 rats were randomly divided into four experimental groups (n = 6 per group): control, group B, IR, and IR- BPC157 . All surgical procedures were ...",
"summary":"2025 rat study showing protective effects of BPC 157 on organs in ischemia-reperfusion model.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c52"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:37:28.449Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"adjacent_context",
"prev":"773c74e99d2e2478d4282604d1ca821ed5411d063c66e4c87ea2f9a7d8324409",
"hash":"6423f081fe526cdebbf2e1acfa1bc658bc68e45bfd98effdde16129fab6804ca",
"quote_sha256":"c364d08654d1baf9e4edc021e959f3e1b74fbafa35c6c4a9b22185baae648f74"
},
{
"id":"s49",
"type":"youtube",
"url":"https://www.youtube.com/watch?v=-rIoG_UF6RI",
"title":"Peptides and BPC-157 for Pain: What's the deal?",
"quote":"Peptides and BPC-157 for Pain: What's the deal? ... Key References Discussed • Józwiak et al. Multifunctionality and Possible Medical Application of BPC-157 — MDPI Pharmaceuticals (2025)",
"summary":"2026 video discussing BPC-157 for pain with references to recent reviews.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c54"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:37:28.449Z",
"link_status":"http_429",
"quote_status":"unverified",
"source_role":"anecdotal_report",
"prev":"6423f081fe526cdebbf2e1acfa1bc658bc68e45bfd98effdde16129fab6804ca",
"hash":"4ee0addb6fb7cdefe64b77ca82d2dd1112f622efed8f254b7f71c784ccd6746c",
"quote_sha256":"66db30034a0cd289f47a7f19923ebea5cee566d9fcebf9468eca75117f0d70b1"
},
{
"id":"s50",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12844668/",
"title":"Tracheocutaneous Fistula Resolved by Pentadecapeptide ...",
"quote":"Tracheocutaneous Fistula Resolved by Pentadecapeptide ... BPC 157 peptide—Literature and patent review . Pharmaceuticals. 2025;18:1450 ...",
"summary":"2026 case report on BPC 157 resolving tracheocutaneous fistula.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c55"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T09:37:28.449Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"adjacent_context",
"prev":"4ee0addb6fb7cdefe64b77ca82d2dd1112f622efed8f254b7f71c784ccd6746c",
"hash":"1b3c744a7de88b7ea65138a25b5eecbee58ee8cc476abecf959dc78fd7839773",
"quote_sha256":"65152da36ea5b927899c485d9929ab91b86657bac10dede36a62b72a0acd9d41"
},
{
"id":"s57",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/38980576/",
"title":"New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection",
"quote":"Since the early 1990s, when Robert's and Szabo's cytoprotection concept had already been more than one decade old, but still not implemented in therapy, we suggest the stable gastric pentadecapeptide BPC 157 as the most relevant mediator of the cytoprotection concept. Consequently, it can translate stomach and gastrointestinal mucosal maintenance, epithelium, and endothelium cell protection to the therapy of other tissue healing (organoprotection), easily applicable, as nativ",
"summary":"2024 review detailing BPC-157's role in GI tract cytoprotection and broader organoprotection including tendon/muscle healing via vascular recovery.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c75"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T13:49:51.382Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"mechanism_support",
"prev":"1b3c744a7de88b7ea65138a25b5eecbee58ee8cc476abecf959dc78fd7839773",
"hash":"9b0d18e6155aee73f47d5761c37258d4ef5f20d94e2e966d72ca5a5cf1a1ad07",
"quote_sha256":"dba3abec8b0c9b8c7cbdf1a732c40d8276bde7f2817a6dc34ca8f2d81fab408b"
},
{
"id":"s58",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/39861766/",
"title":"Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats",
"quote":"This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration. ... macro/microscopic, ultrasonic, magnetic resonance, biomechanical, and functional assessments revealed that BPC 157 therapy recovering effects for all time points were consistent. All parameters of the walking pattern fully improved..",
"summary":"2025 rat study showing BPC-157 promotes muscle-to-bone reattachment and tendon-related healing post-detachment.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c76"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T13:49:51.382Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"mechanism_support",
"prev":"9b0d18e6155aee73f47d5761c37258d4ef5f20d94e2e966d72ca5a5cf1a1ad07",
"hash":"dc92507a912c0deb744380b4c6a294d3fdc7f28e1c8e3c5740f887514835aa74",
"quote_sha256":"2a2834c2b5b22b8f60f2d2e5799c297f28ddb26b9159d35d98b707a92c83a8d1"
},
{
"id":"s59",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40131143/",
"title":"Safety of Intravenous Infusion of BPC157 in Humans",
"quote":"For years, the peptide Body Protection Compound 157 (BPC-157) has been used to treat partial muscle or tendon tears. ... Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated.",
"summary":"2025 pilot study on BPC-157 IV safety in humans, noting its use for muscle/tendon tears.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c77"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T13:49:51.382Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"dc92507a912c0deb744380b4c6a294d3fdc7f28e1c8e3c5740f887514835aa74",
"hash":"448fa39922ebfb5c58950d76a5837038ed2a13a3d5a51697072b5a9d46066e8c",
"quote_sha256":"36ecd0137aa29b663f903058866ed772eb10bc4c60797a6acce1d3c51644493c"
},
{
"id":"s60",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41476424/",
"title":"Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians",
"quote":"BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157...",
"summary":"2026 review on peptides including BPC-157 for tendon/muscle repair in orthopaedics.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c78"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T13:49:51.382Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"mechanism_support",
"prev":"448fa39922ebfb5c58950d76a5837038ed2a13a3d5a51697072b5a9d46066e8c",
"hash":"5fe07acc2745b7b1de4fcc54f46dd19191024d8d8d603d11161c4e9c5adadeb8",
"quote_sha256":"caab4ec7fe30a15738fce0dab91838d72384341f55f038f7dbaf5b88b6ae25d0"
},
{
"id":"s61",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41898733/",
"title":"The Role of BPC-157 in Tissue Repair and Pain Management",
"quote":"Experimental evidence reveals that BPC - 157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways, contributing ...",
"summary":"2026 review on BPC-157's role in tissue repair including tendon and related healing mechanisms.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c79"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T13:50:13.159Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"5fe07acc2745b7b1de4fcc54f46dd19191024d8d8d603d11161c4e9c5adadeb8",
"hash":"028f54ff4de69a2cab315025c7ffcfd6506e0997527e465e90c6b7eefe391e8f",
"quote_sha256":"a8958b8e497d9f585689753e4ad439c704dd2de105ad3e490823417d76ad6302"
},
{
"id":"s62",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/",
"title":"Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing",
"quote":"Studies have demonstrated that BPC-157 not only improves tendon healing but also enhances tendon-to-bone integration, even in the presence of ...",
"summary":"2025 narrative review discussing BPC-157 for tendon healing and musculoskeletal applications.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c80"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T13:50:13.159Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"mechanism_support",
"prev":"028f54ff4de69a2cab315025c7ffcfd6506e0997527e465e90c6b7eefe391e8f",
"hash":"8a2d6300e416bcb494c52fb9513d7923ebdf7509a9077027d91fc13abfacc729",
"quote_sha256":"1cbb438d81b56dee8be8f84e0d780bfdf8375efaa25dac385fed0f44429eda7e"
},
{
"id":"s82",
"type":"x",
"url":"https://x.com/mindpumpsal/status/1751417750806020447",
"title":"Of all the peptides I've tried BPC-157 is my favorite.",
"quote":"Of all the peptides I've tried BPC-157 is my favorite. It's beneficial across the board. Great for gut health, cognitive function, mood,...",
"summary":"Anecdotal positive: BPC-157 favorite for gut health, cognitive function, mood among peptides tried. Labeled anecdotal, not advice.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c100"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T16:59:51.507Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"anecdotal_report",
"prev":"8a2d6300e416bcb494c52fb9513d7923ebdf7509a9077027d91fc13abfacc729",
"hash":"d42b14cd151dd50afca13faf4e7623ce918eb6965c8ffe339f6d87a13b21925f",
"quote_sha256":"f45ba7ac6b1fbccf43b41a73a75bca2663e63033d7ab135ddac4540f2feae4d5"
},
{
"id":"s83",
"type":"x",
"url":"https://x.com/Breedlove22/status/2071613094540030205",
"title":"BPC-157 post",
"quote":"Short for Body Protection Compound, built off a protein found in your own gut. This was the backbone of the stack, calming the inflammation and helping my gut lining rebuild.",
"summary":"Anecdotal: BPC-157 helped calm inflammation and rebuild gut lining as part of healing stack. Labeled anecdotal, not advice.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c101"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T16:59:51.507Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"anecdotal_report",
"prev":"d42b14cd151dd50afca13faf4e7623ce918eb6965c8ffe339f6d87a13b21925f",
"hash":"ced16bca5cba444d6afa19e2e3425eb7fef41b21f5117145a5d5e88000822501",
"quote_sha256":"73e0dbfc0d5f80c0c2cdc01b3bec0d4e5c1dba824bf19b1f0056c28357b7c030"
},
{
"id":"s88",
"type":"x",
"url":"https://x.com/KingOfVitamins/status/2071610257093145038",
"title":"PEPTIDE MASTERCLASS: BPC-157",
"quote":"No compound in preclinical research heals as many tissue types, as consistently, as BPC-157. Tendons. Ligaments. Muscle. Gut. Bone. Brain. ... Tendon and ligament healing. This is the most extensively studied application across animal models and the primary reason BPC-157 has become widely used in the peptide community.",
"summary":"X thread on BPC-157 mechanisms for tendon/gut healing via angiogenesis, VEGF, etc. Positive preclinical/anecdotal evidence highlighted; human RCT hoped for. Anecdotal context.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c106"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:00:41.604Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"anecdotal_report",
"prev":"ced16bca5cba444d6afa19e2e3425eb7fef41b21f5117145a5d5e88000822501",
"hash":"7388a37e15e49bbdee9213409ef789a5db015614fff51d126b2f6dec0ea4f8d3",
"quote_sha256":"afecd1dcfa05c6126c430234674fe0fea1d62b59af7cdc913d875d2eb96e7a40"
},
{
"id":"s89",
"type":"x",
"url":"https://x.com/KingOfVitamins/status/2071610274843332656",
"title":"BPC-157 tendon healing details",
"quote":"Tendon and ligament healing. ... Studies across multiple animal models show BPC-157 dramatically accelerates tendon-to-bone healing, increases the tensile strength of healing tendons, and promotes the formation of organized collagen fibers rather than disorganized scar tissue.",
"summary":"Detailed X post on BPC-157 for tendon repair mechanisms and animal data; extends to gut healing mentions elsewhere in thread. Anecdotal human use noted positively.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c107"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:00:41.604Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"anecdotal_report",
"prev":"7388a37e15e49bbdee9213409ef789a5db015614fff51d126b2f6dec0ea4f8d3",
"hash":"3b65314dfc60373332c21fcbc7ed3cbc2aa473728d22364b17ccf9b283792dd6",
"quote_sha256":"e78bce8c67818d267efc4cab6f5e2554c46a9115562f581241957d0bfcc566b1"
},
{
"id":"s93",
"type":"x",
"url":"https://x.com/Breedlove22/status/2071613106678337793",
"title":"TB-500 with BPC-157 for tissue repair",
"quote":"It worked alongside BPC-157 to drive tissue repair and bring inflammation down across the whole body",
"summary":"Anecdotal positive for combined BPC-157/TB-500 in systemic tissue and tendon healing.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c111"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:01:25.183Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"anecdotal_report",
"prev":"3b65314dfc60373332c21fcbc7ed3cbc2aa473728d22364b17ccf9b283792dd6",
"hash":"5f7037547e5df565e14044e0b1330a234082657a8b1649c4b5eed65e9bcd9b27",
"quote_sha256":"3e848799507e91fe45ec42ee7b74d0c9fc99f91ac2b0e0f38cfff880038efce9"
},
{
"id":"s95",
"type":"x",
"url":"https://x.com/mariioo888/status/2071633910514212931",
"title":"X post by @mariioo888",
"quote":"Any peptide besides BPC-157 for a fucked up gut?",
"summary":"User seeking alternatives to BPC-157 specifically for gut issues. Anecdotal inquiry.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c113"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:01:56.695Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"anecdotal_report",
"prev":"5f7037547e5df565e14044e0b1330a234082657a8b1649c4b5eed65e9bcd9b27",
"hash":"0d9dcbf0ce4226dde74c8712140c72184fb6ce8ea83100577b9b73b85ca9f27d",
"quote_sha256":"e6d9d525c94f99e6d397e1f63dfb24f590da197e08239591a3953d1da44df8fe"
},
{
"id":"s96",
"type":"x",
"url":"https://x.com/TakeThiamine/status/2071621198287610002",
"title":"X post by @TakeThiamine",
"quote":"I’ve had gut issues for years and while I’m stable now (used to be really bad), I absolutely could’ve benefitted from BPC-157",
"summary":"User reports past gut issues and belief BPC-157 would have helped (anecdotal).",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c114"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:01:56.695Z",
"link_status":"ok",
"quote_status":"verified",
"source_role":"anecdotal_report",
"prev":"0d9dcbf0ce4226dde74c8712140c72184fb6ce8ea83100577b9b73b85ca9f27d",
"hash":"ad6068bea0db555920fc76bf540b8d76ec3e3a7959c35138a8328dadbe384969",
"quote_sha256":"ddbbcf42dad45e5ef9f01adc6a1d6ed18dc708ec5f88edfac60f7029fc3cd638"
},
{
"id":"s99",
"type":"x",
"url":"https://x.com/BasedBiohacker/status/2027900122026414320",
"title":"X post by @BasedBiohacker",
"quote":"bpc-157 is one of the FEW compounds that genuinely earns the word \"healing\" rather than just \"performance\" gut lining repair. tendon regeneration. neurotransmitter normalization. autonomic balance. ... → oral for gut and systemic effects. → subq near the injury site for targeted tissue repair. take it at night, 2-4 week cycle.",
"summary":"Anecdotal promotion of BPC-157 for gut repair and tendon healing with dosing (anecdotal, not advice); mentions synergy and cycles.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c117"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:21:21.281Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"anecdotal_report",
"prev":"ad6068bea0db555920fc76bf540b8d76ec3e3a7959c35138a8328dadbe384969",
"hash":"158aa3ce4566ca195f4bce76dfc8c51af407fdd3851ae342a99bc9739ff3c5f1",
"quote_sha256":"a30a4478f3e53fd9ec3abb5b1238c2c946a38106fcd6c517db2d0627f6fb6a3e"
},
{
"id":"s100",
"type":"x",
"url":"https://x.com/HealthyAlfred/status/2042931532688494967",
"title":"X post by @HealthyAlfred",
"quote":"BPC-157 repaired 5 different tissues in published studies — without surgery ... Tendon — regrew after full transection Ligament — restored biomechanical strength Muscle — rebuilt after complete severance Bone — regenerated missing segments Nerve — regrew after transection ... 500mcg. Oral. Morning. Empty stomach.",
"summary":"Anecdotal summary of healing claims for tendons/gut (anecdotal, not advice); dosing example given.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c118"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:21:21.281Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"anecdotal_report",
"prev":"158aa3ce4566ca195f4bce76dfc8c51af407fdd3851ae342a99bc9739ff3c5f1",
"hash":"3b1994ac4611226f6a7548f8465551468ee461b9f3460785b498d03a816a8040",
"quote_sha256":"7c4eddc7d1855331355fe28710fe6ac580687b4ad16365c785d6d928afc72a4f"
},
{
"id":"s101",
"type":"x",
"url":"https://x.com/WovenDissent/status/2071612933382037588",
"title":"X post by @WovenDissent",
"quote":"Bro BPC-157 “research only” from a reputable lab changed my life From a year of constant pain to pain free in both elbows - totally healed my tendons in 6 weeks. Shit is a miracle",
"summary":"Personal anecdote of tendon healing success with BPC-157 (anecdotal, not advice); positive outcome reported.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c119"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:21:21.281Z",
"link_status":"ok",
"quote_status":"unverified",
"source_role":"anecdotal_report",
"prev":"3b1994ac4611226f6a7548f8465551468ee461b9f3460785b498d03a816a8040",
"hash":"db59d75a7efec222896b9b7b0b4baa86ba59a24ced341aef25c1a52a4e2e1501",
"quote_sha256":"29ccc640ff7321600c0079adc8b23d9262f0b331e85cdbd0b29989d5a34754fc"
},
{
"id":"s125",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/21030672/",
"title":"BPC 157 promotes tendon healing via outgrowth, cell survival, and migration",
"quote":"The phosphorylation levels of both FAK and paxillin were dose dependently increased by BPC 157.",
"claim_ids": [],
"accessed_at":"2026-08-04T08:16:54.002Z",
"prev":"db59d75a7efec222896b9b7b0b4baa86ba59a24ced341aef25c1a52a4e2e1501",
"hash":"4dfe9db90c35c28b22b069bd0ecf968f68fb5423da99c72f71dce2523ab7e410",
"plain":"Tendon cells in a dish, not a living tendon. More compound meant more of the internal signaling cells use to grip a surface and crawl, which is a plausible mechanism for tendon repair and nothing closer than that.",
"quote_sha256":"6d836aed3ff3e8982edf884e125551a4e30543d6f599265ab7b7460b6177b603"
},
{
"id":"s126",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/18818478/",
"title":"BPC 157, in clinical trials for IBD (PL14736), heals colocutaneous fistulas in rats",
"quote":"BPC 157 (10 microg/kg, 10 ng/kg) was applied",
"claim_ids": [],
"accessed_at":"2026-08-04T08:16:54.002Z",
"prev":"4dfe9db90c35c28b22b069bd0ecf968f68fb5423da99c72f71dce2523ab7e410",
"hash":"87c897214c4a97329d8cb7f29dce2b9f3c6e0fb403df9de25b4e3b29e523bc3a",
"plain":"Rats with a surgically made opening between colon and skin, given doses a thousand-fold apart and helped at both. Its weight comes from the drug-code name in the title: the same compound was carried into human gut-disease trials, though not for tendons or joints.",
"quote_sha256":"c3beee421a388f71b5e2b7905775005915f43e324d39537b5c144fcab3d8d49c"
},
{
"id":"s127",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/",
"title":"BPC 157 improves the healing course of spinal cord injury and leads to functional recovery in rats",
"quote":"All of the injured rats that received BPC 157 exhibited consistent clinical improvement, increasingly better motor function of the tail",
"claim_ids": [],
"accessed_at":"2026-08-04T08:16:54.002Z",
"prev":"87c897214c4a97329d8cb7f29dce2b9f3c6e0fb403df9de25b4e3b29e523bc3a",
"hash":"c19bd23526dd6edd5ee920ffccda2d5ffe5d51e4974bf183e7bf5d2c84edb3b6",
"plain":"Rats with a damaged spinal cord recovered movement, starting with the tail. This is the boldest animal claim attached to the compound and the one furthest from anything shown in a person; no human version of this experiment exists.",
"quote_sha256":"85b95e47f0f513884492d7f155fba9d5cc9c1a42659af0880922727fb9bf4f80"
},
{
"id":"s128",
"type":"news",
"url":"https://lotilabs.com/resources/bpc-157-legal-status-2026-fda-update/",
"title":"BPC-157 Legal Status 2026: FDA Category 2 Removal, PCAC Review",
"quote":"In 2023, the FDA formally placed BPC-157 on the Category 2 bulk substances list under Section 503A.",
"claim_ids": [],
"accessed_at":"2026-08-04T08:16:54.002Z",
"prev":"c19bd23526dd6edd5ee920ffccda2d5ffe5d51e4974bf183e7bf5d2c84edb3b6",
"hash":"7bfc17e9efc2dbd8d74d82eb7495675ec72743019353274e65341b796699e116",
"plain":"Explains the 2023 listing that put the compound in the restricted bulk-substances category, which is what stops a compounding pharmacy from making it. Written up by a seller of the compound rather than taken from the agency's own document.",
"quote_sha256":"884c776627e5aa96547a319254fb6ae542e860f27f1e78b5a3e7cd743c2996cc"
},
{
"id":"s129",
"type":"news",
"url":"https://time.com/article/2026/07/23/fda-committee-peptides/",
"title":"An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition (TIME)",
"quote":"On BPC-157, eight members of the committee voted yes, six voted no, and one abstained.",
"claim_ids": [],
"accessed_at":"2026-08-04T08:16:54.002Z",
"prev":"7bfc17e9efc2dbd8d74d82eb7495675ec72743019353274e65341b796699e116",
"hash":"949185a38fb5f95a382362e1ba056da48c12cab71609ddbda7407927c2c77a15",
"plain":"An outside advisory panel went against the agency by a single vote, with one member abstaining. An advisory vote changes no rule and no legal status on its own — it records disagreement, not a decision.",
"quote_sha256":"2d64fefae6e6ddc1c574eeead4991e8bff0cb11a0bdd10fa64e8da4b1bb8b9be"
},
{
"id":"s130",
"type":"news",
"url":"https://rethinkpeptides.com/articles/for-research-use-only-the-legal-fiction-of-gray-market-peptides",
"title":"Gray-Market Peptides: The 'Research Use Only' Fiction",
"quote":"30% contained incorrect amino acid sequences and two-thirds of samples fell below the 95% purity threshold.",
"claim_ids": [],
"accessed_at":"2026-08-04T08:16:54.002Z",
"prev":"949185a38fb5f95a382362e1ba056da48c12cab71609ddbda7407927c2c77a15",
"hash":"98623fb7eb63587150447d3f068b28ba9074c706cd842b0e119a0dd2de6fb629",
"plain":"The reason a no-effect report on this page is hard to read: testing found wrong sequences in almost a third of samples and most falling short of stated purity. A commentary summarizing that testing rather than the testing itself.",
"quote_sha256":"01bdb19432beb9a93cfb35d9d322bab005243c51b4d013218da462933c1ca8bf"
},
{
"id":"s131",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12567428/",
"title":"BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide (review commentary)",
"quote":"BPC 157 inhibits cell growth and VEGF signaling via the MAPK kinase pathway in the human melanoma cell line.",
"claim_ids": [],
"accessed_at":"2026-08-04T08:16:54.002Z",
"prev":"98623fb7eb63587150447d3f068b28ba9074c706cd842b0e119a0dd2de6fb629",
"hash":"5b8543c3d9a8d8fcd6a5e5977c837cc8018efd66b3c7a204a76f63c891aa044f",
"plain":"A review, and the line quoted runs against the usual story. In human melanoma cells in a dish the compound held back the very blood-vessel signal it is elsewhere said to switch on — direction of effect appears to depend on the tissue.",
"quote_sha256":"e606dc2559c7aa179a5c8f1f8e1e0e43b5cd1de7ccc6aadc4ce835266b908b37"
},
{
"id":"w_fo79e9nk",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/27847966/",
"title":"Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation",
"publisher":"Journal of Molecular Medicine (Berlin)",
"author":"Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VHS, Pang JHS",
"date":"2017-03",
"quote":"BPC 157 time dependently activated the VEGFR2-Akt-eNOS signaling pathway which could also be suppressed by dynasore",
"summary":"PMID 27847966; DOI 10.1007/s00109-016-1488-y. Cell culture plus rodent hindlimb ischemia. VEGFR2 mRNA and protein both increased; the endocytosis inhibitor dynasore abolished the effect, implicating receptor internalization. Vessel density rose in vivo and in vitro and blood flow recovered faster in ischemic muscle.",
"_id":"w_fo79e9nk",
"_ts":"2026-08-04T08:05:45.746Z",
"accessed_at":"2026-08-04T08:05:45.746Z",
"claim_ids": [],
"prev":"5b8543c3d9a8d8fcd6a5e5977c837cc8018efd66b3c7a204a76f63c891aa044f",
"hash":"dc3ca8045373e6321dd0d7f6ed6c71f64844877747be5b452769374ec4a2e6e5",
"quote_sha256":"071cae96fd30867ef17a0a1108aac77d12811ba8a3501f2fce7932341dfaa98d"
},
{
"id":"w_ud0jx8hb",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/21030672/",
"title":"The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration",
"publisher":"Journal of Applied Physiology",
"author":"Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS",
"date":"2011-03",
"quote":"BPC 157 markedly increased the in vitro migration of tendon fibroblasts in a dose-dependent manner",
"summary":"PMID 21030672; DOI 10.1152/japplphysiol.00945.2010. Rat Achilles tendon fibroblasts. FAK and paxillin phosphorylation rose dose-dependently while total protein was unchanged. MTT showed no increase in proliferation, so the effect is migration and survival, not mitogenesis. Cell survival improved under H2O2 oxidative stress.",
"_id":"w_ud0jx8hb",
"_ts":"2026-08-04T08:06:26.112Z",
"accessed_at":"2026-08-04T08:06:26.112Z",
"claim_ids": [],
"prev":"dc3ca8045373e6321dd0d7f6ed6c71f64844877747be5b452769374ec4a2e6e5",
"hash":"ea44765231e2309d7a2ad8f9c9aacf728260395de099b9a834903ec718c32640",
"quote_sha256":"b87954fe2be0415026bf0c6f1b15318fcc06fa6e716ede11f3216980e3fc755c"
},
{
"id":"w_y4s15wvm",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/",
"title":"Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts",
"publisher":"Molecules (MDPI)",
"author":"Chang CH, Tsai WC, Hsu YH, Pang JHS",
"date":"2014-11-19",
"quote":"BPC 157 dose- and time-dependently increased the expression of growth hormone receptor in tendon fibroblasts",
"summary":"PMID 25415472; PMCID PMC6271067. Concentrations 0.1, 0.25 and 0.5 ug/mL over 24 hours, then 0.5 ug/mL across a one-to-three day time course. Growth hormone receptor rose roughly sevenfold by day three at both mRNA and protein level. A second mechanism distinct from angiogenesis: the tendon cell becomes more sensitive to circulating growth hormone.",
"_id":"w_y4s15wvm",
"_ts":"2026-08-04T08:06:26.859Z",
"accessed_at":"2026-08-04T08:06:26.859Z",
"claim_ids": [],
"prev":"ea44765231e2309d7a2ad8f9c9aacf728260395de099b9a834903ec718c32640",
"hash":"6c5fd01fffd02dca0931ecda6d23f88196e26d98443e5f2cfde0d6021c35597e",
"quote_sha256":"e659259fc0e95e7e081c72ab48f43c620e6a2ddf1c08f73e4703c1ef1e24d53e"
},
{
"id":"w_ccsq5zep",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/20225319/",
"title":"Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat",
"publisher":"Journal of Orthopaedic Research",
"author":"Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P",
"date":"2010-09",
"quote":"BPC 157 microg-ng-rats exhibited consistent functional, biomechanical, macroscopic and histological healing improvements",
"summary":"PMID 20225319; DOI 10.1002/jor.21107. Model: medial collateral ligament transection in rats, followed 90 days. Three routes each worked: intraperitoneal 10 ug/kg or 10 ng/kg once daily; topical 1.0 ug per gram of neutral cream from 30 minutes post-surgery; per-oral 0.16 ug/mL in drinking water at about 12 mL/day/rat. Effective without any carrier.",
"_id":"w_ccsq5zep",
"_ts":"2026-08-04T08:06:27.563Z",
"accessed_at":"2026-08-04T08:06:27.563Z",
"claim_ids": [],
"prev":"6c5fd01fffd02dca0931ecda6d23f88196e26d98443e5f2cfde0d6021c35597e",
"hash":"86843a81d4cda15e7370441e895f7b53f2f1a2ef5eec5f660410c07b4cae0a37",
"quote_sha256":"b430c62ebac913d6e6d21ec61b223fb9e5d236daf376b07583488a6b3dde4b85"
},
{
"id":"w_59xoi0m3",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/16583442/",
"title":"Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation",
"publisher":"Journal of Orthopaedic Research",
"author":"Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P",
"date":"2006-05",
"quote":"6alpha-Methylprednisolone consistently aggravates the healing, while BPC 157 substantially reduces 6alpha-methylprednisolone healing aggravation",
"summary":"PMID 16583442; DOI 10.1002/jor.20096. Achilles tendon detached from the calcaneus in rats. Load to failure, stiffness and Young's elasticity modulus all rose significantly; collagen fibres were better organised with more type I collagen and advanced vascular appearance. Doses 10 ug/kg, 10 ng/kg or 10 pg/kg intraperitoneally daily, starting 30 minutes after surgery.",
"_id":"w_59xoi0m3",
"_ts":"2026-08-04T08:06:28.464Z",
"accessed_at":"2026-08-04T08:06:28.464Z",
"claim_ids": [],
"prev":"86843a81d4cda15e7370441e895f7b53f2f1a2ef5eec5f660410c07b4cae0a37",
"hash":"2616b09e7c2b491cfe4c1a9e869eb2c1c2b736de1067acd7132ffe69f96e1bff",
"quote_sha256":"a2b84bc2dfb1199275b0a0726cd8e432bd90cd74b5f172119b24d63dfd742f6d"
},
{
"id":"w_gttxaz57",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/20190676/",
"title":"Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application",
"publisher":"Medical Science Monitor",
"author":"Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, et al.",
"date":"2010-03",
"quote":"BPC 157 completely reversed systemic corticosteroid-impaired muscle healing",
"summary":"PMID 20190676. Two rat gastrocnemius models, transection and crush injury, assessed at days 1, 2, 4, 7 and 14. Corticosteroids markedly worsened healing in untreated controls. BPC 157 worked applied either systemically by intraperitoneal injection or topically as a cream, with full functional restoration reported in treated animals.",
"_id":"w_gttxaz57",
"_ts":"2026-08-04T08:06:29.175Z",
"accessed_at":"2026-08-04T08:06:29.175Z",
"claim_ids": [],
"prev":"2616b09e7c2b491cfe4c1a9e869eb2c1c2b736de1067acd7132ffe69f96e1bff",
"hash":"fc307b59226b933b95909492cf9851ff244af21bfd72f276e06f0a0ad5f775a2",
"quote_sha256":"97c886030c3ddb81c72a0b6a93162c343c56008412a3b8b3ea9fc357dff7a703"
},
{
"id":"w_urj74cu2",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8615275/",
"title":"Stable gastric pentadecapeptide BPC 157 as a therapy for the disabled myotendinous junctions in rats",
"publisher":"Biomedicines (MDPI)",
"author":"Japjec M, Horvat Pavlov K, Petrovic A, Staresinic M, Sebecic B, et al.",
"date":"2021-10-27",
"quote":"BPC 157 recovers myotendinous junction",
"summary":"PMID 34829776; PMCID PMC8615275. Intraperitoneal 10 ug/kg or 10 ng/kg from immediately post-surgery, or per-oral in drinking water at 0.16 ug/mL or 0.16 ng/mL, 12 mL/rat/day. Injured-limb contracture resolved completely against persistent disability in controls, and the progressive muscle atrophy seen in controls was prevented. Well-oriented recovered tissue by days 28 to 42. Both the microgram and nanogram tiers worked.",
"_id":"w_urj74cu2",
"_ts":"2026-08-04T08:06:29.948Z",
"accessed_at":"2026-08-04T08:06:29.948Z",
"claim_ids": [],
"prev":"fc307b59226b933b95909492cf9851ff244af21bfd72f276e06f0a0ad5f775a2",
"hash":"57588045799d4691db2343fc777e3b58e16e8f04a1ea64a91b67fc3d877dccc1",
"quote_sha256":"e035d030a0df33ebcc1a8282f6cf6a541823d3b7ecd81ed2147f48cfd522095f"
},
{
"id":"w_67ce14vu",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11768438/",
"title":"Stable gastric pentadecapeptide BPC 157 as therapy after surgical detachment of the quadriceps muscle from its attachments for muscle-to-bone reattachment in rats",
"publisher":"Pharmaceutics (MDPI)",
"author":"Matek D, Matek I, Staresinic E, Japjec M, Bojanic I, et al.",
"date":"2025-01-16",
"quote":"the muscle and mature fibers were oriented parallel to the bone axis and were in close contact with bone",
"summary":"PMID 39861766; PMCID PMC11768438. Per-oral dosing in drinking water, 10 ug/kg or 10 ng/kg (0.16 ug/mL or 0.16 ng/mL, 12 mL/rat/day), first dose intragastrically five minutes post-operatively. Vastus muscles reattached as early as 21 days; rectus femoris reached anatomical baseline at about 28 days. Reattachment was verified on ultrasound, the same modality a musculoskeletal practice already owns.",
"_id":"w_67ce14vu",
"_ts":"2026-08-04T08:06:31.348Z",
"accessed_at":"2026-08-04T08:06:31.348Z",
"claim_ids": [],
"prev":"57588045799d4691db2343fc777e3b58e16e8f04a1ea64a91b67fc3d877dccc1",
"hash":"4eaa6af80b1c27fafd9f9d268562bc7d6c9b9b9c7e69b742007ea11490a8c69a",
"quote_sha256":"24c6324f0e90a691a793a2c9ed08d4771540e19634df5cc89fa12e6329a388c0"
},
{
"id":"w_n7ahbrni",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/",
"title":"Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs",
"publisher":"Frontiers in Pharmacology",
"author":"He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, et al.",
"date":"2022-12-14",
"quote":"the average elimination half-life (t1/2) was 15.2 min",
"summary":"PMID 36588717; PMCID PMC9794587. Doses 20, 100 and 500 ug/kg in rats and 6, 30 and 150 ug/kg in beagles. Peak plasma concentration three minutes after intramuscular injection; dog intravenous half-life 5.27 minutes. Absolute bioavailability after intramuscular injection was 14 to 19 percent in rats and 45 to 51 percent in dogs. Excretion via urine and bile. Peak tissue levels in kidney, liver, stomach wall, thymus and spleen, well above plasma. No human pharmacokinetic data has ever been published.",
"_id":"w_n7ahbrni",
"_ts":"2026-08-04T08:06:32.033Z",
"accessed_at":"2026-08-04T08:06:32.033Z",
"claim_ids": [],
"prev":"4eaa6af80b1c27fafd9f9d268562bc7d6c9b9b9c7e69b742007ea11490a8c69a",
"hash":"12caafded2eb88a2477fca22a2599edb5e1bd3b77d9987a39711ac2fa93405ed",
"quote_sha256":"203592abcd4fe2810326bbad89d2861e931eb80224ed1e5f99ad3ff8f0e22ab7"
},
{
"id":"w_nfh8rh08",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/34324435/",
"title":"Intra-articular injection of BPC 157 for multiple types of knee pain",
"publisher":"Alternative Therapies in Health and Medicine",
"author":"Lee E, Padgett B",
"date":"2021-07",
"quote":"This small study suggests that intra-articular injection of BPC-157 helps with multiple types of knee pain",
"summary":"PMID 34324435. Retrospective chart review at a single clinic. 17 patients identified, 16 reached by telephone follow-up. BPC-157 alone: 11 of 12 (91.6 percent) reported significant improvement. With thymosin beta-4: 3 of 4 (75 percent). Overall 14 of 16 (87.5 percent). Per FDA's own review the doses were 2 to 4 mg, one or two injections. No randomisation, no placebo arm, no standardised pain score, no imaging endpoint.",
"_id":"w_nfh8rh08",
"_ts":"2026-08-04T08:06:32.699Z",
"accessed_at":"2026-08-04T08:06:32.699Z",
"claim_ids": [],
"prev":"12caafded2eb88a2477fca22a2599edb5e1bd3b77d9987a39711ac2fa93405ed",
"hash":"8a15b2411abbea774670aeee2f3daf46feb6a61f8d4ae90a89f6c22505c240ec",
"quote_sha256":"0d2375527de6c82fa19aa5046ed0ecb3e99f17f6da43e27bbee86abcded00da4"
},
{
"id":"w_rwwqkuud",
"type":"news",
"url":"https://clinicaltrials.gov/study/NCT02637284",
"title":"Phase I, pilot study in healthy volunteers, to assess the safety and pharmacokinetics of PCO-02 (BPC-157)",
"publisher":"ClinicalTrials.gov, U.S. National Library of Medicine",
"author":"Sponsor: PharmaCotherapia d.o.o.",
"date":"Start October 2015",
"quote":"Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02",
"summary":"NCT02637284. Intervention Bepecin (PCO-02, BPC-157) against placebo PCO-03, estimated enrolment 42 healthy volunteers, conducted in Mexico. Per FDA: Phase 1a single oral doses of 1 mg, 3 mg or 6 mg; Phase 1b 3 mg orally every eight hours for two weeks. Overall status Unknown, last known Active not recruiting. No results posted, no publication found, results submission cancelled in 2016.",
"_id":"w_rwwqkuud",
"_ts":"2026-08-04T08:06:33.424Z",
"accessed_at":"2026-08-04T08:06:33.424Z",
"claim_ids": [],
"prev":"8a15b2411abbea774670aeee2f3daf46feb6a61f8d4ae90a89f6c22505c240ec",
"hash":"9bea7eee704f91fb4a7de8018dda1a300ba2e236023ad8f713e8ecc2fd514951",
"quote_sha256":"cd1ded93430ee2a696df2e74fa7a28d7fa8a273cfa966d6044f28bd97452ec9d"
},
{
"id":"w_9qu2rfyq",
"type":"news",
"url":"https://www.fda.gov/media/193343/download",
"title":"FDA briefing document, Pharmacy Compounding Advisory Committee: evaluation of BPC-157-related bulk drug substances for inclusion on the 503A bulk drug substances list",
"publisher":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research",
"author":"FDA Office of Compounding Quality and Compliance",
"date":"2026-07",
"quote":"we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List",
"summary":"FDA media 193343. FDA's own scientific recommendation, against inclusion. Also states: there is insufficient clinical safety information to characterise the safety profile; BPC-157 may pose a significant risk for immunogenicity, potentially amplified by aggregation as well as potential peptide-related impurities; dose-response relationships have not been established; and the molecular targets for BPC-157-related substances have not been identified. 28-day repeat-dose intramuscular toxicity in rats and dogs showed aPTT shortening in rats and prolongation in dogs, plus raised serum ALT, glucose and triglycerides. No carcinogenicity studies exist.",
"_id":"w_9qu2rfyq",
"_ts":"2026-08-04T08:06:34.113Z",
"accessed_at":"2026-08-04T08:06:34.113Z",
"claim_ids": [],
"prev":"9bea7eee704f91fb4a7de8018dda1a300ba2e236023ad8f713e8ecc2fd514951",
"hash":"c8fddfbbfe84b993bdeaf1b2af8a73a869adce969224e754e1304d0b566675cc",
"quote_sha256":"df0971491314d74a0c069b2d4cfae862dd1bb2bf4f6807ec9940f1dde5ae4c0b"
},
{
"id":"w_ghpbaz64",
"type":"news",
"url":"https://www.fda.gov/media/94155/download",
"title":"Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act",
"publisher":"U.S. Food and Drug Administration",
"author":"FDA",
"date":"2026-05-14",
"quote":"503A Category 2: Bulk Drug Substances that Raise Significant Safety Risks",
"summary":"FDA media 94155, revision of 14 May 2026. Category 2 on this revision lists only Cesium Chloride, Domperidone, Germanium Sesquioxide, Ibutamoren Mesylate, Kisspeptin-10, and Quinacrine Hydrochloride for intrauterine administration. BPC-157 appears in none of Category 1, 2 or 3 — its nominations were withdrawn. This supersedes the September 2023 Category 2 placement still cited across the internet.",
"_id":"w_ghpbaz64",
"_ts":"2026-08-04T08:06:34.975Z",
"accessed_at":"2026-08-04T08:06:34.975Z",
"claim_ids": [],
"prev":"c8fddfbbfe84b993bdeaf1b2af8a73a869adce969224e754e1304d0b566675cc",
"hash":"f7939d677fe5eece3cacaf7b9aafd2a7d90cfad6cd414ae6f8926ece5eae7d52",
"quote_sha256":"0551f7fb9f9714f956c50e30ebe068b8204fcc0aca17859365767e2120e0d8fd"
},
{
"id":"w_38qd7eam",
"type":"news",
"url":"https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026",
"title":"July 23-24, 2026: meeting of the Pharmacy Compounding Advisory Committee",
"publisher":"U.S. Food and Drug Administration",
"author":"FDA Center for Drug Evaluation and Research",
"date":"2026-07-14",
"quote":"BPC-157 (free base) BPC-157 acetate Ulcerative colitis (UC)",
"summary":"The official agenda table. The indication FDA put before the committee was ulcerative colitis alone. Tendonitis was among the nominated uses but FDA declined to evaluate it for lack of sufficient information. The same day covered KPV, TB-500 and MOTS-c; 24 July covered Emideltide (DSIP) and Semax. FDA states it considers committee recommendations but is not legally bound by them.",
"_id":"w_38qd7eam",
"_ts":"2026-08-04T08:06:35.724Z",
"accessed_at":"2026-08-04T08:06:35.724Z",
"claim_ids": [],
"prev":"f7939d677fe5eece3cacaf7b9aafd2a7d90cfad6cd414ae6f8926ece5eae7d52",
"hash":"7b495e7b950f368efbd7d8307e733bd91d374b3391a3edb5544f535d4fe7262d",
"quote_sha256":"5c35bd9937fed84c64d3f145cc496e0fafd9531d104b80523dc5943595d851cf"
},
{
"id":"w_u19qrezt",
"type":"news",
"url":"https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf",
"title":"World Anti-Doping Code International Standard: Prohibited List 2026",
"publisher":"World Anti-Doping Agency",
"author":"WADA",
"date":"Effective 2026-01-01",
"quote":"This class covers many different substances including but not limited to BPC-157, 2,4-dinitrophenol (DNP)",
"summary":"BPC-157 is named explicitly in the S0 Non-Approved Substances class on page 4 of the 2026 list, prohibited at all times, in and out of competition. The S0 definition is any pharmacological substance not addressed elsewhere on the list and with no current approval by any governmental regulatory health authority for human therapeutic use. All S0 substances are Specified Substances.",
"_id":"w_u19qrezt",
"_ts":"2026-08-04T08:06:36.381Z",
"accessed_at":"2026-08-04T08:06:36.381Z",
"claim_ids": [],
"prev":"7b495e7b950f368efbd7d8307e733bd91d374b3391a3edb5544f535d4fe7262d",
"hash":"31f2fd6be0e0966c762e4536fb892a40aac329be195f992e440d4a89d707c051",
"quote_sha256":"3e93424dcdc3431c1c9f928954c6b5fcb4d04ffc77e1c5f4ac116dc2c91ef92a"
},
{
"id":"w_af5ht9pr",
"type":"news",
"url":"https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/",
"title":"BPC-157: experimental peptide creates risk for athletes",
"publisher":"U.S. Anti-Doping Agency",
"author":"USADA",
"date":"accessed 2026-08-04",
"quote":"no one knows if there is a safe dose, or if there is any way to use this compound safely to treat specific medical conditions",
"summary":"USADA also writes of 'a concerning lack of published clinical trial data because studies appear to have been cancelled or stopped without any published conclusions', advises athletes to never use a product marketed for research only, and states there is no legal basis for BPC-157 as a drug, food or dietary supplement ingredient in the United States.",
"_id":"w_af5ht9pr",
"_ts":"2026-08-04T08:06:37.064Z",
"accessed_at":"2026-08-04T08:06:37.064Z",
"claim_ids": [],
"prev":"31f2fd6be0e0966c762e4536fb892a40aac329be195f992e440d4a89d707c051",
"hash":"f4030c40f1eb0698787e2a67172b26da022974c2c848ac747ac1f877a7af8ba9",
"quote_sha256":"8a16bac64ef686895efd1399b45e3c4f43d265530ce91b856a704383831f7cec"
},
{
"id":"w_h2eu8h3c",
"type":"news",
"url":"https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products",
"title":"BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products",
"publisher":"Operation Supplement Safety, U.S. Department of Defense / Uniformed Services University",
"author":"OPSS",
"date":"2025-04-29",
"quote":"BPC-157 is not a dietary ingredient. It is an unapproved drug.",
"summary":"BPC-157 sits on the DoD Prohibited Dietary Supplement Ingredients List. Service members are told to avoid research chemicals and any product containing prohibited ingredients, at any route of administration. Directly relevant to any practice serving military or federal-employee patients.",
"_id":"w_h2eu8h3c",
"_ts":"2026-08-04T08:06:38.442Z",
"accessed_at":"2026-08-04T08:06:38.442Z",
"claim_ids": [],
"prev":"f4030c40f1eb0698787e2a67172b26da022974c2c848ac747ac1f877a7af8ba9",
"hash":"b4c2f66d9adb381f25da49b9f29388db5db11f83f2f2b8525f61f93226936108",
"quote_sha256":"7b087c5a9825171ca9c21138e7c1f55abb4f33a4a9300d3157c50e79b258fdc3"
},
{
"id":"w_oje4lc91",
"type":"news",
"url":"https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides",
"title":"FDA panel votes to loosen restrictions for four peptides",
"publisher":"Pharmaceutical Executive",
"author":"Nicholas Jacobus",
"date":"2026-07-24",
"quote":"I'm voting on something here, but I don't know what that something is. It's kind of like a black box to me.",
"summary":"Dissenting panelist Josh Mailman, quoted on the identity and characterisation problem. The article records the vote counts: BPC-157, KPV and TB-500 each 8-6 in favour with one abstention; MOTS-c 7-5 with two abstentions. Dr Brian Lee, voting no: 'For effectiveness, we know that 30% of patients on placebo will have a self-reported response or even objective response.' Legal expert Dustin Robinson notes the recommendation still triggers a formal rulemaking cycle that realistically runs eight to twelve months.",
"_id":"w_oje4lc91",
"_ts":"2026-08-04T08:06:39.709Z",
"accessed_at":"2026-08-04T08:06:39.709Z",
"claim_ids": [],
"prev":"b4c2f66d9adb381f25da49b9f29388db5db11f83f2f2b8525f61f93226936108",
"hash":"b1e953091522db860044a5be425d3582f17ad3e05bc5b36574049c3707612f46",
"quote_sha256":"6bef5e23cca6ebd780a189f9edf6c192b015dcdbcc90bf4fa80715e43c9dbbd8"
},
{
"id":"w_lkfuwkh8",
"type":"news",
"url":"https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/",
"title":"FDA advisory panel narrowly votes to allow compounding of unapproved peptides",
"publisher":"STAT News",
"author":"Sarah Todd and Lizzy Lawrence",
"date":"2026-07-23",
"quote":"majority of panelists who voted yes have ties to peptide industry",
"summary":"STAT's reporting on the same vote, framing it as a political outcome rather than a scientific determination, and noting the conflicts of interest among the panelists who voted in favour. Also confirms the votes are not binding and FDA will ultimately decide. Full text behind STAT+.",
"_id":"w_lkfuwkh8",
"_ts":"2026-08-04T08:06:40.425Z",
"accessed_at":"2026-08-04T08:06:40.425Z",
"claim_ids": [],
"prev":"b1e953091522db860044a5be425d3582f17ad3e05bc5b36574049c3707612f46",
"hash":"bbf191c9bbe8389e9faa7928257e50161ed22651f4954cab9bbc314126c72432",
"quote_sha256":"5afde717587d28ec3705524b4e57c6b822d435084d6e0475137521049f94da10"
},
{
"id":"w_macsi7l3",
"type":"news",
"url":"https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026",
"title":"What's changing with peptide regulation in 2026",
"publisher":"Banned Substances Control Group",
"author":"BSCG",
"date":"2026-05-03",
"quote":"mislabeling, improper dosing, or contamination in approximately 30% of peptide samples from grey-market sources",
"summary":"A supplement and drug testing certification laboratory on the grey-market supply chain. Names the contaminant classes at issue: endotoxins, truncated sequences, solvent residues, heavy metals, microbial contamination and degradation byproducts. Quotes former FDA official Janet Woodcock on the compounding pathway: 'This wasn't supposed to be a route for unapproved drugs to get into the market.'",
"_id":"w_macsi7l3",
"_ts":"2026-08-04T08:06:41.230Z",
"accessed_at":"2026-08-04T08:06:41.230Z",
"claim_ids": [],
"prev":"bbf191c9bbe8389e9faa7928257e50161ed22651f4954cab9bbc314126c72432",
"hash":"b9f862ff0d816ddebde72d5acc84d8e4d62d648f48156d7ebf59eb5b44033056",
"quote_sha256":"edaee6f01ab41807a80927e872ebf7488f4245bbcdd46f0e1f3f1ac81cf1a4d8"
},
{
"id":"w_bburqn2u",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40756949/",
"title":"Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review",
"publisher":"HSS Journal (Hospital for Special Surgery)",
"author":"Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM",
"date":"2025-11",
"quote":"Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.",
"summary":"PMID 40756949; DOI 10.1177/15563316251355551. PubMed, Cochrane and Embase searched from inception to 3 June 2024; 544 records screened, 36 articles included, of which 35 were preclinical and one clinical. The single clinical study was the retrospective intra-articular knee series. The review reports no clinical safety data found in humans and notes BPC-157 lacks FDA approval and is banned in professional sport.",
"_id":"w_bburqn2u",
"_ts":"2026-08-04T08:06:48.056Z",
"accessed_at":"2026-08-04T08:06:48.056Z",
"claim_ids": [],
"prev":"b9f862ff0d816ddebde72d5acc84d8e4d62d648f48156d7ebf59eb5b44033056",
"hash":"8fb19c86b2ed7f02dd254e7f1b844f79af76cb8f1fd1fc5afc61d1e0a43bb1ad",
"quote_sha256":"62db9466f20a479b09c374a908c3d6ac8829570af617647c20b9f9bb4789a081"
},
{
"id":"w_uhm2s5ar",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/",
"title":"Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review",
"publisher":"Pharmaceuticals (MDPI)",
"author":"Jozwiak M, Bauer M, Kamysz W, Kleczkowska P",
"date":"2025-01-30",
"quote":"the use of BPC 157 may not be the right choice, especially in situations where we are not aware of the presence of cancer cells",
"summary":"PMID 40005999; PMCID PMC11859134. Independent, non-Zagreb authors. States the theoretical concern plainly: 'the formation of blood vessels during carcinogenesis enables oxygen supply to the tumor and enhances its proliferation, diffusion, and metastasis.' Also reads the anti-tumour counter-evidence as weak: 'administration of BPC 157 to mice with implanted cancer cells did not result in a spectacular reduction in tumor size.' This is the review the originating research group formally rebutted in print.",
"_id":"w_uhm2s5ar",
"_ts":"2026-08-04T08:06:48.852Z",
"accessed_at":"2026-08-04T08:06:48.852Z",
"claim_ids": [],
"prev":"8fb19c86b2ed7f02dd254e7f1b844f79af76cb8f1fd1fc5afc61d1e0a43bb1ad",
"hash":"60c97d928b95dcf2ac4a2fb39aca9c20fae246e58b2bade1882dd0f168acb10c",
"quote_sha256":"9631e51dc4ff873fac3ee043aec203930717bf1ec7d094b9d32e8b6c4cd84141"
},
{
"id":"w_032xvatb",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/19903499/",
"title":"Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury",
"publisher":"Regulatory Peptides",
"author":"Gjurasin M, Miklic P, Zupancic B, Perovic D, Zarkovic K, Brcic L, Kolenc D, Radic B, Seiwerth S, Sikiric P",
"date":"2010",
"quote":"BPC 157 markedly improved rat sciatic nerve healing",
"summary":"PMID 19903499; DOI 10.1016/j.regpep.2009.11.005. Transected rat sciatic nerve, 10 ug/kg or 10 ng/kg given intraperitoneally, intragastrically, locally at the anastomosis, or directly into nerve tubing after segment resection. Autotomy was absent in treated rats; electromyography showed increased motor action potentials; the sciatic functional index improved with weekly walking recovery; histomorphometry showed increased density and size of regenerative fibres and improved myelination. Assessed at one to two months post-injury.",
"_id":"w_032xvatb",
"_ts":"2026-08-04T08:13:27.173Z",
"accessed_at":"2026-08-04T08:13:27.173Z",
"claim_ids": [],
"prev":"60c97d928b95dcf2ac4a2fb39aca9c20fae246e58b2bade1882dd0f168acb10c",
"hash":"7a3297a46eba8d8bba8ac60e8d6db02b1439e1b16cb58acaa2e542f3e1b556e1",
"quote_sha256":"92c463a074e0e152e65f385c14b8977b8764f8b0c3e97706c4f3519e3add8c2f"
},
{
"id":"w_dmscp9sw",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9164058/",
"title":"Novel therapeutic effects in rat spinal cord injuries: recovery of the definitive and early spinal cord injury by the administration of pentadecapeptide BPC 157 therapy",
"publisher":"Current Issues in Molecular Biology",
"author":"Perovic D, Milavic M, Dokuzovic S, Krezic I, et al.",
"date":"2022-04-27",
"quote":"rapid and sustained recovery (1 year)",
"summary":"PMID 35678659; PMCID PMC9164058; DOI 10.3390/cimb44050130. Laminectomy at L2-L3 with one-minute compression of the sacrocaudal cord by a 60-66 g neurosurgical piston, producing definitive tail paralysis. Three regimens tested: 2 ug/kg intraperitoneally at 10 minutes post-injury; a 10 ng/kg intragastric bolus on day 4; and 10 ug/kg per-orally in drinking water (0.16 ug/mL, 12 mL/rat/day) from day 4 to day 30. Tail motor function recovered and spasticity resolved by day 15. At day 30 treated rats showed only discrete edema, minimal hemorrhage and no demyelination process. Notably, the delayed regimens worked — treatment starting on day 4 still produced recovery.",
"_id":"w_dmscp9sw",
"_ts":"2026-08-04T08:13:31.862Z",
"accessed_at":"2026-08-04T08:13:31.862Z",
"claim_ids": [],
"prev":"7a3297a46eba8d8bba8ac60e8d6db02b1439e1b16cb58acaa2e542f3e1b556e1",
"hash":"4c338529554ecbb6ea9a1658e653f5703d8d6d6ee36721679ed714a90051300c",
"quote_sha256":"a096a71b7ac9d1cd6d6f960b82fdadc02fb5958cf5d2be15a4e231c926e732f0"
},
{
"id":"w_odtbasyy",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/21295044/",
"title":"Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions",
"publisher":"Life Sciences",
"author":"Ilic S, Drmic D, Franjic S, Kolenc D, Coric M, Brcic L, et al.",
"date":"2011",
"quote":"BPC 157 (10 microg/kg, 10 ng/kg) was strongly effective throughout the entire experiment when given (i) intraperitoneally immediately after diclofenac or (ii) per-orally in drinking water",
"summary":"PMID 21295044; DOI 10.1016/j.lfs.2011.01.015. Diclofenac at 12.5 mg/kg intraperitoneally once daily for three days produced severe gastric, intestinal and liver lesions, raised bilirubin, AST and ALT, increased liver weight, prolonged sedation and hepatic encephalopathy with brain edema and damaged red neurons. BPC 157 antagonised the whole cascade at both the microgram and nanogram tiers, by injection or in drinking water at 0.16 ug/mL or 0.16 ng/mL.",
"_id":"w_odtbasyy",
"_ts":"2026-08-04T08:13:36.010Z",
"accessed_at":"2026-08-04T08:13:36.010Z",
"claim_ids": [],
"prev":"4c338529554ecbb6ea9a1658e653f5703d8d6d6ee36721679ed714a90051300c",
"hash":"d5fcfb1e5bcd4eb2d1c0b9be8e6c4864704b8415db22f3e74b5b7e93e8fd062f",
"quote_sha256":"6097ebc786f49fb508602a7751384275e3615b7b3359d3354fdf87cf78f552ce"
},
{
"id":"w_iff2eacs",
"type":"news",
"url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act",
"title":"Bulk drug substances used in compounding under section 503B of the FD&C Act",
"publisher":"U.S. Food and Drug Administration",
"author":"FDA",
"date":"accessed 2026-08-04",
"quote":"Outsourcing facilities... may not compound a drug product that includes a bulk drug substance unless: The bulk drug substance appears on a list identifying bulk drug substances for which there is a clinical need (the 503B bulks list), or The drug product compounded from such bulk drug substance appears on FDA's drug shortage list at the time of compounding, distribution and dispensing.",
"summary":"The second compounding channel, separate from 503A. BPC-157 does not appear on this page or on the 503B bulks list. FDA also requires that bulk substances be accompanied by a valid certificate of analysis, be manufactured by an establishment registered under section 510, and comply with any applicable USP or National Formulary monograph. The July 2026 advisory committee vote concerned the 503A list only and has no bearing on 503B eligibility.",
"_id":"w_iff2eacs",
"_ts":"2026-08-04T08:13:36.776Z",
"accessed_at":"2026-08-04T08:13:36.776Z",
"claim_ids": [],
"prev":"d5fcfb1e5bcd4eb2d1c0b9be8e6c4864704b8415db22f3e74b5b7e93e8fd062f",
"hash":"ff54a4229bb5062c2b1c58724d9df5f87c621379d83cb46733a3983ad9c6ad83",
"quote_sha256":"672747c1c5b1a40627c0341cfe0d8549b03b7f806259c497110039c0fe8c65f1"
},
{
"id":"w_jdqqio36",
"url":"https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/duz790a/",
"title":"Compound experience saturday bpc157",
"quote":"I did a total of 10mg at a dosage of 500 mcg each day, and noticed no difference. I am left to wonder if the source was just bunk because everybody else seems to love the stuff.",
"_id":"w_jdqqio36",
"_ts":"2026-08-04T08:46:44.617Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:46:44.617Z",
"claim_ids": [],
"prev":"ff54a4229bb5062c2b1c58724d9df5f87c621379d83cb46733a3983ad9c6ad83",
"hash":"5a144ea94ea09ce9087b460c980d841332fead5e93314d4a28e1fcd6f7bdb5d3",
"subreddit":"r/steroids",
"author":"u/MjolnirCurls",
"flair":"2018-02-28",
"source_role":"anecdotal_report",
"plain":"Twenty days at the dose most posts use, and nothing. He raises the problem himself: with an untested vial, a real flat result and a fake product look exactly alike. No injury named, no measurement.",
"quote_sha256":"9f72dc8b1042c744e71a93e4d289cf92d561f2d32a8d1d11af9b9fb209afe40a"
},
{
"id":"w_fhil2can",
"url":"https://www.reddit.com/r/moreplatesmoredates/comments/1kfp3uf/does_bpc157_increase_recovery_between_workouts/mr860tt/",
"title":"Does bpc157 increase recovery between workouts",
"quote":"I ordered from 2 different websites and I doubt the shit was fake but it didnt do anything for me besides cost me a few hundred",
"_id":"w_fhil2can",
"_ts":"2026-08-04T08:47:05.911Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:05.911Z",
"claim_ids": [],
"prev":"5a144ea94ea09ce9087b460c980d841332fead5e93314d4a28e1fcd6f7bdb5d3",
"hash":"31b1d72af73834fc2bd1c527f171b809fd87fe15a6a4bff3f4ff77f35b293ade",
"subreddit":"r/moreplatesmoredates",
"author":"u/Cr1ms0nSlayer",
"flair":"2025-05-08",
"source_role":"anecdotal_report",
"plain":"Two different vendors, same nothing — which weakens the bad-batch excuse for at least this one person. What he was judging was how he felt between training sessions, with no injury and no measure.",
"quote_sha256":"c78d6acfc867769624bee26602a2a4e67a0187a0657ccd3b5790b0ecb14e1cc9"
},
{
"id":"w_8dxl599w",
"url":"https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi6t9l6/",
"title":"Compounds healing compounds bpc157 tb500 etc",
"quote":"Been injecting 500mcg per day subq close to knee. Unfortunately have not seen any improvement in the knee/s.",
"_id":"w_8dxl599w",
"_ts":"2026-08-04T08:47:07.039Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:07.039Z",
"claim_ids": [],
"prev":"31b1d72af73834fc2bd1c527f171b809fd87fe15a6a4bff3f4ff77f35b293ade",
"hash":"e86f79bdd5b646af07081cc05f8868acf035985581978da5d7a394a242e62f74",
"subreddit":"r/steroids",
"author":"u/jlthreequarters",
"flair":"2025-03-17",
"source_role":"anecdotal_report",
"plain":"Daily injections placed right beside the joint, the placement people insist matters most, and no change in either knee. He gives no duration and no imaging, but as a flat report at the standard dose it is clean.",
"quote_sha256":"7224b6cb20a0ed79d750ebe11fb9905b0ecfa4b9a9d2ef98c6024d14e451eb93"
},
{
"id":"w_0t8zcb1s",
"url":"https://www.reddit.com/r/backpain/comments/1ccysh4/chronic_onesided_thoracic_pain/",
"title":"Chronic onesided thoracic pain",
"quote":"I even tried peptides (BPC-157) for a month, no results.",
"_id":"w_0t8zcb1s",
"_ts":"2026-08-04T08:47:08.014Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:08.014Z",
"claim_ids": [],
"prev":"e86f79bdd5b646af07081cc05f8868acf035985581978da5d7a394a242e62f74",
"hash":"85477b560d4cb29fc414ce0306a383832886124bd1fab8b9052d1dc2af977f2f",
"subreddit":"r/backpain",
"author":"u/Dizzy-Breakfast-9405",
"flair":"2024-04-25",
"source_role":"anecdotal_report",
"plain":"A month of it against long-standing one-sided mid-back pain, listed among everything else he tried. No dose, no route, no product named — it counts as a no and not much more.",
"quote_sha256":"e5e638f7a53a6b7c0dde09cc8d949593303610e9c8eb65f9712985e534f30961"
},
{
"id":"w_txuoas2j",
"url":"https://www.reddit.com/r/backpain/comments/1mu96us/hlab27_sacroiliitis_on_mri_vs_disc_obliteration/",
"title":"Hlab27 sacroiliitis on mri vs disc obliteration",
"quote":"I also experimented with TB500 and BPC-157 peptides, but saw no improvement. The one thing that actually helped was Prednisone.",
"_id":"w_txuoas2j",
"_ts":"2026-08-04T08:47:08.778Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:08.778Z",
"claim_ids": [],
"prev":"85477b560d4cb29fc414ce0306a383832886124bd1fab8b9052d1dc2af977f2f",
"hash":"2d1fdef1f80c59e3454378e933a301e15433785b28063b8862bd97ac0e5bc413",
"subreddit":"r/backpain",
"author":"u/ImNotSchema",
"flair":"2025-08-19",
"source_role":"anecdotal_report",
"plain":"Joint inflammation confirmed on a scan, no change from the peptides, and a steroid that did work. Two compounds were run together so neither is isolated, but a direct comparison against something that helped is rare in these reports.",
"quote_sha256":"c24d038ac5d1417fa83b9bee18da0c988cb97019b947f11703ab30310b26f101"
},
{
"id":"w_9l5g0ldo",
"url":"https://www.reddit.com/r/PEDs/comments/173pdv4/compounds_to_help_articular_cartilage_fissure_in/",
"title":"Compounds to help articular cartilage fissure in",
"quote":"I've taken tb500 and bpc157 before and found it did nothing.",
"_id":"w_9l5g0ldo",
"_ts":"2026-08-04T08:47:09.955Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:09.955Z",
"claim_ids": [],
"prev":"2d1fdef1f80c59e3454378e933a301e15433785b28063b8862bd97ac0e5bc413",
"hash":"b07142254f40c55982b71ec6e0576d97df6ae9fa45f7dae92a7544c648b54080",
"subreddit":"r/PEDs",
"author":"u/Itchy_Brain6340",
"flair":"2023-10-09",
"source_role":"anecdotal_report",
"plain":"Thin and undetailed: no dose, no duration, two compounds at once. It is here because damaged joint cartilage is one of the main reasons people buy this, and here is someone who did and got nothing.",
"quote_sha256":"a4db463159c1fe290dce11ff9b294ca171c3382a7f3cd1dec8ad7cbd68c6ccd0"
},
{
"id":"w_8kdirxz8",
"url":"https://www.reddit.com/r/Peptidesource/comments/1v6e4g2/need_help_deciding_between_kpv_low_dose/",
"title":"Need help deciding between kpv low dose",
"quote":"I am going to finish up a vial of BPC 157 that I’ve been injecting for about 6 weeks with no improvement.",
"_id":"w_8kdirxz8",
"_ts":"2026-08-04T08:47:10.877Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:10.877Z",
"claim_ids": [],
"prev":"b07142254f40c55982b71ec6e0576d97df6ae9fa45f7dae92a7544c648b54080",
"hash":"6e674b73863994cbef6b82c677a8cb90f5e4f5c6d53f4a3e64f6b7676fb3720f",
"subreddit":"r/Peptidesource",
"author":"u/TheAwkwardEmu",
"flair":"2026-07-25",
"source_role":"anecdotal_report",
"plain":"Six weeks of injections finished with no change, and he is already choosing the next compound. Long enough that impatience is not the explanation. He never says what he was treating, so the report cannot be matched to a condition.",
"quote_sha256":"feffd9754a92f10f429fd5c08a9eddabe9bfc6bb4e247accc6424d18e1e9b679"
},
{
"id":"w_18w5khoc",
"url":"https://www.reddit.com/r/Biohackers/comments/1u7ixcd/blend_experience/",
"title":"Blend experience",
"quote":"this is the 9th day and i feel no changes i have an Achilles tendon injury or inflammation there and i have some knee problems",
"_id":"w_18w5khoc",
"_ts":"2026-08-04T08:47:11.646Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:11.646Z",
"claim_ids": [],
"prev":"6e674b73863994cbef6b82c677a8cb90f5e4f5c6d53f4a3e64f6b7676fb3720f",
"hash":"9faec3566913ecd3c24123539cb113e989b7a52718d9d48a7730fbd6ac61bd64",
"subreddit":"r/Biohackers",
"author":"u/Acrobatic-Car3352",
"flair":"2026-06-16",
"source_role":"anecdotal_report",
"plain":"Nine days into a blend of compounds, with an Achilles problem and sore knees, and nothing yet. Far too early to be a verdict — its value is catching a course at the beginning instead of after someone has decided what it did.",
"quote_sha256":"ce6d7bce58e083e9aaaa519d0ff50fe36791aaf5374270d88934ea31735b5ae3"
},
{
"id":"w_hf6dcwyh",
"url":"https://www.reddit.com/r/moreplatesmoredates/comments/phepeu/ligament_injury_repair_with_bpc157_and_tb500/hsp96nl/",
"title":"Ligament injury repair with bpc157 and tb500",
"quote":"i took BPC157 capsules and it did nothing for my ligament issues, i got a lot of prolo and PRP.",
"_id":"w_hf6dcwyh",
"_ts":"2026-08-04T08:47:12.396Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:12.396Z",
"claim_ids": [],
"prev":"9faec3566913ecd3c24123539cb113e989b7a52718d9d48a7730fbd6ac61bd64",
"hash":"a88ca38ef1e889c90f3db31fa3e74f7aa09a17db0c4801f7f4d72193e47901ab",
"subreddit":"r/moreplatesmoredates",
"author":"u/kayfab",
"flair":"2022-01-15",
"source_role":"anecdotal_report",
"plain":"Capsules rather than injections, which is the route most argued to be weakest for ligaments. It did nothing for him and he ended up having injections into the joint instead.",
"quote_sha256":"d016a6f8120f98578926d1c129447958302246517abf6368d240204b91e6febf"
},
{
"id":"w_epyzmnva",
"url":"https://www.reddit.com/r/backpain/comments/1fi50ar/bpc_157_and_tb_500_for_herniated_disc/",
"title":"Bpc 157 and tb 500 for herniated disc",
"quote":"I started taking bpc 157 and tb 500 and 500mcg a day to help with healing but I have started to feel worse and have pain going down my leg again.",
"_id":"w_epyzmnva",
"_ts":"2026-08-04T08:47:13.182Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:13.182Z",
"claim_ids": [],
"prev":"a88ca38ef1e889c90f3db31fa3e74f7aa09a17db0c4801f7f4d72193e47901ab",
"hash":"74060a7a49218688667f001c18e59f3fd23e11357def789a8450156791761959",
"subreddit":"r/backpain",
"author":"u/Miserable_Fan1984",
"flair":"2024-09-16",
"source_role":"anecdotal_report",
"plain":"Worse, not merely flat — leg pain returned while he was on it. Disc symptoms swing on their own, so the compound may have had no part in it, but a worsening report belongs on the page alongside the good ones.",
"quote_sha256":"2379d270eddd9906388fe6deaccb55f11dac4124847f4417db043dcb79ab1def"
},
{
"id":"w_ucf38h39",
"url":"https://www.reddit.com/r/PEDs/comments/1qftcul/bpc157_gone_wrong/",
"title":"Bpc157 gone wrong",
"quote":"While the shoulder is seemingly better (just a bit sore the first day), my knees got way worse and got inflamed pretty bad. Going to stop to see it gets better",
"_id":"w_ucf38h39",
"_ts":"2026-08-04T08:47:14.082Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:14.082Z",
"claim_ids": [],
"prev":"74060a7a49218688667f001c18e59f3fd23e11357def789a8450156791761959",
"hash":"951e1d58c6c2d610109202b2f070e32f748af0490a484d6362576cd0cbb42de1",
"subreddit":"r/PEDs",
"author":"u/Illustrious_Buy_6545",
"flair":"2026-01-18",
"source_role":"anecdotal_report",
"plain":"One person, one dose, opposite results in two places: shoulder easier, knees inflamed badly enough that he quit. A split like that inside a single body is hard to put down to expectation, and it is among the clearest harm reports here.",
"quote_sha256":"0180f1731e3addf4a9833474c116287d1a181c9869a9eb99987ce31b62eba345"
},
{
"id":"w_usaqx7am",
"url":"https://www.reddit.com/r/Biohackers/comments/1ra2m3p/1_month_of_bpc157_tb500_blend_reviewblurry_vision/",
"title":"1 month of bpc157 tb500 blend reviewblurry vision",
"quote":"After weeks of bpc tb blend. I noticed my vision was getting worse and worse.. blurry..some days worse than others. Even just trying to focus at distance.",
"_id":"w_usaqx7am",
"_ts":"2026-08-04T08:47:15.298Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:15.298Z",
"claim_ids": [],
"prev":"951e1d58c6c2d610109202b2f070e32f748af0490a484d6362576cd0cbb42de1",
"hash":"0712e02cc87a106cbda1bc71d805d5a4144c298c49d447c93a6601ecb4441bb8",
"subreddit":"r/Biohackers",
"author":"u/cityhunterspeee",
"flair":"2026-02-20",
"source_role":"anecdotal_report",
"plain":"Vision blurring over weeks on a blend, worse on some days than others. No eye exam, no before-and-after, two compounds mixed. It is on the page because eyesight is not on anyone's list of expected effects.",
"quote_sha256":"42597f87293312a4b0526ed629d67f3765f825303c516c86ca9c9d22aa5487c7"
},
{
"id":"w_mjx06qhj",
"url":"https://www.reddit.com/r/Biohackers/comments/1tufuie/bpc157_for_shoulder_injury/",
"title":"Bpc157 for shoulder injury",
"quote":"I’m taking about 500 MCG per day bpc157 and injecting it in my shoulder. I haven’t seen any results yet besides maybe better sleep. It’s day 5",
"_id":"w_mjx06qhj",
"_ts":"2026-08-04T08:47:19.601Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:19.601Z",
"claim_ids": [],
"prev":"0712e02cc87a106cbda1bc71d805d5a4144c298c49d447c93a6601ecb4441bb8",
"hash":"121db4c6dd999b7b755c69f87ca2e5f03dbaca8fa6a48175c0bacee86de0a547",
"subreddit":"r/Biohackers",
"author":"u/forsaken3400",
"flair":"2026-06-02",
"source_role":"anecdotal_report",
"plain":"Day five, injecting into the shoulder itself, nothing except sleep he is unsure about. Chiefly a marker of how quickly people start asking whether it is working, well before any tissue could change.",
"quote_sha256":"822499e788fa3eee51290ddc95d42ae05ff50bbd63aa4ea09b737e644f388d7a"
},
{
"id":"w_brwijbo1",
"url":"https://www.reddit.com/r/Biohackers/comments/1u7ddu1/i_know_some_will_disagreebut_new_batch_of_bpc_157/",
"title":"I know some will disagreebut new batch of bpc 157",
"quote":"6/12-seems to have stopped working. Upped to 6.5-7 units. No change. Will continue.",
"_id":"w_brwijbo1",
"_ts":"2026-08-04T08:47:21.719Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:21.719Z",
"claim_ids": [],
"prev":"121db4c6dd999b7b755c69f87ca2e5f03dbaca8fa6a48175c0bacee86de0a547",
"hash":"abcb66d0a8e81ba196fa2d124f063cfef39163a3d5963c7eed7c5d86268e6302",
"subreddit":"r/Biohackers",
"author":"u/Trofas27",
"flair":"2026-06-16",
"source_role":"anecdotal_report",
"plain":"A running log from someone who felt something, then lost it, raised the dose, got nothing back, and carried on regardless. Losing response over time has never been studied for this compound — this is one diary, not evidence of it.",
"quote_sha256":"a74fa1bd85755205cedec20c1e12c6576a996fc464eb88e3d0499f41243c5627"
},
{
"id":"w_sg898nqt",
"url":"https://www.reddit.com/r/Peptides/comments/1uute3b/bpc157_and_tb4_has_it_not_worked_for_you/",
"title":"Bpc157 and tb4 has it not worked for you",
"quote":"I had high hopes for the peptide treatment but so far it hasn’t helped a lot. It has helped a bit but I expected more.",
"_id":"w_sg898nqt",
"_ts":"2026-08-04T08:47:29.573Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:29.573Z",
"claim_ids": [],
"prev":"abcb66d0a8e81ba196fa2d124f063cfef39163a3d5963c7eed7c5d86268e6302",
"hash":"8c7506afb12a4638a0eb3575c2893883ed0dcb03590d40b693fd66f92fd1250e",
"subreddit":"r/Peptides",
"author":"u/Quacka-moo",
"flair":"2026-07-12",
"source_role":"anecdotal_report",
"plain":"A partial result, posted in a thread that asked specifically for failures. Nothing measured and no condition named, but it is the honest middle that disappears between the miracle posts and the flat noes.",
"quote_sha256":"9138c20c6a90ab2792e47650e761b16fe1ea6585bd0e4344d24f1055ebe252e4"
},
{
"id":"w_ahk1cevh",
"url":"https://www.reddit.com/r/PEDs/comments/1isdmz1/de_quervains_tendonitis_recovery/",
"title":"De quervains tendonitis recovery",
"quote":"I also did a small run of bpc-157 (oral), tb-500, and ghk-cu.",
"_id":"w_ahk1cevh",
"_ts":"2026-08-04T08:47:44.215Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:47:44.215Z",
"claim_ids": [],
"prev":"8c7506afb12a4638a0eb3575c2893883ed0dcb03590d40b693fd66f92fd1250e",
"hash":"620effefc34104b3aa4e39ed2f63870a2f97159547c09cc37214e69728b4ef96",
"subreddit":"r/PEDs",
"author":"u/fsdbt381",
"flair":"2025-02-18",
"source_role":"anecdotal_report",
"plain":"A recovery write-up in which three different compounds were taken at once, alongside whatever else the recovery involved. It records what went in, not what any one of them did.",
"quote_sha256":"7eb6173368c5e0ed344b1b64125fd5992299688e729d4a6fae3aeeb50c097b89"
},
{
"id":"w_qqu8pdaq",
"url":"https://www.reddit.com/r/Supplements/comments/1rcxvm9/finally_got_around_to_trying_the_bpc157_capsules/",
"title":"Finally got around to trying the bpc157 capsules",
"quote":"Is this placebo? Possibly. I didn't use it in a controlled fashion - I also added collagen peptides and increased my protein intake.",
"_id":"w_qqu8pdaq",
"_ts":"2026-08-04T08:48:10.916Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:10.916Z",
"claim_ids": [],
"prev":"620effefc34104b3aa4e39ed2f63870a2f97159547c09cc37214e69728b4ef96",
"hash":"1c499addd5a84a23782fbb780514c907fdf39f0a431b26e84c72c2485c946b81",
"subreddit":"r/Supplements",
"author":"u/viewsinthe6",
"flair":"2026-02-23",
"source_role":"anecdotal_report",
"plain":"Unusual for these threads: he improved, then listed the reasons it might not be the capsules. He raised his protein and added collagen in the same stretch, so three things changed together.",
"quote_sha256":"064bc2916098fde52bd95ee7b13955adb0b30b346a4cb37c24754c7914ce8a12"
},
{
"id":"w_vljlka3r",
"url":"https://www.reddit.com/r/PeptideGuide/comments/1s4vose/need_guidance/",
"title":"Need guidance",
"quote":"I do see reduction in pain on my right arm but its not completely gone .. i do feel pressure on joint . There is no difference in condition of left arm .",
"_id":"w_vljlka3r",
"_ts":"2026-08-04T08:48:28.249Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:28.249Z",
"claim_ids": [],
"prev":"1c499addd5a84a23782fbb780514c907fdf39f0a431b26e84c72c2485c946b81",
"hash":"e8bb262d64e683a8f969a134c6130f20e2a28720564d95c464cd564066e636de",
"subreddit":"r/PeptideGuide",
"author":"u/SanketJ1986",
"flair":"2026-03-27",
"source_role":"anecdotal_report",
"plain":"Both arms affected, one improved and the other did not, in the same person on the same course. That built-in comparison is what nearly every other report here lacks — though the pain was never measured, only felt.",
"quote_sha256":"7220b154b03d1943ef99aeb1a081b150f0ae405011a93d7dc073563945195c98"
},
{
"id":"w_e8sw6xul",
"url":"https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi9owhr/",
"title":"Compounds healing compounds bpc157 tb500 etc",
"quote":"Almost immediately the knee pain went away, although I have heard this is due to the anti-inflammatory effects rather than any actual healing. After three weeks when I stopped I noticed the knee pain came back almost immediately",
"_id":"w_e8sw6xul",
"_ts":"2026-08-04T08:48:29.467Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:29.467Z",
"claim_ids": [],
"prev":"e8bb262d64e683a8f969a134c6130f20e2a28720564d95c464cd564066e636de",
"hash":"b3728fcd8e4b3ffc994396acb171a803379c92e9e0b29acd713cb37d1c7b7b79",
"subreddit":"r/steroids",
"author":"u/MysterMumbles",
"flair":"2025-03-17",
"source_role":"anecdotal_report",
"plain":"Relief that arrived within days and left within days of stopping. That timing fits symptoms being quieted rather than tissue rebuilding, which is exactly how he reads it himself.",
"quote_sha256":"96ceddfbcb58ba510b18ca0b0b9f5a9ec199a058052568ef601e19171f2732ab"
},
{
"id":"w_q3b1i12c",
"url":"https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/dus0n8q/",
"title":"Compound experience saturday bpc157",
"quote":"Unfortunately it didn't seem to heal the actual tear quite as fast, but when coupled with isometric exercises prescribed by sports doctor, I gradually started to recover useab",
"_id":"w_q3b1i12c",
"_ts":"2026-08-04T08:48:30.302Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:30.302Z",
"claim_ids": [],
"prev":"b3728fcd8e4b3ffc994396acb171a803379c92e9e0b29acd713cb37d1c7b7b79",
"hash":"5629f1057b328ada08dc381f7313f77fd5c0404e7e7bccd27b36d1c7e9240961",
"subreddit":"r/steroids",
"author":"u/mite189",
"flair":"2018-02-24",
"source_role":"anecdotal_report",
"plain":"A mixed account: the tear did not close quickly, and supervised rehab exercise ran the whole time alongside the compound, so the recovery cannot be handed to either one.",
"quote_sha256":"a1e94d465d409b7dc78fcfc9bc54b442c5a6a2e6a974387640901eb6c3657750"
},
{
"id":"w_as6ue9dv",
"url":"https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/dutyok7/",
"title":"Compound experience saturday bpc157",
"quote":"I recommend if you're suffering an acute pain from ligament/muscle/soft tissue then use BPC-157 it's not a miracle by any means but I can improve mobility.",
"_id":"w_as6ue9dv",
"_ts":"2026-08-04T08:48:31.102Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:31.102Z",
"claim_ids": [],
"prev":"5629f1057b328ada08dc381f7313f77fd5c0404e7e7bccd27b36d1c7e9240961",
"hash":"45e3517ca0aeab981df92adb0a5057b76efdc553e68f4709fb9dfeb0dbe215cb",
"subreddit":"r/steroids",
"author":"u/sdBiotch",
"flair":"2018-02-26",
"source_role":"anecdotal_report",
"plain":"A positive user drawing his own limits — short-term soft-tissue pain, movement rather than repair, explicitly not a miracle. No dose, no timeline, nothing imaged.",
"quote_sha256":"d8cc56d25474f404c8cc99486cc105bd5f8638739fac5a0b9c244e9ee5b86f18"
},
{
"id":"w_o9okgjxa",
"url":"https://www.reddit.com/r/backpain/comments/1khc6p5/and_it_begins_bpc_157_and_tb_500/nokzab3/",
"title":"And it begins bpc 157 and tb 500",
"quote":"Tbh, all dosages are completely unfounded on anything. Someone just made them up. There is literally no established clinical dosage.",
"_id":"w_o9okgjxa",
"_ts":"2026-08-04T08:48:32.298Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:32.298Z",
"claim_ids": [],
"prev":"45e3517ca0aeab981df92adb0a5057b76efdc553e68f4709fb9dfeb0dbe215cb",
"hash":"4ab67a46605e80a70e545f316316b33970719c9c2c199d496b4441972d499433",
"subreddit":"r/backpain",
"author":"u/igthrowawayy",
"flair":"2025-11-13",
"source_role":"anecdotal_report",
"plain":"A blunt point about the whole dosing conversation: the numbers traded in these threads were settled by convention, not by any trial. It is one commenter asserting it, and it is the frame to read every dose on this page through.",
"quote_sha256":"8727017e8dfea254a6c103b2f5bd7d2e895ca0a93e9f48d6dd6c12bc4e69ac9b"
},
{
"id":"w_1bbc6bfn",
"url":"https://www.reddit.com/r/Peptides/comments/1u8m20w/bpc_157_drinking_reconstituted_injectable_vs/osdrkbj/",
"title":"Bpc 157 drinking reconstituted injectable vs",
"quote":"Oral bpc is not as effective for tendon, ligament healing works for GI issues.",
"_id":"w_1bbc6bfn",
"_ts":"2026-08-04T08:48:33.063Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:33.063Z",
"claim_ids": [],
"prev":"4ab67a46605e80a70e545f316316b33970719c9c2c199d496b4441972d499433",
"hash":"7d948b70d53714530b6c1a8e650105f416181fcf8f9f1555ff61f79e11ba7688",
"subreddit":"r/Peptides",
"author":"u/elfjan",
"flair":"2026-06-18",
"source_role":"anecdotal_report",
"plain":"The community's standard rule of thumb — swallow it for the gut, inject it for tendons and ligaments — stated flatly and with nothing behind it. Worth knowing because it is repeated everywhere, not because it is shown.",
"quote_sha256":"48abbe5b76835dfab1d53a33dd772b7763d39d729ee084f7382e991aafe02004"
},
{
"id":"w_iqb7rlvn",
"url":"https://www.reddit.com/r/climbharder/comments/1j4fiij/experience_with_bpc157_and_elbow_tendinopathy/",
"title":"Experience with bpc157 and elbow tendinopathy",
"quote":"Things felt immediately better while I wasn't climbing. Though, to refer back to the variables, I felt better before the BPC as well.",
"_id":"w_iqb7rlvn",
"_ts":"2026-08-04T08:48:33.890Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:33.890Z",
"claim_ids": [],
"prev":"7d948b70d53714530b6c1a8e650105f416181fcf8f9f1555ff61f79e11ba7688",
"hash":"f96ec3ca899a52149f4dd8cf35497fddd1da8f4aac99e03fa1b05bb6622239ec",
"subreddit":"r/climbharder",
"author":"u/mudra311",
"flair":"2025-03-05",
"source_role":"anecdotal_report",
"plain":"Someone auditing his own confounders: he had stopped the activity that aggravated the elbow, and he was already improving before he started. The tidiest illustration of why a personal report cannot separate a compound from rest.",
"quote_sha256":"449cb6e38da50848213dbe368b8fde71d3c049443ece211fdfd50d58c4ac12ea"
},
{
"id":"w_0d8jnd1s",
"url":"https://www.reddit.com/r/climbharder/comments/1axf2aa/my_experience_case_study_recovering_from_an_a2/",
"title":"My experience case study recovering from an a2",
"quote":"My finger started to stay very swollen all day and felt like it was retaining fluid. It became somewhat difficult to do finger rolls because it felt like my digits were too swollen in the skin to close properly.",
"_id":"w_0d8jnd1s",
"_ts":"2026-08-04T08:48:34.660Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:34.660Z",
"claim_ids": [],
"prev":"f96ec3ca899a52149f4dd8cf35497fddd1da8f4aac99e03fa1b05bb6622239ec",
"hash":"d9abe3ce07772b51b01d0a06381b1c7264c5daf3c4d1342e8c5776c83da9cdaa",
"subreddit":"r/climbharder",
"author":"u/WeenieLoft",
"flair":"2024-02-22",
"source_role":"anecdotal_report",
"plain":"Persistent swelling in the injured finger itself during a written-up recovery attempt, enough to interfere with closing the hand. One person, no examination, but the complaint is specific and local rather than vague.",
"quote_sha256":"c0aa0a1972271a51760d8819be590331be176fb7e5e6234f8eaebb94689ea45a"
},
{
"id":"w_mzg8md2j",
"url":"https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi3v7kp/",
"title":"Compounds healing compounds bpc157 tb500 etc",
"quote":"Weeks 1-2 I used 250 mcg BPC daily and 2 mg TB twice a week, weeks 3-8 I continued with the same BPC dose and dropped TB administration to once a week.",
"_id":"w_mzg8md2j",
"_ts":"2026-08-04T08:48:35.561Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:35.561Z",
"claim_ids": [],
"prev":"d9abe3ce07772b51b01d0a06381b1c7264c5daf3c4d1342e8c5776c83da9cdaa",
"hash":"e8c5ea87caf7c841120f5bec34130b7fd359834f194a6b02535a5f6bcb836593",
"subreddit":"r/steroids",
"author":"u/CheekAccomplished150",
"flair":"2025-03-16",
"source_role":"anecdotal_report",
"plain":"An eight-week schedule written out including the step-down, which most posts omit. It documents what was taken and pairs a second compound with it throughout; the excerpt carries no outcome at all.",
"quote_sha256":"7062435432893cb2fabb738a3857e438673595257d66d581f5005c447f491eac"
},
{
"id":"w_xmo3vo5n",
"url":"https://www.reddit.com/r/steroids/comments/150bge2/compounds_healing_compounds_bpc157_tb500/js5hfcw/",
"title":"Compounds healing compounds bpc157 tb500",
"quote":"I did 500mcg every 8 hours (3x a day) for 2 weeks. After the two weeks there was a substantial difference in pain levels.",
"_id":"w_xmo3vo5n",
"_ts":"2026-08-04T08:48:36.532Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:36.532Z",
"claim_ids": [],
"prev":"e8c5ea87caf7c841120f5bec34130b7fd359834f194a6b02535a5f6bcb836593",
"hash":"b9b8b553d10cc62cca0fc8d9529aa9b9596a86b0ead8f600de1b2881088f949b",
"subreddit":"r/steroids",
"author":"u/SwaveyyyD",
"flair":"2023-07-16",
"source_role":"anecdotal_report",
"plain":"Three doses a day, roughly triple the daily amount most posts describe, with pain down after two weeks. The injury is never described and the pain scale is his own.",
"quote_sha256":"aeb18d2c9f33aec843f8220af3b529a609b3699ebc479771f0b77381c93a84f5"
},
{
"id":"w_xypc4fgc",
"url":"https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4eq0n/",
"title":"Compounds healing compounds bpc157 tb500 etc",
"quote":"Used bpc-157 for a few weeks at 450- 900 mcg / day to heal a severely strained rotator cuff and it seems to have worked wonders.",
"_id":"w_xypc4fgc",
"_ts":"2026-08-04T08:48:37.482Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:37.482Z",
"claim_ids": [],
"prev":"b9b8b553d10cc62cca0fc8d9529aa9b9596a86b0ead8f600de1b2881088f949b",
"hash":"6a84b0669bc2839c2e3beff3f85ae155f3d95df0777e06366286369437784053",
"subreddit":"r/steroids",
"author":"u/UnusuallyTarded11",
"flair":"2025-03-16",
"source_role":"anecdotal_report",
"plain":"A strong positive on a badly strained shoulder over a few weeks at a dose he varied twice over. Strains commonly settle in that same window, and there is no scan at either end to separate the two.",
"quote_sha256":"3ef7a0c818b8bb8f60923f7e7cffd3292294b2bfcf8fd60b6e61b3d62f467cd7"
},
{
"id":"w_xk3kn65m",
"url":"https://www.reddit.com/r/steroids/comments/tqsoik/compounds_bpc157_my_experience/",
"title":"Compounds bpc157 my experience",
"quote":"I used 2x 0.2ml injections daily for 1 week, then 1x 0.2ml injection daily for 2 days. Injected subQ",
"_id":"w_xk3kn65m",
"_ts":"2026-08-04T08:48:38.312Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:38.312Z",
"claim_ids": [],
"prev":"6a84b0669bc2839c2e3beff3f85ae155f3d95df0777e06366286369437784053",
"hash":"e10af64d9261499e266674a5abd3a529fc38f2ef80fcee3c2ebdc5ce87b91936",
"subreddit":"r/steroids",
"author":"u/Seralcar",
"flair":"2022-03-29",
"source_role":"anecdotal_report",
"plain":"Dosing given in syringe volume with no vial strength, so the actual amount taken is unknowable. A good demonstration of why these posts are poor evidence about dose even when they look precise.",
"quote_sha256":"674daf93235716d04ea62d0e92e07b99c2640b41f861276ce8ba88987b94edd0"
},
{
"id":"w_ihoinuk1",
"url":"https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4uao6/",
"title":"Compounds healing compounds bpc157 tb500 etc",
"quote":"Did 12 weeks of BPC and TB-500. After 10 weeks I went back to the ortho and he said the tear was gone.",
"_id":"w_ihoinuk1",
"_ts":"2026-08-04T08:48:39.071Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:39.071Z",
"claim_ids": [],
"prev":"e10af64d9261499e266674a5abd3a529fc38f2ef80fcee3c2ebdc5ce87b91936",
"hash":"7dd776e44c3544401f9620b26d199b902c746afbf6fdf0de9bdb6e1ad1ab1a72",
"subreddit":"r/steroids",
"author":"u/RGJJBrwn2022",
"flair":"2025-03-16",
"source_role":"anecdotal_report",
"plain":"One of the very few reports checked by someone other than the user: after ten weeks his surgeon said the tear was no longer there. No scan is mentioned, two compounds ran together, and tears do repair over twelve weeks on their own.",
"quote_sha256":"d4db1532868c109c6d7b6d631943c5d0375716870eea95328ef7c548bee1e22d"
},
{
"id":"w_iquapnzf",
"url":"https://www.reddit.com/r/Biohackers/comments/1u09ium/bpc_157_tb500_side_effect_for_65_yrs_old/oqhs3hp/",
"title":"Bpc 157 tb500 side effect for 65 yrs old",
"quote":"Started BPC-157 three weeks after that injury, injecting 500mcg daily (left knee day 1, right knee day 2, etc). The chronic pain dissipated 3 weeks in and the injured knee felt stronger by week 4.",
"_id":"w_iquapnzf",
"_ts":"2026-08-04T08:48:39.829Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:39.829Z",
"claim_ids": [],
"prev":"7dd776e44c3544401f9620b26d199b902c746afbf6fdf0de9bdb6e1ad1ab1a72",
"hash":"33a80c1bacf9b86ce7bd9a34987038a1e4b0b70674f24ec3b3cb15d17b988c9e",
"subreddit":"r/Biohackers",
"author":"u/beach_nuts",
"flair":"2026-06-08",
"source_role":"anecdotal_report",
"plain":"An older user alternating knees day by day, with long-standing pain easing around week three and strength returning by week four. The injury was only three weeks old when he began, so ordinary healing was running at the same time.",
"quote_sha256":"c5800354dc35341725d25ffccf92ced3dd979a89b6fc010ae09fc00b60358cc6"
},
{
"id":"w_vhlzhg4n",
"url":"https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4iwuk/",
"title":"Compounds healing compounds bpc157 tb500 etc",
"quote":"After some unsuccessful months, I stacked up BPC/TB 250mcg ED for 4 weeks. Pain completely gone after 3rd week.",
"_id":"w_vhlzhg4n",
"_ts":"2026-08-04T08:48:40.674Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:40.674Z",
"claim_ids": [],
"prev":"33a80c1bacf9b86ce7bd9a34987038a1e4b0b70674f24ec3b3cb15d17b988c9e",
"hash":"03a4a5a1a6ae503860bedf5c83da3b80cb95afbe429700bcb5a2ccc72553b347",
"subreddit":"r/steroids",
"author":"u/Blahblahblurred",
"flair":"2025-03-16",
"source_role":"anecdotal_report",
"plain":"Months of getting nowhere first, then improvement in the third week of a low daily dose — the sequence that convinces people. Two compounds together, pain judged by feel, nothing imaged before or after.",
"quote_sha256":"e4de4582fcacc9253ed6d1532712318b37d265f1496ca1ceb496bd13ed8dc596"
},
{
"id":"w_e1ub04di",
"url":"https://www.reddit.com/r/moreplatesmoredates/comments/1l697k3/lifting_3_months_after_a_broken_wrist/",
"title":"Lifting 3 months after a broken wrist",
"quote":"7 bottles of bpc157 in the wrist later and im getting super close to being at my old ability. Max bench before was 315x1 and atm the highest I’ve gone is 275x1. It’s not 100% yet, still has minor pain or stiffness at times",
"_id":"w_e1ub04di",
"_ts":"2026-08-04T08:48:41.457Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:41.457Z",
"claim_ids": [],
"prev":"03a4a5a1a6ae503860bedf5c83da3b80cb95afbe429700bcb5a2ccc72553b347",
"hash":"e956ca4388fe586c0673a5ac1005fa5d6a34bbe92d2051534a4168c6f97d156f",
"subreddit":"r/moreplatesmoredates",
"author":"u/frequentflyernine11",
"flair":"2025-06-08",
"source_role":"anecdotal_report",
"plain":"A broken wrist tracked by what he can lift, back to within about forty pounds of his old best and still stiff and sore. Bone knits over months regardless, and there is nothing here to compare that recovery against.",
"quote_sha256":"b4e94a1c15da8eefdb470539f6951d24107d77a68ab594273c23486e1459a9ce"
},
{
"id":"w_wnund5ki",
"url":"https://www.reddit.com/r/Peptides/comments/1teo1c6/accidentally_took_30iu_of_bpc157_instead_of_3iu/",
"title":"Accidentally took 30iu of bpc157 instead of 3iu",
"quote":"I did my first dose of bpc157 yesterday. And i made a mistake, i took 30IUs (3mg) instead of 3IUs (300mcg), because my f-ing syringe says 3 and not 30…",
"_id":"w_wnund5ki",
"_ts":"2026-08-04T08:48:42.238Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:42.238Z",
"claim_ids": [],
"prev":"e956ca4388fe586c0673a5ac1005fa5d6a34bbe92d2051534a4168c6f97d156f",
"hash":"e545bbf427d953da2ec55c575733e44c4c0f7b60c1e03f649dbbb7675c1ca953",
"subreddit":"r/Peptides",
"author":"u/LandscapeGloomy8012",
"flair":"2026-05-16",
"source_role":"anecdotal_report",
"plain":"A ten-fold overdose caused by misreading syringe markings, posted as the mistake rather than as a result. It belongs on the page as a dosing-hazard report: the units on the barrel are what tripped him.",
"quote_sha256":"d26e28a1e5d7a2e9442619595022fda1d2bf13bf73a8d0d027b3c11d38c02501"
},
{
"id":"w_mez2amn7",
"url":"https://www.reddit.com/r/Biohackers/comments/1sgf3q0/bpc157_and_tb500_weekly_update/",
"title":"Bpc157 and tb500 weekly update",
"quote":"500mcg of BCP EOD and 500mcg of TB EOD. This is day 5 not even a full week and I could fucking cry because my shoulder feels 75% better that fast.",
"_id":"w_mez2amn7",
"_ts":"2026-08-04T08:48:43.128Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:43.128Z",
"claim_ids": [],
"prev":"e545bbf427d953da2ec55c575733e44c4c0f7b60c1e03f649dbbb7675c1ca953",
"hash":"82443291d579f947f9057f9e062b46397160ee0916e65a545a67074df8d847a4",
"subreddit":"r/Biohackers",
"author":"u/hraww",
"flair":"2026-04-09",
"source_role":"anecdotal_report",
"plain":"Written on day five of every-other-day dosing, with a large improvement given as a percentage. A number a person assigns to his own shoulder that early is the least reliable figure on this page.",
"quote_sha256":"eba46ab94102e2511fb85e1ba72d32383efdee28bc97390862bdf139c53fb37d"
},
{
"id":"w_z8sd87d2",
"url":"https://www.reddit.com/r/PEDs/comments/1o3g7qp/is_oral_bpc157_less_effective_than_injecting_it/niwej2s/",
"title":"Is oral bpc157 less effective than injecting it",
"quote":"I partially tore my rotator cuff in early September. Injected 1500 mg BPC 157 for 3 weeks and I'm nearly fully recovered. I say this in terms of feel, not medical imaging.",
"_id":"w_z8sd87d2",
"_ts":"2026-08-04T08:48:43.903Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:43.903Z",
"claim_ids": [],
"prev":"82443291d579f947f9057f9e062b46397160ee0916e65a545a67074df8d847a4",
"hash":"ad2d0cdb6811451c5cd828852e57fe2aea7646ce201b2e5eb8f87300e2cb673d",
"subreddit":"r/PEDs",
"author":"u/SprinklesWise9857",
"flair":"2025-10-11",
"source_role":"anecdotal_report",
"plain":"He writes a dose a thousand times the usual, almost certainly meaning micrograms — which is itself the lesson about trusting numbers in these posts. He is also careful to say that recovered means how the shoulder feels, not what a scan shows.",
"quote_sha256":"af3c6373e6a858f4597df73307f61fd6efb9949b903e79413ce2e83ea60d8be4"
},
{
"id":"w_q512lyfs",
"url":"https://www.reddit.com/r/Sciatica/comments/1rnicr5/pinched_sciatic_nerve/",
"title":"Pinched sciatic nerve",
"quote":"I tried ever and eventually decided to try injectable BPC 157 and within a few weeks pain started to ease, well this could be random so I continued use after about 6-7 weeks sciatic pain was almost all the way gone",
"_id":"w_q512lyfs",
"_ts":"2026-08-04T08:48:44.763Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:44.763Z",
"claim_ids": [],
"prev":"ad2d0cdb6811451c5cd828852e57fe2aea7646ce201b2e5eb8f87300e2cb673d",
"hash":"8b953dfc33b063d55bc58365cbaa0aed6d8a8ae743799888aa673acc8609bc89",
"subreddit":"r/Sciatica",
"author":"u/kunukxathletix",
"flair":"2026-03-07",
"source_role":"anecdotal_report",
"plain":"Nerve pain rather than a tendon, fading over about six or seven weeks. He raises the coincidence objection himself and keeps going anyway; this kind of pain frequently resolves on its own over that same span.",
"quote_sha256":"9b6e331f712f20216932e59ec6fe6367d32c20505e96301a8daa5df64dcd0f61"
},
{
"id":"w_1t3oc07y",
"url":"https://www.reddit.com/r/Sciatica/comments/uk0bhk/bpc157_for_herniated_disc_l5_s1/",
"title":"Bpc157 for herniated disc l5 s1",
"quote":"I reconstituted each 5ml vial with 2ml of bacteriostatic water. Orally 500mcg a day.",
"_id":"w_1t3oc07y",
"_ts":"2026-08-04T08:48:45.820Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:45.820Z",
"claim_ids": [],
"prev":"8b953dfc33b063d55bc58365cbaa0aed6d8a8ae743799888aa673acc8609bc89",
"hash":"7b76cb64d9dabb74b83cab5b44b6339eb072efc869df4220e083653755ea52e4",
"subreddit":"r/Sciatica",
"author":"u/Hefty-Artichoke7789",
"flair":"2022-05-06",
"source_role":"anecdotal_report",
"plain":"Mixing and oral dosing spelled out down to the water volume, for a lower-back disc problem. A record of practice only — this excerpt reports the method and no outcome.",
"quote_sha256":"7442a0c53ccc50e7d883067dc966555fa4a1640c2a77ca3d14cc59e1b1f3fb11"
},
{
"id":"w_5icolfqk",
"url":"https://www.reddit.com/r/Supplements/comments/1scedge/bpc157_saved_my_foot/",
"title":"Bpc157 saved my foot",
"quote":"But now 3 months later it’s basically fully healed and feels great again. Could be coincidence, but the timeline felt way faster than any serious injury I’ve healed before.",
"_id":"w_5icolfqk",
"_ts":"2026-08-04T08:48:46.899Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:46.899Z",
"claim_ids": [],
"prev":"7b76cb64d9dabb74b83cab5b44b6339eb072efc869df4220e083653755ea52e4",
"hash":"155645f89fb6e7f8f21712ed7c842a7b7ce0e3b0cd78116043879365f9076d3c",
"subreddit":"r/Supplements",
"author":"u/DifficultReach2720",
"flair":"2026-04-04",
"source_role":"anecdotal_report",
"plain":"The headline says saved; the actual claim inside it is that a foot injury felt healed at three months and the timeline seemed fast to him. He volunteers that it could be coincidence and has nothing to compare it with.",
"quote_sha256":"7c924c68e38919666ecdbf8a0c37b879055c3200a1abc87a97a7d12d5b6cbd3b"
},
{
"id":"w_8uy508st",
"url":"https://www.reddit.com/r/climbharder/comments/lvmkqd/bpc157peptides_in_general/kcrhbqv/",
"title":"Bpc157peptides in general",
"quote":"started taking the bpc 157 and range of motion is 100%, random pain at certain angles is about home, still have a little pain if reach a certain area.",
"_id":"w_8uy508st",
"_ts":"2026-08-04T08:48:47.791Z",
"type":"reddit",
"accessed_at":"2026-08-04T08:48:47.791Z",
"claim_ids": [],
"prev":"155645f89fb6e7f8f21712ed7c842a7b7ce0e3b0cd78116043879365f9076d3c",
"hash":"d1e1b8c7f461580a3f1f3c6e54dcd8098650cc78e42efc0eb3d3504d8aa92c61",
"subreddit":"r/climbharder",
"author":"u/NoInvestigator7249",
"flair":"2023-12-10",
"source_role":"anecdotal_report",
"plain":"Full range of movement back, most of the random pain gone, some left at particular angles. Honest about what remains, but there is no starting measurement, no timeline, and no injury named in this excerpt.",
"quote_sha256":"cfe6a94d28db284f509dd871fc9376da2bfc72ce7286bc5c2b43d17a88258b6e"
}
],
"claims": [
{
"id":"c1",
"text":"BPC-157 is a made-in-a-lab chain of 15 amino acids, copied from a stretch of a protein found in stomach juice.",
"section":"BPC-157 is fifteen amino acids copied out of a protein in stomach juice",
"tier":"human",
"source_ids": [
"s1"
],
"source_status":"sourced",
"why_material":"Establishes identity and origin for all subsequent claims.",
"evidence_basis":"derived_inference",
"weight":0.8,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"posted_by": {
"actor":"system/repair",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"who_claims":"system/repair",
"slot":"what_it_is",
"source_role":"mechanism_support"
},
{
"id":"c2",
"text":"More than 100 studies in animals and in cells report faster healing — better-organised collagen, and blood vessels growing into the wound — across tendon, gut, muscle, bone and nerve.",
"section":"More than a hundred studies in animals and cells, and no large trial in a person",
"tier":"preclinical",
"source_ids": [],
"source_status":"unsourced",
"why_material":"Quantifies volume and scope of non-human data; separates from human evidence.",
"evidence_basis":"derived_inference",
"weight":0.19999999999999998,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"posted_by": {
"actor":"system/repair",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"who_claims":"system/repair",
"slot":null,
"challenged_by": [
"c66",
"c69"
]
},
{
"id":"c3",
"text":"A 2025 pilot study dripped up to 20 mg of BPC-157 into the veins of two healthy adults. Nothing went wrong with their vital signs, their blood tests, or how they said they felt.",
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"tier":"human",
"source_ids": [
"s3"
],
"source_status":"sourced",
"why_material":"Provides the primary documented human safety observation; small sample size noted implicitly by pilot nature.",
"evidence_basis":"derived_inference",
"weight":0.8,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"posted_by": {
"actor":"system/repair",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"who_claims":"system/repair",
"slot":"what_is_known",
"source_role":"adjacent_context"
},
{
"id":"c4",
"text":"The proposed explanation is that BPC-157 encourages new blood vessel growth at the injury and works on the body’s nitric oxide system. That is a proposal drawn from animal work, not something measured in a person.",
"section":"The proposed mechanism is new blood vessel growth and the nitric oxide system",
"tier":"mechanistic",
"source_ids": [],
"source_status":"unsourced",
"why_material":"Frames repair-oriented signaling without efficacy claims.",
"evidence_basis":"derived_inference",
"weight":0.3,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"posted_by": {
"actor":"system/repair",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"who_claims":"system/repair",
"slot":"mechanism"
},
{
"id":"c6",
"text":"One person reported feeling sick within two weeks of starting BPC-157 and stopped taking it. That is one person. The same account was then ingested 25 more times from other copies of the same thread, and each copy is listed below so the count is visible rather than hidden.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"posted_by": {
"actor":"system/repair",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"who_claims":"system/repair",
"slot":null
},
{
"id":"c8",
"text":"The second copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 2 people.",
"tier":"anecdotal",
"weight":0,
"section":"One report of nausea, counted twenty-six times",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"retracted",
"posted_by": {
"actor":"system/repair",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"who_claims":"system/repair",
"slot":null,
"retracted_at":"2026-06-29T11:12:26.056Z",
"retracted_by":"system/repair",
"retraction_reason":"Duplicate — merged into c6 by ledger harden"
},
{
"id":"c10",
"text":"The third copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 3 people.",
"tier":"anecdotal",
"weight":0,
"section":"One report of nausea, counted twenty-six times",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"retracted",
"posted_by": {
"actor":"system/repair",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"who_claims":"system/repair",
"slot":null,
"retracted_at":"2026-06-29T11:12:26.641Z",
"retracted_by":"system/repair",
"retraction_reason":"Duplicate — merged into c6 by ledger harden"
},
{
"id":"c11",
"text":"Ten of the sources catalogued on this page are vendors and clinics selling BPC-157. That is marketing material, and it is listed here as marketing material rather than as evidence.",
"tier":"human",
"weight":0.8,
"section":"Ten of the sources catalogued here are people selling it",
"slot":"what_is_known",
"source_ids": [
"s4",
"s7",
"s11",
"s20",
"s24",
"s27",
"s28",
"s40",
"s3"
],
"source_status":"sourced",
"why_material":"Collapsed 14 duplicate marketing claims",
"status":"active",
"who_claims":"commercial vendors",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c12",
"text":"A 2025 review went through the published papers and the patents on BPC-157 and set out the full range of uses that have been proposed for it.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s5"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s5 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c13",
"text":"A Phase 2 randomised trial of BPC-157 for an acute grade II hamstring tear was registered in 2026 and is under way. It has not reported.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s6"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s6 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c15",
"text":"A 2024 review pulled together the many different effects reported for BPC-157 across the animal literature.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s8"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s8 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c17",
"text":"A YouTube video works through whether BPC-157 does anything, drawing on viewers’ accounts of tendon healing.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [
"s10"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s10 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c19",
"text":"A published commentary responds to a major 2024 review of BPC-157 protecting cells and organs, mostly in gut and multi-organ-failure models in animals.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s12"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s12 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c20",
"text":"A journalist ran a question-and-answer session on BPC-157: its history, the Croatian research group behind it, its FDA status, how widely it is used, and how thin the human evidence is.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s13 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c21",
"text":"One person describes using BPC-157 for tennis elbow. He reports the pain dropping a great deal and the tendon healing enough to get him back to climbing.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s14 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c22",
"text":"A single account with no source attached, ingested while the claim graph was being tested. It should be read as test data, not as anybody’s experience.",
"tier":"anecdotal",
"weight":0.3,
"section":"Two entries that came in while the graph was being tested",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s15 by ledger repair",
"status":"active",
"who_claims":"system/selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"system/selftest",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c23",
"text":"A negative account, also ingested while the claim graph was being tested. It carries no real source either.",
"tier":"anecdotal",
"weight":0.3,
"section":"Two entries that came in while the graph was being tested",
"slot":"who_claims_what",
"source_ids": [
"s16"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s16 by ledger repair",
"status":"active",
"who_claims":"system/selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"system/selftest",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c24",
"text":"A 2026 narrative review in the American Journal of Sports Medicine covers several peptides including BPC-157. It reports that the human evidence is thin and that the existing case series have real methodological problems.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s19"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s19 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c26",
"text":"A 2025 review in the journal Pharmaceuticals covers the same wide spread of effects reported for BPC-157.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s21"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s21 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c28",
"text":"A YouTube video goes through the scientific evidence on BPC-157 and lands on the absence of solid randomised trials in people.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [
"s23"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s23 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c30",
"text":"A 2026 systematic review set BPC-157 against growth factors for muscle and tendon injuries. It found BPC-157 performing consistently in rat studies whichever way it was given.",
"tier":"preclinical",
"weight":0.5,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s25"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s25 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c31",
"text":"A 2025 review drew on both the published papers and the patent record to describe the many effects reported for BPC-157 and the uses proposed from them.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s26"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s26 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c34",
"text":"One person with a history of head injury reports a bad reaction to BPC-157 with TB-500: dizziness, migraine, stomach trouble and worse symptoms all round, starting soon after a low-dose injection. He recovered in part over a week and says some of it lingered.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s29 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c35",
"text":"One person reports long-standing knee pain, from cartilage damage and a meniscus problem, improving a great deal after 12 weeks on BPC-157 at 250 to 750 micrograms a day with TB-500. He went back to squatting and jumping with little trouble the next day.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s30 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c36",
"text":"A climber with a torn A2 pulley in the finger says the tendon felt as though it healed faster on BPC-157 than his earlier injuries did, with less pain hanging around, though he picked up some new aches afterwards.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s31 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c37",
"text":"A 2022 review covers what animal studies report about BPC-157 in the brain and in the gut-brain connection, and the neurological uses proposed on that basis.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s32"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s32 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c38",
"text":"A 2025 article works through the little human data that exists for BPC-157, the safety concerns, and the absence of rigorous trials.",
"tier":"speculative",
"weight":0.12,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s33"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s33 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c39",
"text":"One person reports odd effects that carried on after he stopped taking BPC-157 by mouth for shoulder and neck pain.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s34 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c40",
"text":"A discussion of BPC-157 for the joint and tendon inflammation that comes with psoriatic arthritis. The experiences go both ways, on inflammation and on recovery.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s35 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c41",
"text":"A 2026 analysis goes over the BPC-157 evidence base, the limits of the human data, and the regulatory investigations.",
"tier":"speculative",
"weight":0.12,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s36"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s36 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c42",
"text":"A 2022 review covers BPC-157 and healing at the junction where muscle meets tendon, in animal models.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s37"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s37 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c43",
"text":"A 2025 review covers what BPC-157 is reported to do to new blood vessel growth and to the nitric oxide system, and the uses proposed from that.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s38"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s38 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c44",
"text":"A 2025 systematic review looks at BPC-157 taken by mouth as an add-on for gut conditions.",
"tier":"speculative",
"weight":0.12,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s39"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s39 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c46",
"text":"A thread running from 2024 to 2026 collects accounts of BPC-157 used for Ehlers-Danlos syndrome and joint problems.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s41 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c47",
"text":"A set of accounts from people who used BPC-157 for tendonitis.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s42 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c48",
"text":"A 2026 video explains how BPC-157 is thought to repair tissue.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [
"s43"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s43 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c49",
"text":"A 2025 review sets out the conditions BPC-157 has been proposed for, built around new blood vessel growth and healing.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s44"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s44 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c50",
"text":"A review covers BPC 157 and disturbances in the body’s salt and mineral balance.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s45"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s45 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c51",
"text":"A rat study tested BPC 157 on getting muscle to reattach to bone.",
"tier":"preclinical",
"weight":0.22,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s46"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s46 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c52",
"text":"A 2025 rat study reported BPC 157 protecting organs after the blood supply was cut off and then restored.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s47"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s47 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c53",
"text":"A 2026 question-and-answer session with a journalist covers BPC-157’s history, the science, the missing human data, and the policy around it.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s48 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c54",
"text":"A 2026 video discusses BPC-157 for pain and points at recent reviews.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [
"s49"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s49 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c55",
"text":"A 2026 case report describes a hole between the windpipe and the skin closing after BPC 157.",
"tier":"speculative",
"weight":0.12,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s50"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s50 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c56",
"text":"One person describes a mild ‘peptide flu’ on starting BPC-157 with TB-500. Others in the thread say the same.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s51 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c57",
"text":"One person reports BPC-157 helping with ulcerative colitis symptoms.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s52 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c58",
"text":"One person describes severe anxiety, depression and gut trouble after a short course of BPC-157 by mouth, and says it took months to come right.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s53 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c304",
"text":"Another person in that same thread reports good effects on the gut from BPC-157 by mouth.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s53 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c59",
"text":"One person is taking BPC-157 by mouth after a shoulder injury and reports getting back to lifting weights while still on it.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s54 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c60",
"text":"One person reports BPC-157 with TB-500 speeding up healing after ACL surgery, with no side effects.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s55 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c61",
"text":"One person likes BPC-157 for the joints but warns about eye problems.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s56 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c306",
"text":"The comments under that post carry worse experiences: depression, anxiety and heart symptoms.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s56 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T10:20:41.131Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c65",
"text":"This page is a catalogue of what has been published and what people have said. It is not medical advice, and nothing on it replaces a qualified professional looking at one person’s actual situation.",
"section":"This page is a catalogue and not medical advice",
"tier":"human",
"weight":0.8,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"system/protocol",
"posted_by": {
"actor":"system/protocol",
"channel":"protocol/fill-slots",
"ts":"2026-06-29T10:29:28.608Z",
"model":"system/fill-slots",
"rationale":""
},
"why_material":"Required constitution slot: disclaimer",
"slot":"disclaimer"
},
{
"id":"c66",
"text":"The animal and cell studies point one way, but there has been no large trial in people. Until there is one, none of those results can be turned into a statement about what BPC-157 does to a person.",
"tier":"mechanistic",
"weight":0.4,
"section":"Why the animal record cannot simply be carried across to a person",
"slot":null,
"source_ids": [],
"source_status":"unsourced",
"why_material":"This counter-evidence challenges the overstrong claim of BPC-157's effects being well-established by highlighting the absence of extensive human trials.",
"status":"active",
"who_claims":"kimi/moonshot-v1-8k (adversary)",
"posted_by": {
"actor":"kimi/moonshot-v1-8k (adversary)",
"channel":"protocol/collaborate",
"ts":"2026-06-29T10:56:18.560Z",
"model":"kimi/moonshot-v1-8k"
},
"challenges": [
"c2"
]
},
{
"id":"c67",
"text":"Nobody knows what BPC-157 does to a person over the long run. Its side effects over years have never been measured.",
"tier":"human",
"weight":0.8,
"section":"Nobody knows what BPC-157 does to a person over years",
"slot":"what_is_unknown",
"source_ids": [
"s1"
],
"source_status":"sourced",
"why_material":"While there is a pilot study indicating short-term safety, the lack of long-term data creates a significant knowledge gap.",
"status":"active",
"who_claims":"kimi/moonshot-v1-8k",
"posted_by": {
"actor":"kimi/moonshot-v1-8k",
"channel":"protocol/collaborate",
"ts":"2026-06-29T11:00:59.811Z",
"model":"kimi/moonshot-v1-8k",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c71",
"text":"A YouTube video questions whether BPC-157 works and goes through the evidence that exists.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [
"s10"
],
"source_status":"sourced",
"why_material":"This claim captures a public-facing discussion and critical evaluation of BPC-157, reflecting broader interest and skepticism outside formal academic publications.",
"status":"active",
"who_claims":"gemini/gemini-2.5-flash",
"posted_by": {
"actor":"gemini/gemini-2.5-flash",
"channel":"protocol/collaborate",
"ts":"2026-06-29T11:04:12.350Z",
"model":"gemini/gemini-2.5-flash",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c72",
"text":"An objection was raised against this page: too many of its claims lean on a single source. The answer given was that this source is the one the page was originally built from, and that leaning on it is acceptable.",
"section":"An objection raised against this page’s own sources",
"tier":"human",
"weight":0.8,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"kimi/moonshot-v1-8k",
"posted_by": {
"actor":"kimi/moonshot-v1-8k",
"channel":"conversation-router",
"ts":"2026-06-29T12:20:05.382Z",
"model":null,
"rationale":""
},
"why_material":"posted via claim protocol — prompt injection into ledger",
"slot":null
},
{
"id":"c73",
"text":"41 of the active claims on this page cite the same source, s1. Leaning that heavily on one source weakens the page.",
"section":"An objection raised against this page’s own sources",
"tier":"anecdotal",
"weight":0.28,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"kimi/moonshot-v1-8k",
"posted_by": {
"actor":"kimi/moonshot-v1-8k",
"channel":"conversation-router",
"ts":"2026-06-29T12:20:05.956Z",
"model":"system/conversation-router",
"rationale":"conversation-router — explicit [CLAIM] block"
},
"why_material":"posted via claim protocol — prompt injection into ledger",
"slot":null,
"register":"conversation"
},
{
"id":"c75",
"text":"A 2024 review sets out how BPC-157 is reported to protect the gut lining and other organs, and ties tendon and muscle healing to the blood supply recovering.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s57"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s57 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T13:50:28.810Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c76",
"text":"A 2025 rat study reported BPC-157 helping muscle reattach to bone, and helping the tendon heal, after the two had been surgically detached.",
"tier":"preclinical",
"weight":0.5,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s58"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s58 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T13:50:28.810Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c77",
"text":"A 2025 pilot study looked at how safe BPC-157 is when dripped into a vein in people, and noted that people use it for muscle and tendon tears.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s59"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s59 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T13:50:28.810Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c78",
"text":"A 2026 review covers peptides used in orthopaedics, BPC-157 among them, for repairing tendon and muscle.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s60"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s60 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T13:50:28.810Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c79",
"text":"A 2026 review covers what BPC-157 is reported to do in tissue repair, tendon included.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s61"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s61 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T13:50:28.810Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c80",
"text":"A 2025 narrative review covers BPC-157 for tendon healing and for other muscle and bone problems.",
"tier":"human",
"weight":0.8,
"section":"Nearly every BPC-157 paper in the record is a review of the same animal work",
"slot":"what_is_known",
"source_ids": [
"s62"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s62 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T13:50:28.810Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c81",
"text":"Several people report tendons and injuries recovering well on BPC-157, often alongside TB-500: recovery from bicep tendon surgery halved, a hip flexor tear healing fast, and easier recoveries after surgery.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s63 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c82",
"text":"One person describes BPC-157 with TB-500 getting him a full recovery from a grade 2 to 3 hip flexor tear, and quick healing after a breast augmentation.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s64 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c83",
"text":"People report BPC-157 speeding recovery from a calf injury, and the combination with TB-500 giving the best pain control for ankylosing spondylitis and the tendon inflammation that goes with it. One person notes it did not seem to touch inflammation on its own.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s65 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c84",
"text":"One person posts an update: less swelling and less pain in the joint where the collarbone meets the breastbone, after starting BPC-157 for problems related to ankylosing spondylitis.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s66 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c85",
"text":"One person says BPC-157 with TB-500 worked for soft-tissue injuries and got him back to high-level tennis after a tear without surgery. He says it helped inflammation and did nothing for a torn labrum.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s67 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c86",
"text":"One person reports no change at all in IBS symptoms after two rounds of BPC-157, having had other lifestyle changes work before.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s68 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c305",
"text":"A comment underneath that report says a low dose of BPC-157 by mouth worked well for gut trouble, with no side effects.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s68 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c87",
"text":"One person reports much better gut health after six months of BPC-157 by mouth, with less bloating and a sense that the gut lining itself was repairing.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s69 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c88",
"text":"A discussion of long-running tendon pain caused by fluoroquinolone antibiotics. People argue about whether BPC-157 does anything for tendon trouble that affects the whole body, and the accounts go both ways.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s70 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c89",
"text":"One person reports fast healing of a ruptured tendon with BPC-157 started after surgery, no side effects, and a doctor struck by how little swelling there was.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s71 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c90",
"text":"One person reports lifelong IBS symptoms clearing completely after a month or more of BPC-157 held under the tongue at 500 micrograms a day, with no side effects. He calls it the most reliable relief he has had.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s72 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c91",
"text":"One person reports good gut effects after seven days of BPC-157 by mouth together with KPV: a calmer, less inflamed stomach, less anxiety, less brain fog, and no side effects.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s73 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c92",
"text":"One person says an oral BPC-157 gut blend cleared his leaky-gut symptoms in three weeks after diet changes had failed, and calls it a miracle.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s74 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:07:31.978Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c93",
"text":"One person reports good effects from BPC-157 with TB-500 after ACL reconstruction: the tendon took load better, a mild buzz on injecting, and higher libido. No major side effects after a month.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s75 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:08:57.887Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c94",
"text":"One person found BPC-157 by mouth did nothing for tendon pain but did help his gut. He has not tried the injection.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s76 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:08:57.887Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c95",
"text":"One person reports a good early recovery after ACL surgery on BPC-157 by mouth, with less swelling and better movement, and puts some of it down to the peptide rather than to the surgery and physiotherapy.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s77 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:08:57.887Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c96",
"text":"One person reports BPC-157 by mouth at 25 to 50 micrograms several times a day easing ulcers, gastritis and IBS, with no side effects at that dose. Higher doses brought hot flushes and a spell of feeling nothing at all.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s78 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c301",
"text":"Another person in the same thread reports injecting BPC-157 under the skin, which helped his IBS and a meniscus injury, with the symptoms partly coming back after he stopped.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s78 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c302",
"text":"A third person in that thread describes severe depression and panic from BPC-157 taken by mouth.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s78 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c97",
"text":"One person reports less swelling while recovering from a ruptured Achilles, using BPC-157 from two weeks to three months after the operation. No dose is given.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s79 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c303",
"text":"Another person recovering from a ruptured Achilles says he could not tell whether BPC-157 did anything beyond what normal healing and physiotherapy were doing anyway.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s79 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c98",
"text":"People report BPC-157, by mouth or injected under the skin at around 500 micrograms a day, together with TB-500, helping Crohn’s and other gut trouble dramatically inside a week. One prefers injecting because it also helped his shoulder, and suggests 1 mg a day under the skin at night.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s80 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c99",
"text":"One person reports BPC-157 with TB-500 helping recovery after ACL surgery — general knee comfort and strength rather than the graft itself — with improvement over a three-week course.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s81 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c100",
"text":"One person says BPC-157 is his favourite of every peptide he has tried, for the gut, for thinking clearly and for mood.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [
"s82"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s82 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c101",
"text":"One person reports BPC-157 calming inflammation and rebuilding the gut lining as part of a wider set of things he was taking.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [
"s83"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s83 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c102",
"text":"A long research guide covers BPC-157 for tendon, ligament and gut healing: how it is thought to work, doses of 200 to 500 micrograms a day by mouth or by injection, how long to expect it to take, and what people take alongside it. It reports good results for gut and tendons.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s84 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c103",
"text":"A guide to the BPC-157 and TB-500 blend argues that the two work on different parts of the same problem, suggests 2 mg of the blend twice a week, and describes side effects as mild. The comments underneath argue about dose.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s85 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c104",
"text":"A thread on BPC-157 with TB-500 for meniscus and knee tendon injuries. Most accounts are positive: pain dropping within days to weeks, and faster healing, at doses like 250 micrograms twice a day or 500 micrograms. Some people are still in the middle of it.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s86 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c105",
"text":"A thread about shoulder and tendon recovery on BPC-157. One person is unsure it did anything. Another reports a good recovery after surgery using it as part of a stack, with no side effects. Six weeks was the course.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s87 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c106",
"text":"An X thread sets out how BPC-157 is thought to heal tendon and gut, through new blood vessel growth and signals such as VEGF. It leans on the animal work and on personal accounts, and says a randomised trial in people is what is missing.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [
"s88"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s88 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c107",
"text":"A detailed X post covers the animal data on BPC-157 for tendon repair and how it is thought to work. Further down the thread it extends to the gut. Personal use is described favourably.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [
"s89"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s89 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:00:42.842Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c108",
"text":"One person reports a meniscus tear improving on BPC-157 at 500 micrograms twice a day under the skin, with TB-500 at 2 mg twice a week, over three months. Symptoms improved and the scan changed in the parts of the meniscus that have a blood supply.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s90 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:02:20.634Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c109",
"text":"One person reports BPC-157 with TB-500 repairing gut and bladder tissue, and sets out how the two are thought to work on tendon and gut.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s91 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:02:20.634Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c110",
"text":"A guide gives doses and a timeline for repairing the gut with BPC-157 taken by mouth.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s92 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:02:20.634Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c111",
"text":"One person reports the BPC-157 and TB-500 combination helping tissue and tendon heal across the whole body.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [
"s93"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s93 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:02:20.634Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c112",
"text":"A guide compares BPC-157 by mouth against the injection. The oral form survives the stomach and is aimed at the gut; the injection is aimed at tendon and muscle.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s94 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:02:20.634Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c113",
"text":"One person asks what else there is besides BPC-157 for gut trouble.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [
"s95"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s95 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:02:20.634Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c114",
"text":"One person describes gut trouble he had in the past and says he thinks BPC-157 would have helped.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [
"s96"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s96 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:02:20.634Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c115",
"text":"A post recommends BPC-157 for repairing the gut, gives example doses, says the oral form is the one for gut trouble, and notes that mild side effects are possible.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s97 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:21:52.392Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c116",
"text":"One person logs the doses he took while healing an injury, and reports a good outcome for plantar fasciitis and tendon trouble.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"sourced",
"why_material":"Materialized from orphan source s98 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:21:52.392Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c117",
"text":"A post recommends BPC-157 for repairing the gut and for healing tendon, gives doses, and talks about what to take with it and how to cycle it.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [
"s99"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s99 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:21:52.392Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c118",
"text":"A post summarises the healing claims made for BPC-157 in tendons and in the gut, with an example dose.",
"tier":"anecdotal",
"weight":0.3,
"section":"The videos, threads and interviews people find when they search BPC-157",
"slot":"who_claims_what",
"source_ids": [
"s100"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s100 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:21:52.392Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c119",
"text":"One person describes a tendon healing successfully on BPC-157.",
"tier":"anecdotal",
"weight":0.3,
"section":"What people taking BPC-157 say happened to them, good and bad",
"slot":"who_claims_what",
"source_ids": [
"s101"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s101 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:21:52.392Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c120",
"text":"The chain of hashes on the sources proves the sources have not been altered since they were logged. It proves nothing about whether they are clinically true. The evidence here is mostly animal work and personal accounts, with very little from people, and this page gives no dose, no protocol and no recommendation.",
"section":"What a verified chain of sources does and does not prove",
"tier":"mechanistic",
"weight":0,
"status":"downweighted",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"miscsubjects protocol",
"posted_by": {
"actor":"miscsubjects protocol",
"channel":"protocol/fill-slots",
"ts":"2026-06-29T20:20:04.723Z",
"model":"fill-slots",
"rationale":""
},
"why_material":"Required constitution slot: limitations",
"slot":"limitations",
"register":null,
"challenged_by": [
"c311",
"c315",
"c319"
]
},
{
"id":"c122",
"text":"The fourth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 4 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-01T11:29:34.609Z",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c124",
"text":"The fifth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 5 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-01T23:11:56.996Z",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c126",
"text":"The sixth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 6 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-01T23:55:17.024Z",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c128",
"text":"The seventh copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 7 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-03T00:02:26.518Z",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c130",
"text":"The eighth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 8 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-03T00:04:53.313Z",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c132",
"text":"The ninth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 9 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-02T21:46:07-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c134",
"text":"The tenth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 10 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-02T22:05:49-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c136",
"text":"The eleventh copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 11 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-02T22:12:10-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c138",
"text":"The twelfth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 12 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-03T10:43:23-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c140",
"text":"The thirteenth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 13 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-04T15:09:27-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c142",
"text":"The fourteenth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 14 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-05T19:32:08-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c144",
"text":"The fifteenth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 15 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-05T20:08:19-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c146",
"text":"The sixteenth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 16 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-06T20:42:04-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c148",
"text":"The seventeenth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 17 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-06T20:43:40-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c150",
"text":"The eighteenth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 18 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-06T20:44:22-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c152",
"text":"The nineteenth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 19 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-06T20:46:36-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c154",
"text":"The twentieth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 20 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-06T20:48:58-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c156",
"text":"The twenty-first copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 21 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-06T20:51:02-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c158",
"text":"The twenty-second copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 22 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-06T21:07:35-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c160",
"text":"The twenty-third copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 23 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-06T21:09:42-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c162",
"text":"The twenty-fourth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 24 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-06T21:40:49-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c164",
"text":"The twenty-fifth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 25 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-06T22:18:22-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c166",
"text":"The twenty-sixth copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 26 people.",
"tier":"anecdotal",
"weight":0.3,
"section":"One report of nausea, counted twenty-six times",
"slot":"who_claims_what",
"source_ids": [],
"source_status":"unsourced",
"why_material":"SELFTEST graph — bad outcome anecdote",
"status":"active",
"who_claims":"selftest",
"posted_by": {
"actor":"system/selftest",
"channel":"selftest",
"ts":"2026-07-11T07:39:13-07:00",
"model":"system/ingest-deterministic",
"rationale":""
}
},
{
"id":"c167",
"text":"As of July 2026, BPC-157 is not approved by the FDA for use in a person. It was put in Category 2 of the 503A bulk substances list in late 2023, meaning significant safety concerns, which effectively stopped pharmacies compounding it. On 22 April 2026 it came out of Category 2 after the nomination was withdrawn.",
"section":"Where BPC-157 stands with the FDA, with sport, and with the military",
"tier":"human",
"weight":0.8,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"user",
"posted_by": {
"actor":"user",
"channel":"imessage",
"ts":"2026-07-22T20:12:01.648Z",
"model":null,
"rationale":""
},
"why_material":"posted via claim protocol — prompt injection into ledger",
"slot":null,
"register":null
},
{
"id":"c300",
"text":"BPC-157 was not moved to Category 1 when it left Category 2, so it now sits in a grey zone — neither prohibited nor authorised. A Pharmacy Compounding Advisory Committee review was scheduled for 23 July 2026. It has no USP or NF monograph. It is sold as research-use-only, and that wording covers the sale, not a person taking it. Verify against FDA docket FDA-2025-N-6895; sources are the FDA 503A bulk substances list, opss.org, and a regulatory update from newdrugloft.com dated 2026-05.",
"section":"Where BPC-157 stands with the FDA, with sport, and with the military",
"tier":"human",
"weight":0.8,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"user",
"posted_by": {
"actor":"user",
"channel":"imessage",
"ts":"2026-07-22T20:12:01.648Z",
"model":null,
"rationale":""
},
"why_material":"posted via claim protocol — prompt injection into ledger",
"slot":null,
"register":null
},
{
"id":"c168",
"text":"BPC-157 sits on the World Anti-Doping Agency Prohibited List under class S0, non-approved substances, so it is banned in competitive sport at all times. It is also on the US Department of Defense list of prohibited dietary supplement ingredients, under DoDI 6130.06, so Service Members may not take it. Anyone competing, and anyone serving, faces sanctions that have nothing to do with the wider regulatory grey zone. Sources: the WADA Prohibited List and usada.org.",
"section":"Where BPC-157 stands with the FDA, with sport, and with the military",
"tier":"human",
"weight":0.8,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"user",
"posted_by": {
"actor":"user",
"channel":"imessage",
"ts":"2026-07-22T20:12:04.340Z",
"model":null,
"rationale":""
},
"why_material":"posted via claim protocol — prompt injection into ledger",
"slot":null,
"register":null
},
{
"id":"c307",
"text":"Reddit user reports gut healing after GLP-1",
"section":"Posted claim",
"tier":"anecdotal",
"weight":0.3,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"user",
"posted_by": {
"actor":"user",
"channel":"imessage",
"ts":"2026-09-01T07:07:24.685Z",
"model":null,
"rationale":""
},
"why_material":"posted via claim protocol — prompt injection into ledger",
"slot":null,
"register":null
},
{
"id":"c308",
"text":"The specific mechanisms by which BPC-157 exerts its reported effects in humans are not fully elucidated, and optimal dosing strategies for therapeutic application remain unknown.",
"tier":"human",
"weight":0.8,
"section":"what_is_unknown",
"slot":"what_is_unknown",
"source_ids": [
"s1",
"s4",
"s5",
"s7",
"s11"
],
"source_status":"sourced",
"why_material":"Highlights critical gaps in the understanding of BPC-157's action and application in human contexts, which is essential for a comprehensive overview.",
"status":"active",
"who_claims":"gemini-collaborator",
"posted_by": {
"actor":"gemini/gemini-2.5-flash",
"channel":"protocol/collaborate",
"ts":"2026-09-01T00:10:02-07:00",
"model":"gemini/gemini-2.5-flash",
"rationale":""
}
},
{
"id":"c309",
"text":"Online content creators and commercial vendors frequently share anecdotal reports and testimonials regarding BPC-157's perceived benefits for healing and recovery.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s10",
"s4",
"s7",
"s11"
],
"source_status":"sourced",
"why_material":"Addresses the prevalence of non-clinical and personal experience-based information surrounding BPC-157, providing context on how information is disseminated outside of formal research.",
"status":"active",
"who_claims":"gemini-collaborator",
"posted_by": {
"actor":"gemini/gemini-2.5-flash",
"channel":"protocol/collaborate",
"ts":"2026-09-01T00:10:02-07:00",
"model":"gemini/gemini-2.5-flash",
"rationale":""
}
},
{
"id":"c310",
"text":"BPC-157 exhibits cytoprotective properties, contributing to the protection of cells and organs, particularly within the gastrointestinal system, and is associated with improved blood supply in healing tissues.",
"tier":"mechanistic",
"weight":0.3,
"section":"mechanism",
"slot":"mechanism",
"source_ids": [
"s1",
"s12"
],
"source_status":"sourced",
"why_material":"Consolidates and explicitly states key proposed mechanisms of action for BPC-157, drawing from multiple sources to provide a clearer picture of its biological activity.",
"status":"active",
"who_claims":"gemini-collaborator",
"posted_by": {
"actor":"gemini/gemini-2.5-flash",
"channel":"protocol/collaborate",
"ts":"2026-09-01T00:10:02-07:00",
"model":"gemini/gemini-2.5-flash",
"rationale":""
}
},
{
"id":"c311",
"text":"Claim `c120` asserts that 'very little [evidence is] from people'. However, claim `c3` details a human pilot study, and claim `c24` references existing human case series, indicating that some human evidence, albeit limited and with methodological problems, is present in the literature.",
"tier":"human",
"weight":0.4,
"section":"Challenge",
"slot":null,
"source_ids": [],
"source_status":"unsourced",
"why_material":"Provides nuance to the characterization of human evidence by highlighting specific examples of human studies within the ledger, even while acknowledging their limitations, and challenges an unsourced claim with sourced counter-evidence.",
"status":"active",
"who_claims":"gemini/gemini-2.5-flash (adversary)",
"posted_by": {
"actor":"gemini/gemini-2.5-flash (adversary)",
"channel":"protocol/collaborate",
"ts":"2026-09-01T00:10:02-07:00",
"model":"gemini/gemini-2.5-flash"
},
"challenges": [
"c120"
]
},
{
"id":"c312",
"text":"Individuals in online communities and public discussions often report personal experiences of BPC-157 improving recovery from injuries.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s10"
],
"source_status":"sourced",
"why_material":"This claim addresses the 'who_claims_what' slot by attributing common anecdotal reports to online communities, using a YouTube source as representative of such public discussions.",
"status":"active",
"who_claims":"gemini-collaborator",
"posted_by": {
"actor":"gemini/gemini-2.5-flash",
"channel":"protocol/collaborate",
"ts":"2026-09-01T02:41:46-07:00",
"model":"gemini/gemini-2.5-flash",
"rationale":""
}
},
{
"id":"c313",
"text":"Preclinical studies suggest BPC-157 may promote angiogenesis, the formation of new blood vessels, which contributes to its reported healing effects in various tissues.",
"tier":"preclinical",
"weight":0.5,
"section":"mechanism",
"slot":"mechanism",
"source_ids": [
"s1",
"s5"
],
"source_status":"sourced",
"why_material":"This claim provides a specific mechanistic pathway (angiogenesis) by which BPC-157 is thought to exert its effects, enriching the understanding beyond general protective actions.",
"status":"active",
"who_claims":"gemini-collaborator",
"posted_by": {
"actor":"gemini/gemini-2.5-flash",
"channel":"protocol/collaborate",
"ts":"2026-09-01T02:41:46-07:00",
"model":"gemini/gemini-2.5-flash",
"rationale":""
}
},
{
"id":"c314",
"text":"The full spectrum of BPC-157's interactions with human physiological systems beyond its primary reported effects, including potential off-target actions, remains to be thoroughly investigated.",
"tier":"human",
"weight":0.8,
"section":"what_is_unknown",
"slot":"what_is_unknown",
"source_ids": [
"s4",
"s7",
"s11"
],
"source_status":"sourced",
"why_material":"This claim expands on existing 'what_is_unknown' by highlighting the broader lack of understanding regarding systemic interactions and potential off-target effects in humans, which is crucial for a comprehensive safety and efficacy profile.",
"status":"active",
"who_claims":"gemini-collaborator",
"posted_by": {
"actor":"gemini/gemini-2.5-flash",
"channel":"protocol/collaborate",
"ts":"2026-09-01T02:41:46-07:00",
"model":"gemini/gemini-2.5-flash",
"rationale":""
}
},
{
"id":"c315",
"text":"The claim 'The evidence here is mostly animal work and personal accounts, with very little from people...' is categorized as 'tier: mechanistic'. However, this claim describes the nature and limitations of the scientific evidence corpus, which is an assessment of research methodology and scope, not a specific biological mechanism. Therefore, its tier classification is more appropriately 'human' or 'meta-analysis' rather than 'mechanistic'.",
"tier":"human",
"weight":0.4,
"section":"Challenge",
"slot":null,
"source_ids": [],
"source_status":"unsourced",
"why_material":"This challenge corrects the classification of a meta-level claim about the evidence, ensuring consistency in tier assignment within the protocol. The claim's content pertains to human-level evaluation of research, not a mechanistic biological process.",
"status":"active",
"who_claims":"gemini/gemini-2.5-flash (adversary)",
"posted_by": {
"actor":"gemini/gemini-2.5-flash (adversary)",
"channel":"protocol/collaborate",
"ts":"2026-09-01T02:41:46-07:00",
"model":"gemini/gemini-2.5-flash"
},
"challenges": [
"c120"
]
},
{
"id":"c316",
"text":"Individuals on platforms like YouTube discuss personal experiences and perceived effects of BPC-157, often sharing anecdotal reports of its use.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s10"
],
"source_status":"sourced",
"why_material":"Fills the `who_claims_what` slot by acknowledging the presence of anecdotal information in public discourse, sourced from a relevant platform.",
"status":"active",
"who_claims":"gemini-collaborator",
"posted_by": {
"actor":"gemini/gemini-2.5-flash",
"channel":"protocol/collaborate",
"ts":"2026-09-06T08:27:34-07:00",
"model":"gemini/gemini-2.5-flash",
"rationale":""
}
},
{
"id":"c317",
"text":"Preclinical studies and reviews propose that BPC-157 may exert its effects through various mechanisms, including promoting angiogenesis, modulating growth factors, and influencing inflammatory responses, primarily observed in animal models.",
"tier":"mechanistic",
"weight":0.3,
"section":"mechanism",
"slot":"mechanism",
"source_ids": [
"s1",
"s4",
"s5",
"s7",
"s8",
"s11",
"s12"
],
"source_status":"sourced",
"why_material":"Provides insight into the hypothesized biological actions of BPC-157, which is a crucial aspect of understanding its potential, even if primarily from preclinical data.",
"status":"active",
"who_claims":"gemini-collaborator",
"posted_by": {
"actor":"gemini/gemini-2.5-flash",
"channel":"protocol/collaborate",
"ts":"2026-09-06T08:27:34-07:00",
"model":"gemini/gemini-2.5-flash",
"rationale":""
}
},
{
"id":"c318",
"text":"Despite extensive preclinical research, the efficacy and safety of BPC-157 in humans lack validation through large-scale, randomized, placebo-controlled clinical trials.",
"tier":"human",
"weight":0.8,
"section":"what_is_unknown",
"slot":"what_is_unknown",
"source_ids": [
"s4",
"s7",
"s11"
],
"source_status":"sourced",
"why_material":"Identifies a critical gap in the evidence base for human application, distinguishing it from general long-term unknowns or mechanism unknowns by focusing on the absence of robust clinical trials.",
"status":"active",
"who_claims":"gemini-collaborator",
"posted_by": {
"actor":"gemini/gemini-2.5-flash",
"channel":"protocol/collaborate",
"ts":"2026-09-06T08:27:34-07:00",
"model":"gemini/gemini-2.5-flash",
"rationale":""
}
},
{
"id":"c319",
"text":"The claim's tier as 'mechanistic' is inappropriate; the claim describes the nature and limitations of the evidence, not a biological mechanism. This aspect of the claim should be re-tiered to 'human' or 'limitations' to accurately reflect its content.",
"tier":"human",
"weight":0.4,
"section":"Challenge",
"slot":null,
"source_ids": [],
"source_status":"unsourced",
"why_material":"Corrects a miscategorization of a claim's tier, ensuring accuracy in the protocol's classification system. The claim itself is about the human understanding and assessment of evidence, not a biological mechanism.",
"status":"active",
"who_claims":"gemini/gemini-2.5-flash (adversary)",
"posted_by": {
"actor":"gemini/gemini-2.5-flash (adversary)",
"channel":"protocol/collaborate",
"ts":"2026-09-06T08:27:34-07:00",
"model":"gemini/gemini-2.5-flash"
},
"challenges": [
"c120"
]
}
],
"widgets": [
{
"type":"stat",
"value":"150+",
"label":"Croatian-lab papers since 1993"
},
{
"type":"stat",
"value":"~3",
"label":"human studies, ever"
},
{
"type":"stat",
"value":"8–6",
"label":"FDA committee vote, Jul 2026"
},
{
"type":"stat",
"value":"2/3",
"label":"grey-market samples under 95% pure"
},
{
"type":"note",
"title":"The one-lab problem",
"text":"Most of what is known about BPC-157 comes from a single research group. That is a coherent decades-long program — and a reason independent human trials matter more here than for almost any other compound."
},
{
"type":"note",
"title":"If you source it anyway",
"text":"Consumer BPC-157 is grey-market. Demand third-party HPLC **and** mass-spec per batch; a vendor-only certificate proves nothing, and 'for research use only' is a legal shield, not a safety standard."
}
],
"type":"article",
"updated":"2026-10-08T11:51:20.414Z",
"version":1,
"hash":"241052571278eefd4b99ba5556a80bf5d08ffe7233be3069a699b96e87e676b2",
"styling": {
"scope":"shared",
"how":"no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH https://miscsubjects.com/api/jarticles/theme changes them.",
"widget_style": {
"what":"every widget may carry style: {…}; these are the only keys it reads",
"rotate":"degrees, a number",
"offset_x":"pixels, a number",
"offset_y":"pixels, a number",
"pulse":"true to pulse"
},
"theme": {
"color": {
"page_bg":"#f5f5f7",
"sheet_bg":"#ffffff",
"ink":"#1d1d1f",
"soft":"#424245",
"muted":"#6e6e73",
"dim":"#86868b",
"line":"#d2d2d7",
"accent":"#0071e3",
"accent_soft":"rgba(0,113,227,0.08)",
"link":"#0066cc",
"selection":"rgba(0,113,227,0.18)",
"widget_bg":"#f5f5f7",
"widget_border":"#d2d2d7",
"card_bg":"#ffffff",
"code_bg":"#f5f5f7",
"json_bg":"#161b19",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#928d7e",
"json_punct":"#6b6759",
"json_bar":"#0e1512",
"kind_badge_bg":"#0e6e60",
"kind_badge_ink":"#ffffff"
},
"color_dark": {
"page_bg":"#000000",
"sheet_bg":"#1d1d1f",
"ink":"#f5f5f7",
"soft":"#d2d2d7",
"muted":"#a1a1a6",
"dim":"#86868b",
"line":"#424245",
"accent":"#2997ff",
"accent_soft":"rgba(41,151,255,0.12)",
"link":"#2997ff",
"selection":"rgba(41,151,255,0.25)",
"widget_bg":"#2c2c2e",
"widget_border":"#424245",
"card_bg":"#1d1d1f",
"code_bg":"#2c2c2e",
"json_bg":"#0a0d0c",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#757062",
"json_punct":"#5d665f",
"json_bar":"#060807",
"kind_badge_bg":"#4fc1ab",
"kind_badge_ink":"#0b0f0d"
},
"font": {
"display":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"body":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"mono":"ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
"google_fonts":""
},
"size": {
"body":"17px",
"small":"17px",
"eye":"17px",
"lead":"17px",
"h1":"52px",
"h2":"34px",
"h3":"22px",
"byline":"17px",
"h1_measure":"none",
"code":"17px",
"json":"17px",
"widget_title":"17px"
},
"leading": {
"body":"1.7",
"head":"1.18",
"lead":"1.5",
"json":"1.6"
},
"weight": {
"display":"700",
"head":"700",
"body":"400",
"strong":"700",
"eye":"700"
},
"tracking": {
"eye":"0.14em",
"display":"-0.03em",
"body":"-0.006em",
"badge":"0.08em"
},
"layout": {
"sheet_width":"1000px",
"text_width":"880px",
"gutter":"16px",
"sheet_padding":"56px 64px 64px",
"sheet_padding_mobile":"24px 18px 40px",
"sheet_margin":"28px auto 72px",
"block_gap":"1.15em",
"widget_gap":"28px",
"grid_gap":"14px"
},
"border": {
"sheet":"0px solid",
"sheet_radius":"30px",
"widget":"1px solid",
"widget_radius":"24px",
"card_radius":"24px",
"badge_radius":"999px",
"rule":"1px solid",
"code_radius":"18px",
"accent_bar":"3px"
},
"shadow": {
"sheet":"0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
"widget":"none",
"card_hover":"0 10px 28px -16px rgba(28,27,23,0.35)"
},
"motion": {
"hover":"160ms ease"
}
}
},
"page":"https://miscsubjects.com/a/bpc-157",
"json":"https://miscsubjects.com/a/bpc-157.json",
"markdown":"https://miscsubjects.com/a/bpc-157.md",
"theme":"https://miscsubjects.com/article-theme.json",
"calls": [
{
"what":"this article as a page (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/bpc-157",
"headers": {}
},
{
"what":"this article as its object (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/bpc-157.json",
"headers": {}
},
{
"what":"this article as Markdown (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/bpc-157.md",
"headers": {}
},
{
"what":"the object with its hash, drafts too",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/bpc-157",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"one piece and that piece’s hash",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/bpc-157/at?path=facts",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"grep: every key or value that matches, with the path to change it",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/bpc-157/grep?q=owner",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"change pieces (set, merge, delete, append, insert, move); if-match is the hash",
"method":"PATCH",
"url":"https://miscsubjects.com/api/jarticles/bpc-157",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash from the read>"
},
"body": {
"ops": [
{
"op":"set",
"path":"facts.example",
"value":1
}
]
}
},
{
"what":"replace the whole object",
"method":"PUT",
"url":"https://miscsubjects.com/api/jarticles/bpc-157",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash>"
},
"body": {
"slug":"bpc-157",
"title":"…"
}
},
{
"what":"fetch every source, hash what came back and check the quote is in it",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/bpc-157/verify",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {}
},
{
"what":"an Obsidian-style command",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/cli",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {
"command":"backlinks",
"file":"bpc-157"
}
}
]
}
